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BIOMARKERS OF DISEASE PROGRESSION AND CHEMOTHERAPEUTIC 
RESISTANCE IN CANINE OSTEOSARCOMA 
 
 Osteosarcoma is the most common primary bone malignancy in both humans and 
dogs.  Over 10,000 canine patients develop this highly aggressive cancer annually and 
many succumb to metastatic disease in less than a year.  In recent years, canine 
osteosarcoma has been increasingly recognized as an excellent model for the disease in 
humans, especially with regard to the molecular biology of the disease.  Thus, research 
targeted at canine osteosarcoma benefits not only dogs but the field of human oncology 
as well.  Research into the genetic and molecular derangements of osteosarcoma in both 
species has identified a number of oncogenes and tumor suppressor genes that may 
contribute to tumorigenesis.  Additionally, some mediators of invasion and metastasis 
have been recognized (e.g. Ezrin, matrix metallopeptidases).  Despite this, only a limited 
number of studies have been performed that examine the molecular genetics of  
osteosarcoma in the context of patient outcome. 
 Thus, with the aim of identifying new target genes and pathways that contribute to 
disease progression and chemoresistance in osteosarcoma, we first performed 
transcriptomic and genomic analyses of primary tumors from dogs that had experienced 
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good or poor outcomes following definitive treatment for osteosarcoma.  These broad 
survey experiments yielded a selection of targets for future investigation.  To further 
focus in on the genes that were most deranged from "normal" expression patterns, we 
compared gene expression patterns from tumors to those of normal bone.  This study 
provided valuable perspective on genes that were identified in the outcome-based 
experiments, allowing selection of four promising gene targets to pursue.  We next set out 
to validate in vitro models of canine osteosarcoma so that mechanistic studies could be 
pursued.  Assays to test species and short tandem repeat identity were adapted to cell 
lines in use in our facility and presumed osteosarcoma cell lines were verified to be bone-
derived via PCR testing of a bone-specific marker.  Additionally, four anti-human 
antibodies were validated for use in canine samples. 
 Two genes whose expression progressively altered with increased tumor 
aggressiveness where chosen for further study:  insulin-like growth factor 2 mRNA 
binding protein 1 (IGF2BP1) and n-Myc downstream regulated gene 2 (NDRG2).  
IGF2BP1 has been identified as an oncofetal protein and its mRNA was strongly 
overexpressed in patients with the worst outcome while it was virtually undetectable in 
normal bone.  We identified one possible mechanism for dysregulation of this gene in 
OSA and we also discovered that knock down of this gene in a canine osteosarcoma cell 
line inhibited cell invasion.  NDRG2 has been dubbed a tumor suppressor in a number of 
different tumor types yet had not been previously investigated in osteosarcoma.  We 
found NDRG2 mRNA to be underexpressed in all tumors relative to normal bone; 
patients with poor outcomes had the lowest expression levels.  Multiple isoforms of the 
gene were found to be expressed in canine samples:  these were cloned and transfected 
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into a low-NDRG2-expressing cell line.  Exogenous expression of NDRG2 in this in vitro 
system enhanced sensitivity to doxorubicin, one of the drugs most commonly used to 
treat osteosarcoma.  Additionally, three possible mechanisms of dysregulation of this 
gene were identified. 
 The studies presented herein progress from fact-finding surveys to in-depth 
functional examination of two genes that likely contribute to osteosarcoma invasion and 
chemoresistance.  Furthermore, additional genes identified in our survey experiments 
offer promise for future studies into molecular mechanisms of osteosarcoma metastases 
and chemotherapeutic resistance.  Finally, these studies have laid the groundwork for the 
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Literature Review and Project Rationale 
 
Osteosarcoma in the Dog 
 Osteosarcoma (OSA) is a primary bone tumor of mesenchymal origin that occurs 
in canine patients at a rate of roughly eight per 100,000 pet dogs per year in the United 
States, totaling over 8,000 new cases annually (1).  It is the most common primary bone 
tumor and the most frequent sites affected are the metaphyseal regions of long bones, 
particularly the front limbs (2-4).  Large and giant breed dogs are most often affected by 
appendicular OSA:  mixed breed as well as purebreds are at risk but, some breeds, 
including Greyhounds and Rottweilers, appear to have an elevated susceptibility (5-8).  
Age distribution of OSA patients is bimodal with a small peak in young animals (18-24 
months) and a larger peak in older dogs (median = 7 years), the youngest patients tend to 
have the most aggressive disease and concordantly poor survival (3, 7, 9).  Axial OSA 
also occurs in dogs but is less common (~25% of cases) and tends to involve a more 
varied population:  it will not be addressed further (9).  Although large body size is the 
primary OSA risk factor in dogs, other factors, including prior bone fracture, surgical 
implants, radiation treatment and infarction have been identified as possible contributors 
to tumorigenesis at the site of such trauma (7, 10-18). 
 2
 Osteosarcoma patients typically present with lameness and localized swelling of 
the affected limb; pathologic fractures are relatively common in cases where the tumor 
has significantly weakened the existing bone matrix (9, 19, 20).  Radiographically, OSA 
appears as a simultaneously osteolytic and osteoblastic lesion, with destruction of normal 
bone and aberrant growth of tumor "bone," this has been described as having a "sunburst" 
appearance (20, 21).  The radiographic appearance of new periosteal bone formation has 
been dubbed Codman's triangle and, while not always present in OSA, does occur in 
some patients (9).  Osteosarcoma tumors are histologically characterized by eosinophilic 
matrix (osteoid) and cells with large nuclei, multiple nucleoli and various stromal 
components.  A wide range of differentiation states are observed.  There are many 
different histotypes of OSA including osteoblastic, chondroblastic, fibroblastic, 
telangectatic, giant cell, and poorly differentiated:  these classifications identify the 
primary cell type within the tumor but do not appear to affect clinical outcome except in 
the case of the highly vascular telangectatic OSA, a tumor histotype typically associated 
with a poor outcome (20-22).  
 The primary cause of morbidity and mortality in OSA patients is aggressive 
metastatic disease of the lungs.  Less than 10% of dogs present with clinically detectable 
metastasis (≥1cm3) at the time of OSA diagnosis (9).  It is estimated that upwards of 90% 
of OSA patients without detectable metastatic disease have micrometastases at 
presentation and many of these dogs will subsequently develop lung metastases (19, 23).  
Prior to the addition of systemic chemotherapy to treatment protocols, post amputation 
survival was generally 3-4 months; this was extended by the addition of adjuvant 
chemotherapy protocols (9, 24).  Thus, treatment failures are primarily failures to treat 
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distant disease and improved management of distant disease can extend disease-free 
survival.   
 Standard of care treatment for OSA involves amputation of the affected limb 
followed by adjuvant chemotherapy with doxorubicin, a platinum-based drug or a 
combination of the two aimed at inhibiting distant disease (9, 25-29).  More recently, a 
limb-sparing surgical technique has been developed and is implemented in cases where 
amputation is not desired or is unfeasible (30, 31).  In some cases, radiation therapy is 
used as a palliative treatment but shows limited benefit as a curative agent (32-36).   
 Several prognostic factors have been identified in canine OSA.  One of the 
strongest predictors of outcome is the presence of clinically detectable metastases at 
diagnosis:  although pulmonary metastasectomy has been described in a number of 
canine patients, it is not frequently pursued and does not always confer prolonged 
survival (9, 37).  Time to development of lung metastases and the number of pulmonary 
metastases developed have also been identified as prognostic factors as have serum 
alkaline phosphatase levels (ALP) and histological grade (22, 38, 39).  Humeral location 
and large tumor size have been related to a negative outcome (3, 9, 27, 40, 41).  Lymph 
node metastases are notably rare in OSA but their presence has been identified as a 
negative prognostic indicator (22, 42).  Furthermore, microvascular density of the tumor 
may serve some prognostic function, as tumors with very high microvascular density 
have demonstrated a shorter time to metastases (43).  Finally, recent work indicates that 
elevated pre-treatment monocyte and lymphocyte counts, albeit still within normal 
ranges, are associated with shorter disease-free intervals (DFI) (44).   
 4
 Long term disease-free survival is influenced by treatment protocols as well as 
other prognostic factors noted above.  Amputation alone has demonstrated a median 
survival time of less than 20 weeks although it can be considered a palliative treatment 
when owners do not wish to pursue chemotherapy.  The vast majority of patients treated 
with amputation alone are euthanized within a year due to metastatic disease (19).  The 
addition of systemic adjuvant chemotherapy to treatment protocols increases median 
survival to 10-11 months with some patients surviving disease-free for well over a year 
(27, 29, 45-50).  In dogs that present with clinically detectable metastases, survival time 
is dramatically shortened (days to weeks) but the addition of chemotherapy and palliative 
radiation to treatment protocols nonetheless improves survival (51).  Limb sparing 
techniques have introduced an interesting twist to patient survival as it appears that 
localized infection around the surgical site may actually prolong time to metastasis (52-
54).  Unfortunately, despite these advances, one-year survival is only 30% (55, 56). 
 
Comparative Oncology:  Canine Osteosarcoma as a Model for Human Osteosarcoma 
 Canine OSA is an exemplary model for the same disease in humans (1, 4, 57, 58).  
Not only do dogs share an environment with their human companions, the tumor lesions 
are also virtually identical:  they occur in the same locations, present the same 
histologies, and primarily metastasize to the same organ (59).  Many of the above-noted 
prognostic factors in dogs are also shared by human patients (60).  Furthermore, greater 
than 10 times more canine patients present for OSA annually than human patients (61), 
dramatically increasing the potential study pool.  Unfortunately, survival following 
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treatment is equivalently poor in human patients with a 5-year survival rate of 60% and 
only 15% for patients who present with metastatic disease (57). 
 Perhaps the greatest value of the canine model is that these tumors are 
spontaneous and not the result of laboratory-induced chromosomal aberrations or gene 
mutations (57-59, 62).  A number of mouse models of OSA exist but these have been 
induced in controlled experiments and do not represent the genetic diversity in humans or 
even the relatively inbred canine population (63-66).  The somewhat inbred nature of the 
pet dog population, however, is beneficial in that this limited genetic variance can aid in 
identifying genetic markers of disease or progression that may otherwise be masked in 
the more-diverse human population (67, 68).  Indeed, canine OSA studies have identified 
breed-specific genetic factors that may predispose to OSA and/or influence prognosis.  
For instance, a recent comparison of OSA cytogenetic aberrations between Golden 
Retrievers and Rottweilers revealed that there was a strong influence of genetic 
background on resulting tumor karyotypes (68).  Additionallly, heritability of an OSA-
predisposing phenotype in Scottish Deerhounds was determined to have a Mendelian 
dominant effect (69).  Thus, identification of causative factors in this inbred population 
may help identify previously unknown or cloaked factors in the human disease.   
 Additional benefits of dogs as a model system include a relatively large body size 
and similar metabolic rate to humans that allow more-direct translation of treatment 
protocols between species; also, dogs' faster disease progression allows for shorter study 
periods to assess clinical outcomes (21).  In fact, clinical trials in dogs with OSA have 
successfully translated into the human population:  muramyl tripeptide (MTP) increased 
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survival time in canine OSA patients and, similarly, increased time to relapse in humans 
with OSA (70-72) 
 Treatments between canine and human patients are quite similar with tumor 
removal and adjuvant chemotherapy as the primary treatment protocols (9, 21, 58).  
However, human patients tend to receive a wider selection of chemotherapy protocols 
and also often receive neoadjuvant chemotherapy to de-bulk the tumor prior to surgery 
(57, 73-75).  While this latter strategy is successful as a treatment option, it reduces 
scientific value of tumor tissue removed at the time of surgery as gene expression 
signatures are dramatically altered by exposure to these drugs.  In this sense, canine 
tumors that were naïve to chemotherapy at the time of amputation provide an excellent 
resource for discovery of OSA biomarkers and novel treatment targets that may well 
translate across species. 
 The greatest difference between OSA in dogs and humans is that appendicular 
OSA primarily affects human adolescents whereas the majority of canine patients are 
middle-aged or older (21, 57, 76).  Despite this, faster growing children are most prone to 
developing the disease and this seems a relevant link to the large-breed tendency toward 
developing OSA in canines:  genetic makeup contributing to large size and fast growth 
likely predispose to oncogenic transformation in bone in both systems. 
 Finally, a number of molecular characteristics are shared between canine and 
human OSA (57).  Recent work by Paoloni and colleagues compared gene expression 
signatures of canine and human OSA and normal tissue samples (77).  Hierarchical 
clustering of these gene expression signatures was unable to differentiate between the two 
species on the basis of gene expression.  Furthermore, they identified several progression-
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related genes in canine samples that were verified as prognostic factors in an independent 
human OSA sample set. 
 
Molecular Pathogenesis of Osteosarcoma 
 There is no known etiology for OSA in either dogs or humans but a number of 
molecular contributing factors have been identified in recent years.  The most common 
chromosomal aberration observed in OSA is aneuploidy, however, hallmark 
translocations like those observed in a number of sarcomas have not been identified in 
OSA (78).  With regard to gene expression signatures, the most common unifying factor 
in both human and canine OSA is that there is no unifying factor:  dysregulation of many 
genes has been observed but they are not consistent among individuals (21). 
 Several human disease syndromes predispose patients to developing OSA and 
mutations in the contributing genes have been studied extensively in canine and non-
syndrome-related human OSA.  In humans with hereditary retinoblastoma, mutations of 
the tumor suppressor gene RB1 lead to childhood retinoblastoma as well as secondary 
tumors including OSA (79-83).  This pathway is also often dysregulated in canine OSA 
cell lines and human patients without germ-line mutations, indicating that spontaneous 
mutation of the gene may promote osteosarcomagenesis (84-86).  Interestingly, however, 
in a study of 21 canine primary tumors, altered expression of the RB1 gene was not 
observed (87).  Whether or not functional RB1 protein confers any survival advantage to 
OSA patients is unclear as studies have found dissimilar results in different patient 
populations (84, 86, 88).   
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 Similarly, in Li-Fraumeni syndrome, TP53 mutations are inherited and predispose 
patients to a number of tumors, often OSA (89-92).  TP53 is a pro-apoptotic tumor 
suppressor gene that demonstrates dominant negative behavior when mutated in the 
DNA-binding domain, effectively inhibiting wild-type TP53 from activating target genes 
(93).  As TP53 is involved in a negative feedback loop governing its own expression, 
these dominant negative mutations lead to excessive buildup of TP53 protein in the cell; 
this mechanism is commonly observed in tumors via immunohistochemistry (IHC) (94).  
Additionally, TP53 expression can be ablated by a number of large-scale mutations, 
including rearrangement of intron 1 which has been observed in several human OSA cell 
lines (95, 96).  Beyond Li-Fraumeni syndrome, aberrant TP53 expression is observed in 
many canine and human OSA tumors from patients without germ-line mutations, 
suggesting a possible role for this gene in tumorigenesis and/or progression (85, 87, 97-
102).  In one study of 24 primary canine OSAs with TP53 mutations, these mutations 
correlated significantly with decreased survival time following surgery (103).  
Furthermore, a study of 167 canine osseous tumors found that, of all subtypes, OSAs 
expressed more TP53 protein than any others and that TP53 overexpression in OSA 
correlated with breed predisposition for development of the disease (104).  In a number 
of human OSA studies, however, TP53 expression has not been correlated with clinical 
outcome (100-102).  It is also important to note that TP53 mutations, like RB1 mutations, 
while found in a number of OSA samples, are by no means necessary to induce disease or 
metastasis (105). 
 Rothmund-Thomson syndrome (RTS) has also been identified as predisposing to 
OSA in human patients but only in the subset of patients with mutations in the DNA 
 9
helicase RecQ protein-like 4 (RECQL4) (106).  In a population of 33 RTS patients, 29 
RECQL4 sequence-effecting mutations were observed and eleven of these patients 
developed OSA (107).  In a study addressing the frequency of RECQL4 mutations in 
spontaneous non-RTS-related OSAs, however, no mutations in this gene were observed 
other than a small number of SNPs that were also present in normal tissue (108).  Werner 
syndrome is another cancer predisposition syndrome caused by helicase dysfunction:  
Werner Syndrome, RecQ helicase-like (WRN/RECQL2) is the culprit in this case.  A 
smaller percentage of these patients develop OSA than RTS patients, but OSA is, 
nonetheless, more prevalent in this group than in the population at large (109, 110).  The 
WRN gene shares functionality with the Bloom syndrome, RecQ helicase-like 
(BLM/RECQL3) gene, another gene mutated in the cancer-predisposing Bloom syndrome 
(BS) (111, 112).  As the primary role of these three helicase genes is maintenance of 
genomic stability, it logically follows that loss of function mutations would lead to 
genomic instability, increased genomic mutation rates and a higher likelihood of cancer.  
Additionally, both the BLM and WRN helicases have been shown to physically interact 
with TP53 and support its role in apoptosis (113-115).  Thus, disruption in these genes 
not only encourages genetic mutation but inhibits appropriate cellular response to 
mutation and DNA breaks.  While patients harboring loss-of-function mutations in the 
RECQ genes are prone to developing OSA, spontaneous mutations do not appear to be 
major contributing factors to osteosarcomagenesis in the general population (61, 78).   
 In addition to these human mutation syndromes, a number of individual gene 
mutations have been identified as contributing to osteosarcomagenesis.  Many of these 
genes are involved with the TP53 or RB1 pathways in one way or another, suggesting 
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that dysregulation of these tumor suppressor pathways is an important step in 
tumorigenesis (78).  For example, the INK4A locus on human chromosome 9p21 encodes 
two gene products crucial to regulation of both the TP53 and RB1 pathways.  The larger 
gene product, Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A/p16INK4A), affects 
RB1 expression via modulation of Cyclin D and is often suppressed in OSA either by 
locus deletion or other mechanisms (116-118).  CDKN2A also suppresses expression of 
Cyclin-Dependent Kinase 4 (CDK4) in a healthy cell.  In cases of OSA where neither the 
RB1 gene nor the CDKN2A gene are mutated, amplification or over-expression of the 
CDK4 gene has been observed, identifying an additional point for dysregulation in this 
pathway (84, 119).  Similarly, in canine OSA cell lines, dysregulation in CDKN2A has 
been observed in cells with low levels of the RB1 protein (85).   
 An alternate gene product from the INK4A locus, p14ARF, stabilizes TP53 by 
direct binding as well as down-regulation of Mouse Double Minute 2 (MDM2), a protein 
that promotes degradation of TP53 (120, 121).  An inverse correlation between wild type 
TP53 expression and p14ARF expression has been observed in OSA indicating that 
downstream targets of the TP53 pathway can be effectively dysregulated by p14ARF loss 
even when normal TP53 functionality is present (122).  Similarly, MDM2 amplification 
has been demonstrated in OSA resulting in rapid and inappropriate degradation of the 
TP53 gene product and dysregulation of downstream targets (123, 124).  Interestingly, 
MDM2 and CDK4 localize to Hsa 12q15 and 12q13, respectively; amplification of this 
entire region is not uncommon in OSA and leads to dysregulation of both TP53 and RB1 
pathways via degradation of TP53 and overexpression of a downstream RB1 target (125, 
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126).  Similarly, the COPS3 gene, overexpression of which results in TP53 degradation, 
has been identified as being overexpressed in OSA (127). 
 The v-Myc Myelocytomatosis Viral Oncogene Homolog (MYC) and the related 
neuroblastoma-derived v-Myc Myelocytomatosis Viral Related Oncogene (MYCN) have 
both been identified as oncogenes that can be overexpressed in OSA (100, 128-130).  
Additionally MYC expression has been associated with methotrexate and cisplatin 
resistance in OSA (131, 132) and mouse models of MYC alteration have demonstrated 
that reduction of MYC expression can cause tumor regression (133).  A number of other 
genes that interact with the MYC genes have been identified as being dysregulated in 
OSA.  Platelet-Derived Growth Factor (PDGF-β), Insulin-Like Growth Factor II mRNA 
Binding Protein I (IGF2BP1) and N-MYC Downstream Regulated Gene 2 (NDRG2) are 
three notable cases.  PDGF has been shown to activate MYC transcription and in at least 
one OSA cell line, overexpression of this mRNA is coincident with MYC overexpression 
(134).  IGF2BP1 is also known as CRD-BP for its role in binding to the coding region 
determinant portion of MYC mRNA and stabilizing the transcript, effectively increasing 
its translatability (129, 135).  MYC directly binds to the NDRG2 promoter and suppresses 
the transcription of this putative tumor suppressor gene (136).  Additionally, genes 
discussed above in the context of their involvement with TP53 and RB1 such as 
p16INK4A, p14ARF and MDM2 have also been found to modulate MYC activity, 
emphasizing the entwined nature of many of these pathways (137-141).   
 Several other oncogenes have been identified as being overexpressed in OSA, 
including FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) (100, 130), v-erb-
b2 Erythroblastic Leukemia Viral Oncogene Homolog 2 (ERBB2/HER-2) (142, 143), and 
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Glioma-Associated Oncogene Family Zinc Finger 1 (GLI1) (144, 145).  Interestingly, 
GLI1 localizes to Hsa 12q13-14, the same region occupied by CDK4, MDM2 and 
Tetraspanin 31 (TSPAN31).  TSPAN31, also called "sarcoma associated sequence" has 
been found to be amplifed in OSA, often concurrently with other genes in this region 
(126).  Thus, this region may be a hotspot for osteosarcomagenesis with a single 
chromosomal amplification being able to simultaneously induce GLI1 expression, 
suppress RB1 expression and degrade TP53 protein.  GLI1 is part of the hedgehog (HH) 
signaling pathway, a pathway that plays a major role in bone development and 
dysregulation of which has been implicated in the proliferation of OSA cells (146-148).  
Ligands for the pathway, Sonic Hedgehog (SHH), Desert Hedgehog (DHH) and Indian 
Hedgehog (IHH) bind to the Patched receptor (PTCH).  Upon binding, Smoothened 
(SMO) is de-repressed and activates downstream transcription factors GLI1 and GLI2.  
This cascade carries on to regulate cell-cycle control mechanisms including Cyclins and 
MYC (149).  Inhibition of the HH pathway has reduced proliferation in OSA models 
(150). 
 As OSA is a tumor of bone, it naturally follows that expression of bone 
development factors is often abnormal.  The role of genes such as Runt Related 
Transcription Factor 2 (RUNX2) and Osterix (OSX/SP7) in osteosarcomagenesis has been 
investigated but is still unclear.  RUNX2 is modulated by RB1 interaction and exerts 
transcriptional control over bone-specific genes including Osteocalcin and Alkaline 
Phosphatase (151, 152).  The end results of RUNX2 overexpression, however, are 
contradictory:  in some cases it mediates apoptosis and prevents transformation (153, 
154) whereas, in others, it appears to be pro-proliferative and pro-transformation (155-
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158).  OSX is a downstream target of RUNX2 and so it is not surprising that the role of 
this gene has been equally confounding.  OSX expression inhibited tumor growth and 
metastasis in one murine OSA model (159) yet enhanced proliferation in a different 
model (160).  Thus, it has been suggested that cellular context may dictate whether 
RUNX2 and OSX are pro- or anti-tumorigenic (61).   
 Tumors essentially begin as excessive tissue growth diseases; thus, the expression 
of growth factors and their receptors has been an attractive line of investigation in OSA.  
Insulin-Like Growth Factor I (IGF1) was found to be a potent mitogen in the human OSA 
cell line MG-63 indicating that some tumors may be inhibited by blockade of this 
pathway (161).  This responsiveness is likely due to the frequent overexpression of the 
IGF1 Receptor (IGF1R) in OSA; numerous antibodies and small-molecule inhibitors 
have been generated to inactivate this receptor and are in clinical trials (162-166).  
Similarly, dysregulation in Vascular Endothelial Growth Factor Receptor (VEGFR), 
Platelet Derived Growth Factor Receptor (PDGFR), Epidermal Growth Factor Receptor 
(EGFR), Fibroblast Growth Factor Receptor (FGFR2), Met Proto-Oncogene (MET) and 
their ligands have all been observed in OSA (162, 167-175).  Due to the redundancy of 
many of these growth factors, it has been suggested that the expression of these pathways 
in OSA represent bystander effects as opposed to bona fide requirements for tumor 
establishment and progression (78).   
 In conclusion, TP53 and RB1 pathways as well as growth factor signaling 
disruptions are, undoubtedly, large contributors to tumor growth and evasion of apoptosis 
in this system.  Genome-wide studies have identified countless additional molecules that 
may be involved in osteosarcomagenesis that, as yet, have received only limited study.  
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With regard to patient treatment and survival, however, discovering mechanisms of 
tumorigenesis in this disease is of less immediate importance than determining how and 
why these tumors metastasize and developing effective treatments to counter this next 
stage of OSA progression. 
 
Metastasis 
 The term metastasis describes both the process by which tumor cells become 
established in a distant organ as well as the resulting lesion.  The development of 
metastasis is, essentially, a bipartite process in which cells from the primary tumor must 
first escape the tissue of origin then become established in a new and, presumably, hostile 
tissue.  This process is of such great import to cancer that it is considered one of the 
"hallmarks of cancer" (176, 177).  Indeed, as noted previously, failure to control 
metastatic disease is the primary cause of morbidity and mortality in OSA patients. 
 As malignant tumors grow, they also invade surrounding tissue, the first step in 
the metastatic cascade (176, 178).  Tumor cells and associated stromal components break 
down extracellular matrix in neighboring tissue by expressing matrix metallopeptidases 
(MMPs) and by altering intercellular interactions (179-181).  In a number of different 
tumor types, expression of MMPs has demonstrated prognostic significance:  tumors with 
the highest MMP levels show the most evidence of metastasis (182-184).  MMPs have 
also been identified as contributing to OSA invasion and metastasis:  MMP-1, 2 and 9 
have all been known to be expressed in these tumors (185, 186).  Until recently, it was 
presumed that a small population of metastatic subclones arose within a tumor then 
escaped to form metastases.  While this is still accepted to a degree, the permissive nature 
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of the tumor microenvironment has received increasing interest in recent years.  Were 
metastasis due to only a small population of metastatic subclones, the gene expression 
differences of this group should not be apparent on large scale genomic studies.  
However, the seminal work of van de Vijver and colleagues, in which they analyzed 
almost 300 primary breast carcinomas, demonstrated that gene expression signatures 
differ between patients depending on prognosis and time to metastasis (187).  Similarly, 
in a murine OSA model, gene expression signatures differed between highly metastatic 
and less aggressive tumor types (188).  These studies and others provided strong evidence 
that more-aggressive tumors have different phenotypes in both tumor cells and stroma 
compared to their less-aggressive counterparts.  
 Tumor cells that escape the primary tumor utilize blood or lymphatic vessels to 
travel to distant sites.  Tumors have been described as highly vascular entities, indeed, 
were they to rely on existing vascular supply, their size would be dramatically limited 
(189).  Thus, tumors utilize a variety of mechanisms to attract or grow new vessels 
termed neovasculature.  Some neovasculature is formed by "sprouting" angiogenesis, a 
process in which an existing blood vessel receives extracellular signals that induce the 
sprouting off of new vessels.  The subsequent coalescing endothelial cells polarize 
toward the initiating signal, often FGF and/or VEGF, form a lumen, and provide new 
blood supply to the target region (190).  Intussusceptive angiogenesis is a process by 
which existing vessels are rapidly multiplied:  endothelial cells expand to form a pillar 
inside the lumen which then divides the resulting two vessels from each other (191).  This 
form of angiogenesis has concerned cancer researchers as it is unlikely that anti-
angiogenic agents will be effective against this process simply because the endothelial 
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cells are not dividing (190).  Thus, it may serve as a means for tumors to develop 
resistance to anti-angiogenic drugs.   
 Endothelial progenitor cells (EPC) are a relatively new topic of study but it has 
been determined that this population can be recruited from the bone marrow to form 
vessels de novo (190, 192).  Angiogenic signaling molecules such as VEGF mobilize 
these EPCs and direct them to sites of tissue damage, ischemia or growing tumor lesions 
(193).  Furthermore, EPCs may secrete additional angiogenic factors themselves, 
exponentially amplifying recruitment signals (192).  Due to this positive feedback loop, 
inhibition of EPC recruitment by tumors may be highly beneficial to tumor and 
metastasis control.  Vessel co-option is the term used to describe tumor expansion 
specifically around existing blood vessels (190).  In several tumor types, especially those 
in highly vascular tissue, the initial avascular tumor mass contacts and travels along 
vessels in lieu of secreting angiogenic factors to develop neovasculature (194, 195).  As 
tumor size increases, it may outstrip the original blood supply and begin to secrete pro-
angiogenic factors (196).  It has been determined that VEGF is also a player in this 
process as are angiopoietins, thus, VEGF inhibition could successfully target many types 
of neovasculogenesis (196, 197). 
 The process of vasculogenic mimicry was first identified in highly aggressive 
melanoma cells but has been since noted in many tumor types (190, 198).  This 
phenomenon occurs when tumor cells begin expressing endothelial cell markers and 
organize into luminal structures that can convey fluids.  There is evidence that this occurs 
in OSA and is mediated by VE-cadherin and VEGF among other factors (199, 200).  VE-
cadherin is an endothelial-specific cell adhesion molecule whose activation in tumor cells 
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appears to be necessary for vascular mimicry (201).  Additionally, siRNA mediated 
knockdown of VEGF inhibited vascular mimicry in OSA cells:  whether this was due to 
downstream VE-cadherin signaling or different pathway effects is unclear (199).  Tumor 
cells that take part in this mimicry have undergone a dramatic phenotypic switch from the 
source tissue and, thus, pose a challenge to researchers seeking to undermine 
angiogenesis in tumors.  The lymphatic route of metastasis and lymphangiogenesis is 
important in a number of cancers (e.g. breast cancer) but seems to be of less relevance in 
OSA considering the remarkable rarity of associated lymph node metastases. 
 Once tumor cells manage to escape the primary tumor and enter the vascular 
system, they must exit the circulation and take up residence in a new tissue to form a 
metastasis.  Not all tumors form macroscopic metastases and some metastases do not 
become macroscopic until after the primary tumor is excised (202).  In OSA, however, up 
to 15% of patients present with macrometastases at the time of diagnosis indicating that 
primary tumors don't necessarily suppress metastasis growth while in situ as has been 
observed in other cancer types (202).  Tumor metastases generally demonstrate a 
preference for which distant tissue they will arise in (203).  It has been postulated that 
some tissues or niches in a given tissue provide an accommodating environment and 
metastases will undergo fewer selection pressures should the initiating cells terminate 
their migration there (204).  This "seed and soil" hypothesis has been argued extensively 
and is often invoked to explain why metastases occur in regions that are not the first 
major capillary bed encountered by circulating tumor cells (176, 205).  However, what is 
currently unclear is whether cells in the primary tumor evolve mechanisms that will 
support colonization of distant sites or if selection pressures in those distance sites induce 
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changes in metastatic cells when they arrive.  It is likely a combination of both scenarios 
that leads to only a small proportion of circulating tumor cells surviving the initial 
encounter with foreign tissue then, over time, adapting to that tissue (176).   
 A number of large-scale genomic studies comparing gene expression in 
metastases to primary tumors have been performed and some have identified genes that 
play a role in establishing metastases at distant sites.  For instance, the cytoskeletal linker 
protein Ezrin promotes establishment of metastasis in OSA by conferring a survival 
advantage on tumor cells that express it when they reach distant sites.  Suppression of 
Ezrin expression dramatically reduced survival of tumor cells in non-osteoid tissues 
(206).  Similarly, β4-Integrin is upregulated in highly metastatic OSA cells and interacts 
with Ezrin, filling a pro-metastatic role (207).  Additionally, the NOTCH signaling 
pathway and associated microRNAs have been linked with OSA metastasis success in 
distant tissues (208).  Conversely, Fas expression has been inversely correlated to 
metastatic potential of OSA cells (209).  Surface expression of Fas on OSA cells that 
have entered lung tissue leads to apoptosis induction; thus, Fas-negative cells receive 
positive selective pressures in the lungs and the resulting lesions express significantly less 
Fas than primary tumors.  This phenomenon has been observed in human OSA, canine 
OSA and mouse models of the disease (210-213).   For many targets identified by new 
large genomic studies, the stage of metastasis that is promoted by a given target is not 
immediately apparent.  Thus, at this time, elucidating the precise roles of differentially 





Tools for Identification of Molecular Contributors to Carcinogenesis and Metastasis 
 Computer processing power and associated genome/transcriptome analysis 
technologies have grown by leaps and bounds since the Human Genome Project was first 
initiated in 1989 and since the human genome was published in 2001 (214).  
Consequently, researchers are now able to generate and analyze vast data sets in order to 
identify dysregulated genes and pathways in cancer. 
 Microarray technology was adapted from Southern blotting as a means to probe 
many oligonucleotide sequences on a solid scaffold (215).  It has been applied to a 
number of different uses, one of which probes mRNA sequences.  Since the early years 
of development, millions of expressed sequence tags (ESTs) for a variety of species have 
been published; thus, current expression arrays probe in excess of 40,000 gene tags in a 
given species (216).  These expression arrays allow broad assessment of global 
expression patterns in tumors and serve as excellent survey tools for discovering new 
markers of disease.  Similarly, this technology has also been applied to expression 
analysis of microRNAs (217).  Microarrays have also been used for comparative genomic 
hybridization (CGH), a technique that probes copy number of loci in genomic DNA 
(218).  This technology is especially useful in cancer profiling to assess amplification and 
deletion status of chromosomal regions.  Fluorescence in situ hybridization (FISH) can 
serve the same purpose but requires the user to focus on specific target regions of 
chromosomes as opposed to surveying the entire genome (218).  The latest development 
in genome and transcriptome analysis is deep sequencing.  This technology provides not 
only sequence data but also copy number analysis for gDNA, mRNA, microRNA and/or 
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any other oligonucleotide of interest (219).  This data-intensive methodology is already 
challenging microarray dominance of the field and will likely replace microarray 
technology when costs become similar (220).   
 With these data-intensive technologies, data management and interpretation 
becomes challenging.  Expression microarrays are pre-processed with a variety of 
algorithms prior to analysis to normalize the data.  These algorithms differ from each 
other in the linearity of variance relative to expression as well as absolute expression 
values (221).  Resulting pre-processed data can differ greatly across algorithms (222).  
Furthermore, microarray chips can possess physical flaws that are not immediately 
apparent yet compromise portions of data (223).  Thus, it is standard practice to validate 
microarray expression of individual biomarkers with reverse transcription quantitative 
polymerase chain reaction (qRT-PCR) (224).  Deep sequencing removes some of these 
unknown variables by generating such a huge volume of data that small errors are 
outweighed.  Beyond identification of individual factors related to disease and 
progression, microarray or deep sequencing data can be processed with gene association 
algorithms (e.g. Ingenuity, GeneGo) to identify dysregulated pathways (223).  This 
pathway analysis supersedes error caused by chip flaws or algorithm differences as 
pathways must possess multiple dysregulated genes to cross significance thresholds. 
 High throughput proteome analyses have also been devised, for instance matrix-
assisted laser desorption ionization-time-of-flight-mass spectrometry (MALDI-TOF-MS) 
following 2-dimensional gel electrophoresis has been used to identify differentially 
regulated proteins in canine mammary carcinoma (225).  This technology can also be 
used to analyze post translational modifications of proteins including phosphorylation, 
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ubiquitination and acetylation among others (226).  Beyond the new high-throughput 
methodologies, older standard molecular biology techniques are still very much in use, 
especially for researchers seeking to go beyond identification of gene dysregulation and 
investigate the functional roles of gene products.  
 
Molecular Mechanisms of Gene Regulation 
 Following identification of dysregulated genes or pathways in cancer, researchers 
must determine the mechanism underlying this dysregulation for effective therapeutic 
targeting of the gene products.  Genes and their mRNA and protein products are 
regulated at many levels; this complexity adds to the difficulty of devising treatments but 
also provides the opportunity to design more-targeted therapies with potentially fewer 
side effects. 
 Chromosomal aberrations are a frequent cause of gene dysregulation in many 
different types of cancer.  This category includes locus amplification and deletion as well 
as translocations.  In locus amplification, a region of a chromosome is preferentially 
copied excessively; this mechanism has been observed to cause amplification of the 
ERBB2 and MYCN genes in breast cancer and neuroblastoma, respectively (227, 228).   
Locus deletion occurs when regions of chromosomes are lost due to breakage or failed 
crossover events.  If these regions contain tumor suppressor genes, the result can be 
malignant transformation.  One such example is the CDKN2A region:  it is frequently 
homozygously deleted in both OSA and the related Ewing sarcoma (117, 229, 230).  
Translocations occur when a piece of chromosome is traded between two non-
homologous chromosomes resulting in fusion genes.  This often puts an oncogene under 
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the translational control of a highly active, unrelated promoter (e.g MYC-Ig translocation 
in Burkitt's lymphoma and bcr-abl in leukemias) (94).  This has been observed in a 
number of tumor types but is not a typical cause of OSA.  
 In order for transcription of DNA to proceed at an optimal rate, transcription 
factors must assemble on the promoter regions of genes.  Transcription factor binding site 
mutations as well as mutations in the transcription factors themselves can cause a gene to 
be silenced or constitutively activated.  Silencing of a tumor suppressor gene via 
promoter mutations can have devastating effects.  For example, at least two germ line 
mutations in the RB1 promoter have been identified that inhibit binding of transcription 
factors and effectively silence the gene; these mutations were identified in retinoblastoma 
familial clusters (231).  Similarly, RB1 binds to the MYC oncogene promoter and 
suppresses transcription.  Mutation in the RB1 binding domain, the MYC promoter 
binding site, or overall suppression of RB1 protein can lead to overexpression of the 
oncogene product (232).  The tumor suppressor TP53 forms homodimers and 
homotetramers and acts as a transcriptional transactivator (94, 233).  Mutation in the 
DNA binding domain of even one allele of this gene has a dominant negative effect 
because much of the wild type protein will be dimerized with mutant protein.  This 
results in the failure of TP53 to transactivate targets involved in apoptosis and subsequent 
apoptotic escape by mutant cells (233). 
 Aberrant control of the epigenetic complement of genes is observed in many 
different tumor types and leads to dysregulation of involved genes without the need for  
mutations (234).  Methylation of CpG islands, especially in the promoter region of genes, 
is a normal mechanism of cellular control of transcription:  high levels of methylation 
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effectively silence nearby genes.  Hyper- and hypo-methylation of genes has been 
observed in a number of different tumor types and is directly related to repression of 
tumor suppressor genes and release of oncogene or mitogen expression.  For instance, the 
Insulin-Like Growth Factor II (IGF2) locus is imprinted in normal cells - one copy of the 
gene is naturally silenced by methylation.  In OSA, however, it has been observed that 
the IGF2 locus can undergo loss of imprinting, releasing the second allele from 
suppression and initiating expression of this mitogen from both alleles (235).  On the 
opposite end of the spectrum, the gene Wnt Inhibitory Factor 1 (WIF1) is often 
downregulated in OSA by hypermethylation; this blockade releases downstream targets 
promoting tumorigenesis and metastasis (236).  Similar gene effects can be caused by 
histone acetylation or lack thereof.  Acetylation of histones by histone acetyltransferases 
(HATs) opens up chromatin structure to make DNA more accessible to transcription 
machinery and transcription factors.  Histone Deacetylases (HDACs) perform the 
opposite function, removing acetyl groups and rendering DNA less accessible and 
thereby less transcribed (237).  Several drugs targeting HDACs have been applied to anti-
cancer treatments with the intent of inhibiting deacetylation of tumor suppressor type 
genes.  One such drug, valproic acid, has been found to sensitize both human and canine 
OSA cells to doxorubicin chemotherapy indicating that a gene or genes that promote cell 
death in response to doxorubicin are suppressed by deacetylation of regional histones 
(238).  
 This discussion, thus far, has focused on DNA, however, a number of post-
transcriptional and post-translational disruptions also contribute to tumorigenesis and 
progression.  The relatively new field of microRNA study has yielded much insight into 
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the post-transcriptional control of mRNA transcripts (239, 240).  MicroRNAs are small, 
non-coding RNA sequences that can act as tumor suppressors or oncogenes depending on 
which transcripts they target.  In these targets, they can effect translational repression and 
mRNA degradation, effectively limiting the amount of protein generated from a given 
transcript (241).  Expression of microRNAs is partially controlled by epigenetic factors 
which adds an additional layer of complexity to any strategy aimed at targeting them 
(242).  In OSA, a number of microRNA-transcript interactions have been identified that 
either promote or inhibit tumor growth.  For instance, in U2OS cells, microRNA-31 was 
able to inhibit proliferation and promote apoptosis in the face of a defective TP53 
pathway (243).  Conversely the "oncomiR" microRNA-21 is overexpressed in OSA 
tissues and cell lines; knockdown of this microRNA decreases cell invasion and 
migration (244).  These microRNAs may be under- or overexpressed by any of the 
mechanisms previously discussed for protein-coding genes.  Additionally, cancer cells 
can evade microRNA regulation of transcripts by removing microRNA response 
elements frequently found in the 3' untranslated region (UTR) .  Many genes possess a 
constitutive UTR that is present on all transcripts and a longer UTR that is only present if 
the first poly-adenylation signal in the gene is not used.  Recent studies have found that 
cancer cells tend to have more constitutive UTRs relative to long UTRs; this effectively 
removes microRNA response elements from the RNAs and limits control over translation 
(245). 
 Post-translational protein modification as well as altered control of protein half-
life can also contribute to disruptions in cellular behavior.  One such disruption was 
alluded to previously with regard to MDM2 downregulation of TP53 protein.  MDM2 is 
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a ubiquitin E3 ligase which ubiquitylates TP53 protein, targeting it for degradation, and, 
thus, greatly decreasing its half-life (246).  MMPs are also targeted by post-translational 
mechanisms and their overexpression that contributes to invasion is partially due to 
failures in post-translational balance (247).  Additionally, survey experiments of OSA 
have determined that many proteins are excessively phosphorylated in tumor cells 
suggesting hyperactivity of kinases (248).  One such highly phosphorylated protein is 
RB1:  in a resting cell, it exists in its least phosphorylated form but when cells transition 
to rapid division, it is highly phosphorylated, thus, inappropriate phosphorylation of RB1 
may drive proliferation (249).  In conclusion, genes can be dysregulated at the DNA, 
RNA and protein levels; determining the means of dysregulation is an important step in 
designing targeted therapies that can allow proper cell-control functions to reassert 
themselves in tumor cells. 
 
Chemoresistance:  Mechanisms and Associated Genes 
 Gene dysfunction not only drives tumorigenesis and progression but also provides 
the means for cancer cells to resist chemotherapy.  Treating a patient with 
chemotherapeutic regimens exerts strong selective pressure on tumor cells:  those that 
have activated genes that reduce their susceptibility to drugs will survive treatment and 
continue proliferating while those that have not will die.  Chemoresistance comes in 
many forms, from molecular pumps that remove drugs from cells to impaired DNA 
damage response mechanisms that allow damaged cells to continue dividing.  As 
metastatic disease following systemic chemotherapy is the primary cause of negative 
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outcomes in OSA, it is important to identify chemoresistance mechanisms so that drugs 
can be designed to subvert these mechanisms. 
 Some mechanisms of chemoresistance are likely in place in tumor cells long 
before they ever encounter therapeutic agents.  For instance, evasion of apoptosis is a 
"hallmark of cancer" and derangement in pathways that allow this also contributes to 
chemoresistance (250).  The TP53 pathway is one such apoptotic mechanism and LOH of 
TP53 and related genes has been associated with chemoresistance in OSA (251, 252).  
Similarly, Parathyroid Hormone Related Protein (PTHrP) has been shown to inhibit 
apoptosis in OSA cells by blocking the TP53 pathway as well as mitochondrial apoptosis 
pathways (253).  Finally, dysregulation of microRNAs that target apoptotic pathway 
members has been identified as a mechanism of OSA chemoresistance in several studies 
(254, 255). 
 Decreased membrane permeability to drugs has also been implicated in OSA 
chemoresistance as one study found significantly less drug accumulation in resistant 
murine cell lines (256).  This phenomenon may also be attributable to cellular 
mechanisms that remove drugs from cells such as ABC transporters that confer multi-
drug resistance (257).  Chemoresistance in OSA has been strongly correlated with 
expression of these transporters and inhibition of these genes has been shown to increase 
drug sensitivity (257, 258).  In addition to removing drugs, tumor cells can limit the 
effects of drugs by altering regulation of genes that detoxify them and/or suppress the 
accumulation of reactive oxygen species (ROS).  One such gene, Glutathione S-
Transferase P1 (GSTP1), not only detoxifies drugs but also modulates the expression of 
protein kinases that have been implicated in cell survival following stress (259, 260).  
 27
Overexpression of this gene in OSA has been correlated with chemoresistance and 
knockdown in experimental models has increased sensitivity to both cisplatin and 
doxorubicin (259). 
 Several microarray studies comparing gene expression signatures from 
chemoresistant OSA to chemosensitive OSA have been undertaken in human, canine and 
mouse models (261-266).  Most of these studies, however, are comparing good-responder 
patients to poor-responder patients and, while this inevitably includes chemoresistance as 
a factor, these expression profiles may also include initial tumor aggressiveness that is 
unrelated to chemoresistance.  Thus, it is important to follow up survey studies with work 
examining the genes identified and defining their roles in OSA.  Bruheim and colleagues 
compared gene expression signatures of OSA xenografts based upon their resistance to 
different chemotherapeutic regimens and found a number of genes to be differentially 
regulated between ifosfamide, doxorubicin and cisplatin treatments (261).  Of all the 
survey experiments mentioned here, this study goes furthest toward identifying 
chemoresistance genes that are not necessarily related to tumor aggressiveness.  HDAC 
activity likely leads to suppression of genes that confer chemosensitivity to doxorubicin 
as both human and canine OSA cell lines have been shown to have increased sensitivity 
when pre-treated with the HDACi valproic acid (238).  Follow-up studies by the same 
group have used microarrays to identify which pathways are altered by VPA, increasing 
the body of knowledge regarding gene contributions to chemoresistance (267). 
 Significant progress has been made in identifying genes and pathways that 
contribute to chemoresistance in OSA but more contributors are identified with each new 
related publication.  Mastering the mechanisms that promote chemoresistance and 
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metastasis in this disease and, hence, devising new therapies, can lead to great 
improvements in patient survival. 
 
Project Rationale 
 Osteosarcoma continues to defy medical treatments and, even with state-of-the art 
therapies, causes a high mortality rate in both dogs and humans that develop this cancer.  
At the initiation of this research, there had been several reports of microarray studies of 
gene expression in human OSA but none in dogs despite the much higher incidence rate 
in this species (262-264).  Considering the many similarities between dogs and their 
human companions, we set out to explore gene expression in this model with the aims of 
identifying genes that may provide prognostic information for patients of both species 
and defining new gene targets for drug development.  Thus, we first hypothesized that 
primary tumor gene expression signatures would vary based upon patient outcome.  This 
hypothesis is explored in Chapter 2 (Expression profiling in canine osteosarcoma: 
identification of biomarkers and pathways associated with outcome) where we 
performed microarray analysis of gene expression in two cohorts of dogs:  those that 
responded well to definitive treatment and those that responded poorly.  These two 
cohorts were defined on the basis of disease free interval (DFI) and were straddled 
around the median DFI of 200 days.  Fold change and pathway analyses were used to 
identify genes and pathways that were different between the two cohorts.  Additionally, 
quantitative RT-PCR was performed on select microarray-identified genes to validate the 
microarray data and to generate expression-based classification models.  These models 
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identified several genes that were predictive of outcome in this population and may be 
useful for developing prognostic profiles. 
 Having identified some promising targets in Chapter 2, we next wanted to 
examine gene expression and copy number aberrations in the context of normal tissues.  
As OSA is typically classified as karyotypically chaotic, we hypothesized that copy 
number alterations (CNAs) would be associated with dysregulation of some genes 
important in tumorigenesis and progression.  Additionally, we hypothesized that tumor 
gene expression profiles would differ from normal bone gene expression profiles and 
these differences would provide context for the biomarker identification begun in Chapter 
2.  Chapter 3 (Gaining perspective:  Gene expression analysis of canine 
osteosarcoma in relation to normal bone) explores these hypotheses with expression 
microarrays and array comparative genomic hybridization (aCGH).  We first developed a 
methodology for obtaining high-quality RNA from normal bone samples that were 
obtained from amputees.  Next, expression microarrays were performed on these samples 
and resulting expression profiles were compared to tumor expression profiles from 
Chapter 2.  Over two thousand genes were dysregulated between normal bone and all 
primary tumors, identifying a vast number of tumor-specific genes for future study.  
Additionally, only a subset of biomarkers identified in Chapter 2 were significantly 
dysregulated from normal bone; this allowed us to narrow our pool of genes for 
prognostic use.  Array CGH analysis emphasized the previously-reported chaotic nature 
of OSA karyotypes and identified CNAs that correlated to mRNA expression for several 
genes including MYC and PTEN.   
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 Prior to moving forward with functional investigations of specific genes in in 
vitro models, we first wanted to validate these models for species identity, uniqueness 
and tissue of origin.  Cell line contamination has been acknowledged for decades but only 
recently have funding agencies and publication groups begun requiring cell line 
validation (268, 269).  Additionally, many tools for molecular biology studies are not yet 
available for canine samples so we found it necessary to validate several anti-human 
antibodies for use in dog tissues and cell lines.  As it has been estimated that 18% to 36% 
of all cell lines are contaminated (270), we hypothesized that some proportion of cell 
lines in our facility would be contaminated.  Thus, in Chapter 4 (Validation of in vitro 
models for canine osteosarcoma), we adapted a species-specific PCR to test cell lines 
for species identity and applied a commercially available short tandem repeat (STR) 
genotyping kit to canine cell lines to determine if they were derived from different 
individuals.  Both contamination and genetic drift were detected in these studies, 
emphasizing the need for good cell culture practices.  Additionally, we performed 
quantitative RT-PCR on presumed OSA derived cell lines to evaluate expression of the 
OSA marker RUNX2.  Furthermore, we successfully validated anti-human antibodies for 
use in future canine studies. 
 Having verified that the seven available canine OSA cell lines were, indeed, 
canine, OSA and derived from different individuals, we next pursued functional studies 
of two genes identified in Chapters 2 and 3:  IGF2BP1 and NDRG2.  The first, IGF2BP1, 
has been identified as an oncofetal gene in several tumor systems and was overexpressed 
in poor responder tumors relative to good responder tumors.  It was also overexpresssed 
in all tumors relative to normal bone, suggesting a stepwise upregulation of this gene 
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with increasing tumor aggressiveness.  Thus, we hypothesized that IGF2BP1 expression 
would be increased in tumors relative to paired normal bone samples and that inhibition 
of this transcript in in vitro systems would alter indices of tumor aggressiveness.  
Chapter 5 (Overexpression of the oncofetal protein IGF2BP1 contributes to an 
invasive phenotype in canine osteosarcoma) explores mRNA and protein expression of 
IGF2BP1 via qRT-PCR, western blot and immunohistochemistry (IHC) in primary 
tumors, normal bone and canine OSA cell lines as well as the outcome of expression 
modification in vitro.  Findings indicate that only a subset of primary tumors overexpress 
IGF2BP1 and that IHC staining of primary tumor tissue does not correlate with outcome.  
However, in vitro, siRNA mediated knockdown of IGF2BP1 transcript reduced invasion 
in OSA cells.  Additionally, no CNAs were found to be associated with altered gene 
expression for IGF2BP1 but 3' untranslated region shortening correlated with outcome in 
good and poor responder cohort samples, identifying one method by which this gene may 
escape regulation in OSA. 
 NDRG2 was identified in Chapters 2 and 3 as a gene whose expression was 
suppressed in a progressive fashion with highest expression in normal bone and least 
expression in poor-responder primary tumors.  Very little is known about the structure 
and function of the protein product(s) of this gene but it has been identified as a putative 
tumor suppressor in several cancer types.  Thus, we set out to explore the expression 
profile of this gene in cell lines as well as tumor and tissue samples and hypothesized that 
suppression of this gene in OSA contributes to tumor aggressiveness.  Chapter 6 (The 
putative tumor suppressor gene, NDRG2, contributes to doxorubicin resistance in 
canine osteosarcoma) explores this hypothesis via analyzing mRNA and protein 
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expression of NDRG2 in tissues and cell lines as well as determining the functional 
outcome of restoring expression of this gene in an in vitro model.  We identified two 
expressed isoforms of NDRG2 in canine samples and, although isoform expression did 
not correlate with outcome, exogenous expression of these isoforms in the in vitro model 
altered cellular chemoresistance.  Additionally we determined that, in this system, 
NDRG2 expression positively correlates with bone morphogenetic protein 4 (BMP4) 
expression in cells expressing exogenous transcript.  Seeking to determine the means of 
NDRG2 (dys)regulation in OSA, we analyzed MYC transcript expression, CNAs and cell 
response to the demethylating agent 5-azacytidine.  Thus, we determined that NDRG2 
regulation is multifactorial and may be determined by a combination of MYC-based 
suppression, copy number loss and hypermethylation. 
 The primary overarching goal of this dissertation was to identify new gene targets 
in OSA that contribute to disease progression and/or chemoresistance.  To reach this 
goal, we utilized an inverse pyramid methodology, starting with broad whole-genome 
and transcriptome studies.  Results from these studies were exhaustively analyzed to 
identify a smaller pool of genes for further study.  Characterization and functional 
analyses of two of these genes were then pursued to better define their roles in OSA, 
potentially laying the groundwork for development of targeted therapies in the future. 
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Background:  Osteosarcoma (OSA) spontaneously arises in the appendicular skeleton of 
large breed dogs and shares many physiological and molecular biological characteristics 
with human OSA. The standard treatment for OSA in both species is amputation or limb-
sparing surgery, followed by chemotherapy. Unfortunately, OSA is an aggressive cancer 
with a high metastatic rate. Characterization of OSA with regard to its metastatic 
potential and chemotherapeutic resistance will improve both prognostic capabilities and 
treatment modalities.  Methods:  We analyzed archived primary OSA tissue from dogs 
treated with limb amputation followed by doxorubicin or platinum-based drug 
chemotherapy. Samples were selected from two groups:  dogs with disease free intervals 
(DFI) of less than 100 days (n=8) and greater than 300 days (n=7). Gene expression was 
assessed with Affymetrix Canine 2.0 microarrays and analyzed with a two-tailed t-test. A 
subset of genes was confirmed using qRT-PCR and used in classification analysis to 
predict prognosis. Systems-based gene ontology analysis was conducted on genes 
selected using a standard J5 metric. The genes identified using this approach were 
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converted to their human homologues and assigned to functional pathways using the 
GeneGo MetaCore platform.  Results:  Potential biomarkers were identified using gene 
expression microarray analysis and 11 differentially expressed (p<0.05) genes were 
validated with qRT-PCR (n=10/group). Statistical classification models using the qRT-
PCR profiles predicted patient outcomes with 100% accuracy in the training set and up to 
90% accuracy upon stratified cross validation. Pathway analysis revealed alterations in 
pathways associated with oxidative phosphorylation, hedgehog and parathyroid hormone 
signaling, cAMP/Protein Kinase A (PKA) signaling, immune responses, cytoskeletal 
remodeling and focal adhesion.   Conclusions:  This profiling study has identified 
potential new biomarkers to predict patient outcome in OSA and new pathways that may 
be targeted for therapeutic intervention. 
 
INTRODUCTION 
Osteosarcoma (OSA) is the most common malignant primary bone tumor of 
children and accounts for roughly 5% of all childhood cancers in the United States.  
Characteristically, OSA is found in the metaphyseal regions of long bones in the 
appendicular skeleton. More than 15% of patients present with clinically detectable 
pulmonary metastases and it is estimated that 80% or more have micrometastases at 
presentation (1).  Advances in treatment such as multi-agent chemotherapy have 
improved prognosis over the last several decades with five-year survival rates up to 70%.  
Despite these advances, patients that present with metastases or those whose tumors are 
refractory to neoadjuvant chemotherapy continue to have a poor prognosis (1).  This 
suggests that within the same histologic type of tumor, different genetic mechanisms may 
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be operating, altering response to chemotherapy and metastatic capability in some 
tumors. 
Osteosarcoma is also the most common primary bone malignancy in dogs.  The 
majority of these tumors occur in the appendicular skeleton of middle-aged large and 
giant breeds.  Roughly 10,000 new cases of OSA are identified in dogs annually.  
Standard treatment involves amputation or limb-sparing surgery followed by adjuvant 
chemotherapy with doxorubicin, a platinum-based drug, or a combination of the two drug 
types (2).  Median disease-free interval (DFI) following amputation has ranged from 165 
to 470 days depending on adjuvant chemotherapy protocol and study size (3-7).  Median 
survival time in dogs undergoing amputation alone ranges from 134 to 175 days (3-7).  
Like their human companions, pulmonary metastases are typically the cause of terminal 
morbidity.  It has been suggested that up to 90% of canine patients may present with 
microscopic metastases that are undetectable via routine imaging (2).  The high 
variability in DFI suggests that canine OSA exhibits variable metastatic capability, rate 
and/or resistance to adjuvant chemotherapy, similar to the disease in humans. 
Canine OSA shares many features with human OSA, making dogs a valuable 
comparative model.  Pet dogs develop OSA primarily in the metaphyseal regions of long 
bones, as do human patients.  The lesions are histologically identical (2).  The similarities 
between the molecular characteristics of human and canine OSA have been established 
(see (8) for review).  Furthermore, Thomas and colleagues recently demonstrated that 
some of the same genetic aberrations identified in human OSA are also seen in canine 
OSA with both breed-dependent and independent associations (9).  Among the genetic 
changes identified, Wilms tumor 1 (WT1), tumor protein p53 (TP53), cyclin-dependent 
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kinase inhibitor 2A (CDKN2A), phosphatase and tensin homolog (PTEN) and 
retinoblastoma 1 (RB1) tumor suppressors as well as v-myc myelocytomatosis viral 
oncogene homolog (MYC) and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog (KIT) oncogenes were shown to be affected by cytogenetic abnormalities in 
76% of their samples (9).  Similarly, comparative analysis of gene expression profiles in 
human and canine OSA determined that the diseases were indistinguishable by 
hierarchical clustering (10). Treatment and chemotherapeutic regimens are also similar 
with the notable exception that most amputee dogs do not undergo neoadjuvant 
chemotherapy, so tumors collected at the time of amputation are naïve to drugs.  Dogs 
also provide a valuable model system in that their tumors arise “naturally,” they share an 
environment with humans, and they metabolize drugs at a similar rate.  Finally, dogs are 
more genetically diverse than mouse model systems and share more genetic homology 
with humans than mice (8).  Thus, genetic prognostic screening in dogs has strong 
potential applicability to the human disease (11).  
In recent years, it has become clear that the tumor microenvironment plays a 
strong role in metastatic events even if metastatic subclones are only a small proportion 
of tumor cells (12, 13). For example, van de Vijver and colleagues demonstrated that 
gene expression analysis of primary tumors can divide breast cancer patients into “good” 
and “poor” prognostic groups based on the tumors’ intrinsic metastatic ability (14).  
Thus, gene expression profiles of primary tumors provide information about metastatic 
potential and patient prognosis even if distant disease is not detectable or present.   
Gene expression analysis of primary tumors can also elucidate novel 
chemotherapeutic targets by defining individual gene changes and/or whole pathway 
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derangements (15, 16).  Identification of such differences between “good” and “poor” 
prognostic groups in OSA will allow for more personalized treatment of disease based on 
an individual’s tumor expression profile.   
The current study utilized Affymetrix GeneChip Canine Genome 2.0 arrays  to 
explore differences in gene expression between  primary OSA tumors taken from client 
dogs with a DFI of less than 100 days (“poor responders”)  and those with a DFI greater 
than 300 days (“good responders”) following definitive treatment and chemotherapy.  
Individual genes with significant changes in expression were validated using qRT-PCR 
and explored for their ability to correctly classify good and poor responders using four 
different machine learning schemes.   A broader, systems approach was used to identify 
changes in groups of interacting genes or pathways that may contribute to metastatic 
progression and resistance to therapy. We have found evidence of altered expression of 
several genes and pathways and have verified that the Hedgehog signaling pathway is 
comparatively downregulated in the poor responding group. 
 
METHODS 
Chemotherapy-naïve primary tumor samples were selected from the Colorado 
State University Animal Cancer Center’s tissue archive based on the criteria that the 
patient had undergone surgical amputation followed by chemotherapy with doxorubicin 
and/or a platinum-based drug (Table 2.1).  Limb-spare surgical samples were excluded 
from the study as differences in DFI are associated with post operative infections 
common to the procedure (17, 18).  Samples were collected at the time of amputation 




































nitrogen and stored at -80oC.  Disease-free intervals (DFI) were calculated based upon the 
presence of metastatic disease and samples were divided into cohorts of DFI<100 days 
and DFI>300 days.  These cohorts were defined to select samples distant from the 
median DFI of 200 days so that expression differences could be analyzed in very good 
and very poor responders. 










184844 40 4.4 MC Greyhound L Prox Humerus Osteoblastic Doxorubicin 
208911 60 8.0 FS Doberman L Prox Humerus Giant cell Carboplatin 
173175 69 5.0 MC Rottweiler L Dist Femur Osteoblastic Cisplatin 
223986 77 7.0 MC Greyhound L Dist Femur Osteoblastic Carboplatin 
153599 90 9.0 FS Mix L Tibia Giant cell Cisplatin 
222189 91 6.1 FS Greyhound L Prox Humerus Osteoblastic Doxo & Carbo 
204714 94 8.0 FS Greyhound L Prox Tibia Giant Cell Doxorubicin 
208756 95 10.2 FS Labrador Ret. L Dist Humerus Osteoblastic Cisplatin 
146719 97 8.8 MC Mix R Dist Femur Fibroblastic Doxorubicin 
212759 97 10.8 MC Golden Ret. L Prox Humerus Osteoblastic Doxorubicin 
177466 307 7.6 FS Mix L Dist Radius Osteoblastic Cisplatin 
188084 329 10.4 MC Rottweiler R Dist Radius PD Doxorubicin 
190030 356 13.4 MC Mix L Dist Humerus Osteoblastic Doxorubicin 
180223 384 11.5 FS Mix R Prox Femur Osteoblastic Cisplatin 
208513 467 7.1 MC Greyhound L Prox Humerus Osteoblastic Doxorubicin 
180119 619 10.4 FS Mix R Dist Femur Osteoblastic Cisplatin 
193231 694 12.4 MC Mix L Dist Radius Osteoblastic Doxorubicin 
174513 734 10.1 FS Malamute L Dist Radius Osteoblastic Doxo & Carbo 
155214 787 8.7 MC Labrador Ret. R Tibia Osteoblastic Doxorubicin 
168327 885 8.0 FS Golden Ret. L Dist Radius Osteoblastic Carboplatin 
 DFI = disease-free interval, Dx = diagnosis, MC = castrated male, FS = spayed female,  
L = left, Dist = distal, Prox = proximal, R = right, PD = poorly-differentiated,  
“Doxo & Carbo” = Doxorubicin and Carboplatin combination therapy, 
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Samples were freeze-fractured, homogenized, extracted with Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) and purified with RNeasy clean up (Qiagen, Valencia, 
CA, USA) per the manufacturers’ protocols.  Resultant RNA was quantified via 
spectrophotometry and assayed for quality on Agilent (Santa Clara, CA, USA) and Bio-
Rad (Hercules, CA, USA) bioanalyzers at the Rocky Mountain Regional Center for 
Excellence (RMRCE) Genomics Core at CSU.  Only samples exhibiting minimal 
degradation as evidenced by RNA Integrity Numbers (RIN) greater than 8 were used for 
microarrays. 
Eight samples from each DFI cohort were selected and array analysis with 
GeneChip Canine 2.0 Genome Arrays (Affymetrix, Santa Clara, CA, USA) was 
performed in two batches (batch 1, n=6; batch 2, n=10) at CSU’s RMRCE Genomics 
Core per Affymetrix protocols.  One sample was removed from analysis after data 
collection based upon pathologist review and review of hospital records that determined 
the sample was not OSA but hyperreactive osteoid tissue.  Briefly, the One-Cycle Target 
Labeling and Control Reagents package (Affymetrix, Santa Clara, CA, USA) was used to 
synthesize cDNA from total RNA spiked with prokaryotic Poly-A RNA as a control. The 
Sample Cleanup Module (Affymetrix, Santa Clara, CA, USA) was used to purify the 
cDNA which was then used for synthesis of biotin-labeled cRNA.  cRNA was purified, 
quantified and fragmented before hybridization with the GeneChips.  Hybridized chips 
were washed, stained using streptavidin-conjugated phycoerythrin dye (Invitrogen, 
Carlsbad, CA, USA) and enhanced with biotinylated goat anti-streptavidin antibody 
(Vector Laboratories, Burlingame, CA, USA) using an Affymetrix GeneChip Fluidics 
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Station 450 and Genechip Operating Software. The Affymetrix GeneChip scanner 3000 
was used to acquire images.  
Microarray data was preprocessed using Probe Logarithmic Intensity Error 
(PLIER) estimation (19) and Robust Multichip Average (RMA) (20) algorithms with log2 
transformations.  PLIER and RMA methods were compared as part of the data discovery.  
A standard unpaired 2-tailed t-test with a false discovery rate correction for multiple 
comparisons was used. Uncorrected p-values were used to rank probesets.  CIMminer 
was used to generate clustered images of the data with the following parameters:  
unsupervised clustering on both axes, average linkage and Euclidean distance (21).  
Quantitative RT-PCR was performed on an expanded set of 20 OSA samples 
including the same 15 samples used in the array analysis plus an additional five samples 
that met the selection criteria of amputation, chemotherapy, appendicular location of 
tumor and DFI (n=3 in the DFI>300 cohort and n=2 in the DFI<100 cohort).  These 
additional 5 samples increased the number of samples in each cohort to ten.  The sample 
set was expanded so that expression of genes of interest could be assessed in independent 
samples in addition to those from the microarray study.  cDNA was synthesized using the 
QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA) with 1μg input 
RNA.  Quantitative real time PCR was performed in duplicate using iQ SYBR Green 
Supermix (Bio-Rad, Hercules, CA, USA) and 25 ng equivalent RNA input in 25 μL 
reactions on a Stratagene Mx3000P instrument.  Thermal cycling was performed on the 
Mx3000p instrument (Stratagene) with the following parameters:  95°C for 10m followed 
by 40 cycles of 95°C for 30s and 60°C for one minute.  Data collection was performed at 
the end of the 60°C step.  Dissociation curve ramps were performed at the end of the 
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cycle to verify that only a single product was generated.  Data analysis was performed 
with the Mx3000p software.  Primers (Table 2.2) were designed based upon NCBI 
RefSeq mRNA sequences with PrimerQuest (Integrated DNA Technologies, Coralville, 
IA, USA) and were cross-checked for specificity using UCSC In-Silico PCR (22, 23).  



































Table 2.2 – Primer sequences and amplicon size for selected genes. 
Primer Sequence (5’ to 3’) Size of Amplicon 
HPRT1 S TGC TCG AGA TGT GAT GAA GG 
HPRT1 AS TCC CCT GTT GAC TGG TCA TT 
191 bp 
   
ADHFE1 S CCA ACA GTG GCT TCG ATG TGC TTT 
ADHFE1 AS TGC TGG CCG AGT GAT AGG ATT TGA 
104 bp 
   
AGTR1 S TGA CTT TGC CAC TAT GGG CTG TCT 
AGTR1 AS AGG CGG GAC TTC ATT GGA TGA ACA 
178 bp 
   
CCDC3 S TGA ACC AGA AGC TCA GCG AGA AGT 
CCDC3 AS TAG ATT CCC TGG CAA GAG GCA ACA 
162 bp 
   
DHH S ACA ACC CGG ACA TCA TCT TCA AGG 
DHH AS ATG TTC ATC ACC GCA ATG GCC AAG 
109 bp 
   
FBP1 S TCC TGT ACC CAG CGA ACA AGA AGA 
FBP1 AS TGC CTT CTC CAT GAT GTA GGC CAT 
89 bp 
   
IGF2 S TCG TGG AAG AGT GCT GTT TCC GTA 
IGF2 AS TCG TAT TGG AAG AAC TTG CCC ACG 
154 bp 
   
IMP1 S TTG CAG AAT TTG ACA GCG GCT GAG 
IMP1 AS TTT GGT GCA GCT GCT TAA CTT GGG 
118 bp 
   
NDRG2 S ATA AGT CTT GCT TCC AGC CGC TCT 
NDRG2 AS TCA GGT ACT GCA GAA TGC AAG GGA 
183 bp 
   
PTCH2 S CAT ATT CCT GCT GGC ACA TGC CTT 
PTCH2 AS GAA GAC AAG CAT CAC GGC TGC AAA 
229 bp 
   
SCN1B S TCG TGG CAG AGA TGG TTT ACT GCT 
SCNIB AS ACA CCC GTA CAG TTC TCC TTG CTT 
121 bp 
   
SMO S TGG TGC TCA TTG TGG GAG GTT ACT 
SMO AS ACT CAG CCT GGT TGA AGA AGT CGT 
210 bp 
S = sense, AS = antisense, bp = base pairs 
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region of the gene.  Primers were designed to amplify all possible isoforms noted in 
NCBI and were not specific to the Affymetrix probe region.  Expression levels were 
normalized to hypoxanthine phosphoribosyltransferase 1 (HPRT1) expression as it was 
consistently expressed at a moderate level in our arrays and has previously been used as a 
canine housekeeping gene (24) (primer sequences courtesy of Dr. Luke Wittenburg, 
CSU).  Standard curves, dissociation curves and amplification data were collected using 
Mx3000P (Stratagene, La Jolla, CA, USA) software and analyzed with the 2(-ΔΔCt) 
method (25) followed by an unpaired 2-tailed t-test as well as REST2009 software (26, 
27).  In all cases, amplification efficiencies were greater than 90%.  Quantitative RT-PCR 
products were electrophoresed on a 2% agarose gel in 1x TBE and visualized under UV 
light with ethidium bromide to verify product size. 
The pathway analysis pipeline used in this study has been previously described 
(28). Briefly, the University of Pittsburgh Gene Expression Data Analysis suite 
(caGEDA) (29) with a standard J5 metric, a threshold of 4 and a jackknife of 4 was used 
to select unique genes for pathway analysis following both PLIER and RMA 
preprocessing.  The DAVID Gene ID conversion tool was used to link canine identifiers 
to their human counterparts (30, 31) and identifiers absent from the database were hand-
annotated by BLAST and BLAT comparisons of the target sequence; GeneGo MetaCore 
was used to assign functional pathways.  Pathways were assigned independently to 
PLIER and RMA preprocessed data and the resulting pathways were compared. 
WEKA software was used to generate classification models to test the analytical 
value of qRT-PCR-derived expression changes (32).  Classification models were built 
using a Support Vector Machine (SVM), a J48 decision tree, and logistic regression (33).  
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Models were generated with the full (n=20) data set and tested for sensitivity and 
specificity using stratified tenfold cross-validation.  Tenfold cross-validation randomly 
selects 90% of the data for training the model, and uses the other 10% of the data to test 
the model.  The process is repeated ten times and the ten model error rates are averaged 
to compute an overall error rate. 
RESULTS 
Tumor Donors 
The DFI<100 group was composed of 5 castrated males and 5 spayed females 
with an average age of 7.73 years (range: 4.4-10.8) at the time of diagnosis.  The 
DFI>300 group was also composed of 5 castrated males and 5 spayed females with an 
average age of 9.96 years (range: 7.1-13.4) at the time of diagnosis.  The samples used in 
the microarray study were a subset of these as described in the “Methods” section.  Dog 
breed, chemotherapy type, tumor phenotype and tumor location are included in Table 1.   
Affymetrix Canine 2.0 Genome Array Analysis 
Criteria for assessing differential regulation of probesets were based on the 
preprocessing algorithm used as both PLIER and RMA have benefits and drawbacks.  
Briefly, PLIER exhibits higher signal reproducibility and differential sensitivity for low 
expressing genes  yet the variance can be unstable on a log scale, whereas RMA 
demonstrates fold change compression at the low end of expression, but the variance is 
stable on a log scale (19).  Thus, selection criteria for genes to validate with qRT-PCR 
were:  PLIER fold change greater than 3 with an uncorrected p-value less than 0.05 
and/or RMA fold change greater than 2 with an uncorrected p-value less than 0.05.  False 
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discovery rate correction yielded no significant genes so uncorrected p-values were used:  
this is not surprising in this natural, diverse patient population. 
Affymetrix Canine 2.0 gene array analysis yielded 75 probesets matching the 
PLIER criteria and 68 probesets matching the RMA criteria. Twenty-eight probesets and 
twenty-three genes were shared (Figure 2.1A & 2.1B, blue labels) between the two 
selection criteria yielding 115 total probesets for further investigation (Figure 2.1C).  
Unsupervised hierarchical clustering of the 75 PLIER-selected probesets grouped the 
dogs according to their respective disease free interval groups (Figure 2.1A, X-axis).  
This hierarchical clustering also grouped the probesets relative to fold change differences 
between the DFI<100 day group and the DFI>300 day group (Figure 2.1A, Y-axis).  This 
pattern indicates that, based on the genes showing the greatest expression differences, 
dogs that have a longer disease-free interval (X-axis, left half) have more-similar primary 
tumor gene expression to each other than to dogs with a short DFI (X-axis, right half), 
even those of the same breed.  Hierarchical clustering of the 68 RMA-selected probesets 
yielded similar results with all but one of the dogs (208911 DFI<100) clustering in their 
respective DFI groups. (Figure 2.1B).    The differences in sample clustering, the ranges 
of expressed values, and the differences in shared gene clustering (i.e. genes shared 
between the two algorithms are clustered primarily in half of the PLIER dendogram but 
spread throughout the RMA dendogram) underscore the fact that different algorithms 
yield different results and illustrate the value of applying multiple algorithms. 
Quantitative RT-PCR Analysis of Putative Biomarkers and Array Validation 
Thirty-six genes were assayed for expression via qRT-PCR in 20 OSA samples to 




Figure 2.1 - Fold change analysis of microarray data. Clustered image maps derived 
from gene array analysis of 15 canine osteosarcomas. Data was preprocessed with 
PLIER (A) and RMA (B) algorithms. Probesets were selected based upon fold change 
greater than 3 (PLIER) or greater than 2 (RMA) and an uncorrected p-value < 0.05. (C) 
Number of probesets meeting selection criteria from each algorithm that were shared and 
unshared between the two. 
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via a method not subject to multiple sampling errors.  Of these, 8  demonstrated 
significantly different (p<0.05) expression between the two cohorts as calculated by both 
the 2(-ΔΔCt) method (25) with a 2-tailed t-test and the REST2009 (27) iterative method that 
accounts for amplification efficiency.  qRT-PCR expression is plotted as 2(-ΔCt) in Figure 
2.2.  Higher expression levels between cohorts and among genes can be visualized as an  
increased 2(-ΔCt) value. Fold changes and statistical calculations stated in the text were 
calculated with REST2009 as this program consistently demonstrated higher stringency  
for significance than the 2(-ΔΔCt) method with t-test.  We observed significant down-
regulation of insulin-like growth factor II (IGF2, fold change=18.52, p=0.003, Figure 
2.2A) in our poor-responder cohort (DFI <100).  Other significantly down-regulated 
genes in the DFI <100 cohort were:  alcohol dehydrogenase, iron containing 1 (ADHFE1, 
fold change=3.56, p=0.001, Figure 2.2B), coiled-coil domain containing 3 (CCDC3, fold 
change=7.30, p<0.001, Figure 2.2C), sodium channel, voltage-gated, type I, beta 
(SCN1B, fold change= 3.72, p=0.002, Figure 2.2D), angiotensin II receptor, type 1 
(AGTR1, fold change=7.14, p=0.003, Figure 2.2E), and n-myc downstream-regulated 
gene family member 2 (NDRG2, fold change=4.29, p=0.005, Figure 2.2F).  Up-regulated 
genes in the DFI <100 cohort were:  fructose-1,6-bisphosphatase 1 (FBP1, fold 
change=5.94, p=0.006, Figure 2.2G) and IGF2 mRNA binding protein 1 (IMP1, fold 
change=6.81, p=0.047, Figure 2.2H).  The remaining 28 genes displayed qRT-PCR fold 
changes similar in amplitude and direction  to at least one of the applicable Affymetrix 
probesets with only one exception.  Although these genes did not meet significance 
criteria on qRT-PCR, there is a strong correlation between the qRT-PCR data and the 











































































































































































Figure 2.2 - qRT-PCR validation of genes selected from fold change analysis of 
microarray data. Expression represented as 2(-ΔCt) for eight genes selected from fold 
change analysis of gene array data that were significant on qRT-PCR validation with 
20 samples. Higher values indicate higher expression between cohorts and among 
genes. Fold change and p-values calculated via the REST2009 method. Error bars 
represent standard error. Insulin-like growth factor II (IGF2, A), alcohol 
dehydrogenase, iron containing 1 (ADHFE1, B), coiled-coil domain containing 3 
(CCDC3, C), sodium channel, voltage-gated, type I, beta (SCN1B, D), angiotensin II 
receptor, type 1 (AGTR1, E), n-myc downstream-regulated gene family member 2 
(NDRG2, F), fructose-1,6-bisphosphatase 1 (FBP1, G), and IGF2 mRNA binding 
protein 1 (IMP1, H).  
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Pathway Analysis 
Pathway analysis was utilized to examine the microarray data in a biologically 
relevant manner and to rule out the false positives commonly found in fold change 
analysis.  To select differentially-expressed genes from the greater-than 40,000 probesets 
in an unbiased fashion, we utilized the J5 metric as described previously (29).  For the 
PLIER-processed data, this yielded 3179 total probesets and 1783 unique annotated or 
identifiable gene identities with human homologs.  The RMA-processed data yielded 
1374 total probesets with 764 unique identifiers.  Probesets that were not associated with 
a human homolog in the Affymetrix or DAVID databases were hand-annotated, where 
possible, using NCBI BLAST and/or UCSC BLAT.  These datasets were then analyzed 
with the MetaCore platform to assign functional pathways to each individual dataset as 
well as to the identifiers common to both PLIER and RMA datasets.  Figure 2.3 displays 
significantly altered pathways (p<0.001) by ascending p-value for PLIER (a), RMA (b), 
and combined RMA/PLIER (c) analyses.  Sixty-nine significant pathways were identified 
using the PLIER dataset (Figure 2.3A) and eight significant pathways were identified 
using the RMA dataset (Figure 2.3B).  Analysis of identifiers common to both RMA and 
PLIER datasets yielded 379 shared identifiers and ten significant pathways (Figure 2.3C). 
The pathway expression differences between good and poor responders primarily 
involved genes associated with oxidative phosphorylation, bone development, 
cAMP/Protein Kinase A (PKA) signaling, cell adhesion, cytoskeletal remodeling and 
immune response.  Many of the pathways show modulation in commonly observed 
“cancer” signatures including matrix metalloproteinases, transforming growth factors, 
wingless-type MMTV integration site family members (WNTs) and nuclear factor kappa- 
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Figure 2.3 - Pathway analysis, most significant pathways. Top ranked pathways from 
GeneGo MetaCore pathway analysis following probeset selection with GEDA's J5 
metric. Pathways are ranked based upon p-value, bars represent inverse log of the p-
value. (A) Top 25 pathways generated from PLIER preprocessed array data (of 69 
meeting significance criteria of p < 0.001). (B) Eight significant pathways generated 
from RMA preprocessed array data. (C) Top ten significant pathways from an analysis 
considering only genes common to both RMA and PLIER scoops. 
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light-chain-enhancer of activated B cells (NF-κB) downstream targets, as well as actin 
and myosin cytoskeletal components (Appendix A, Figures A.1-A.3). 
qRT-PCR Analysis of the Hedgehog Pathway 
The identification of hedgehog pathway components in each pathway (Figure 2.4) 
and fold change analysis (HHIP, Figure 2.1A and 2.1B), led us to examine expression of 
nine genes in the pathway via qRT-PCR:  hedgehog interacting protein (HHIP), patched 
(PTCH1 and PTCH2), smoothened (SMO), glioma-associated oncogene family zinc 











Figure 2.4 - Hedgehog and Parathyroid Hormone Signaling Pathways in Bone and 
Cartilage Development. Red symbols indicate degree of up-regulation of gene target in 
DFI < 100 days relative to DFI > 300 days, blue symbols indicate relative down-
regulation. Numbers in symbols indicate specific array processing algorithm, 1 = PLIER, 
2 = RMA. 
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genes, DHH, SMO, and PTCH2, demonstrated significant down-regulation in the poor-
responder cohort (Figure 2.5).  Sonic hedgehog was unexpressed in 17 of 20 samples and 
only minimally expressed in the remaining three (Figure 2.5 inset). 
 
 
Figure 2.5 - qRT-PCR analysis of the Hedgehog pathway. Fold change from qRT-
PCR of eight genes in the hedgehog pathway. Genes were selected for analysis based 
upon significance of the hedgehog pathway in pathway analysis. Fold change 
calculated via the 2(-ΔΔCt) method (* = p < 0.05). Error bars represent standard 
deviation and are asymmetrical due to the exponential fold change calculations. Inset: 
expression represented as 2(-ΔCt) for hedgehog ligands, error bars represent standard 
error. 
 76
Data Classification  
Four classification models were generated based on the qRT-PCR gene 
expression patterns of fifteen genes, the eleven significant genes plus four genes that 
were members of the Hedgehog signaling pathway or were selected in the fold-change 
analysis of both the RMA and PLIER normalized data sets:  GLI3, HHIP, RAN binding 
protein 3-like (RANBP3L) and peptidoglycan recognition protein 1 (PGLYRP1).  The 
accuracies for each of these models during model generation and cross validation are 










times using 90% of the samples to train the model and 10% to test the model. The J48 
decision tree selected two genes that were most predictive for all samples:  ADHFE1 and 
NDRG2.  It successfully predicted cohort for all of the 20 samples.  When the same 
model was built with stratified cross-validation using 90% of samples to train the model 
and 10% to test the model, it predicted cohort with a 75% success rate.  A Support Vector 
Machine algorithm was used to generate two models.  The first, incorporating all 15 
Table 2.3 – Results of classification modeling.   














Full Training Seta 100%c 100% 100% 100% 
Stratified Cross- 
Validationb 
75% 90% 90% 90% 
a Full training sets included data for all 20 samples to both build and test the model. 
b Stratified cross-validation models were built with 90% of the samples and tested with 
the remaining 10% through multiple iterations. 
c Percent of samples correctly classified by the model. 
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genes, predicted cohort with a 100% success rate and 90% in cross-validation.  The 
second SVM model incorporated only the 3 most heavily weighted genes from the 
previous model, CCDC3, FBP1 and ADHFE1.  It also predicted cohort with 100% 
success rate and 90% in cross-validation.  Logistic regression including the three most 
predictive genes from the SVM model predicted cohort with a 100% success rate and 
90% in cross-validation.   
 
DISCUSSION 
In this study, we analyzed gene expression in chemotherapy-naïve primary OSA 
tumors from 20 dogs with the aim of identifying a gene signature of aggressive metastasis 
and/or resistance to chemotherapy following definitive treatment with limb amputation 
and adjuvant therapy with doxorubicin and/or a platinum drug.  The purpose of this aim 
was 3-fold.  First, it provides a basis for development of a prognostic screen; such a tool 
would be of great value to the clinicians diagnosing and treating the more than 8,000 new 
cases of canine OSA every year.  Additionally, pet owners would benefit greatly from a 
more accurate projected survival time when weighing their dog’s quality of life and their 
own monetary obligations in treatment decisions.  Secondly, analysis of gene signatures 
may allow elucidation of single genes or genetic pathways that may be manipulated for 
treatment purposes.  Finally, dogs are an excellent model for human OSA and 
identification of markers and pathways leading to disease progression and resistance to 
therapy in dogs may be translated to the pediatric clinical setting to improve prognosis 
and treatment of human OSA. 
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We utilized qRT-PCR to confirm the differential expression of eleven genes 
between primary OSA from good (DFI>300 days) and poor (DFI<100 days) responding 
dogs (Figs. 2 and 5).  Transcriptional profiles of an additional 28 genes selected from fold 
change analysis of the microarray data were assessed via qRT-PCR and, although 
differential expression was observed in many, significance criteria for the qRT-PCR 
analysis were not met (data not shown).  Nineteen of these qRT-PCR targets were 
selected for analysis before pathologist review identified one of the “tumors” as 
hyperplastic tissue without neoplasia.  Removal of that sample and subsequent 
reprocessing of microarray data removed some of these targets from the RMA and 
PLIER fold change lists.  Despite their failure to achieve significance in our fold-change 
analysis, the qRT-PCR data for these targets still correlates strongly with the array data 
on a sample-by-sample basis. Two of these genes, IMP1 and AGTR1, were verified as 
differentially expressed by qRT-PCR analysis (Figure 2), possibly due to the increased 
sample number used in each group for this analysis.  From the additional 28 genes that 
failed to show statistically significant differences by qRT-PCR, eleven of these gene 
targets were selected by the fold change analysis of either RMA or PLIER processed data 
shown in Figure 1. The failure of these gene targets to reach significance in the qRT-PCR 
analysis may reflect the variability in microarray preprocessing algorithms as well as 
differences in expression values based on primer design as primers used in this study 
were not designed to align with Affymetrix probe locations.  In addition, since our qRT-
PCR analysis used a larger number of samples than the microarray study, some of the 
microarray hits may have been false positives that have now been removed from the list 
of putative biomarkers thanks to the qRT-PCR analysis. 
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Although these genes were primarily assessed by qRT-PCR for their prognostic 
potential, they may also have functional roles in metastatic progression and resistance to 
chemotherapy.  IMP1 (6.93 fold up-regulated in the poor-responders), also known as 
IGF2BP1 and not to be confused with the family of IGF binding proteins, is a member of 
a family of three oncofetal proteins (IMP1-3) whose function is to bind and regulate 
mRNA stability  in the cytoplasm during development.  IMP1 expression is stimulated by  
Wnt/β-catenin signaling and has many regulatory targets, some of which are implicated 
in cancer: stabilization of c-myc (34, 35) and CD44 mRNAs (36), translational 
suppression of IGF2 (37), and localization of β-actin mRNA to sites of actin 
polymerization (38).  These targets can affect cell growth and survival as well as 
metastatic mechanisms such as invadopodia formation and cell adhesion (39).  IMP1 
over-expression has been associated with poor prognosis in numerous cancer types 
including human ovarian and colorectal carcinomas (39, 40).  
IGF2 (15.4 fold down-regulated in the poor-responders) has been shown to be 
down-regulated in response to IMP1 as well as to hedgehog pathway inhibition and the 
observed alterations in these factors/pathways may account for some down-regulation of 
IGF2 (41).  Additionally, IGF2 expression is modulated by numerous other factors 
including parathyroid hormone (PTH), cortisol, and transforming growth factor beta 
(TGF-β) (42).  Finally, our pathway analysis shows reduction in PTH related protein 
(PTHrP) and subsequent modulation of the PTH pathway suggesting IGF2 may be 
comparatively under-expressed in poor-responders due to decreased PTHrP expression in 
that cohort.  It is important to note that the observed down-regulation of IGF2 (and all 
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other genes discussed here) is relative between cohorts and that the mRNA was expressed 
in all samples, but to a lesser degree in poor-responders. 
FBP1 (5.94 fold up-regulated in the poor-responders) is involved in 
gluconeogenesis and is expressed in the liver and, to a lesser extent, most other cell types.  
Its action opposes that of phosphofructokinase and its expression can lead to increased 
cellular glutathione and an apoptosis-resistant phenotype (43).  Bigl and colleagues 
examined FBP1 expression in several types of breast cancer and found it to be up-
regulated in invasive lobular carcinoma when compared to normal tissue but down-
regulated in other tumor types suggesting a variable role depending on tumor type (44).  
ADHFE1 is an iron-activated alcohol dehydrogenase with widely conserved 
motifs that is found in multiple tissue types.  It has been shown to oxidize gamma-
hydroxybutyrate and is 3.50 fold down-regulated in the poor-responders (45).  CCDC3, 
also down-regulated in the poor-responders (7.10 fold), encodes a 270 amino acid protein 
with a putative coiled-coil domain near the C-terminus.  Recent reports indicate that this 
protein is secreted by both adipocytes and endothelial cells and is under both hormonal 
and nutritional control (46).  Interestingly, CCDC3 was identified as a factor contributing 
to ifosfamide resistance in a mouse xenograft model using human OSA cell lines.  
Bruheim and colleagues reported a 40-fold down-regulation of this gene in resistant 
tumor cells(47).  As none of the dogs in the current study received ifosfamide, this gene 
may contribute generally to both metastasis and chemotherapeutic resistance. 
Chioni et al. recently elucidated a role for SCN1B in cellular adhesion and 
migration in breast cancer cell lines.  Their mildly metastatic cell line demonstrated 
increased expression of SCN1B compared to the highly metastatic cell line; furthermore, 
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siRNA-mediated knockdown of SCN1B decreased adhesion and increased migration in 
the mildly metastatic line (48).  Our observed 3.70 fold down-regulation of SCN1B in the 
poor-responders indicates that the tumor environment may become more pro-migratory 
due to reduced expression of this factor. 
The putative tumor suppressor gene NDRG2 (4.57 fold down-regulated in the 
poor-responders) is expressed in an inverse relationship to proliferation in normal tissues 
and has been observed to be down-regulated in numerous tumor types, especially in 
response to myc oncogene expression (See (49) for review).  Recent cytogenetic analysis 
of canine OSA revealed breed independent myc amplification in 40% of the cases, 
suggesting this is a common chromosomal aberration in both canine (9) and human OSA 
(50).  Tepel and colleagues demonstrated epigenetic promoter modifications as a 
mechanism for suppression of this gene in glioblastoma (51).  Recent evidence has 
identified numerous mechanisms by which NDRG2 acts as a tumor suppressor and 
invasion attenuator:  anti-proliferative suppression of AP-1 in colorectal carcinoma (52), 
anti-invasive suppression of NF-κB in fibrosarcoma and melanoma cell lines (53), pro-
apoptotic involvement in the p53 pathway (54), and reduction in invasion and 
intracellular β-catenin in NDRG2-transfected cell lines (55).  Kim and colleagues 
demonstrated that NDRG2 expression decreases with increasing tumor stage in colon 
carcinoma, indicating that this may be an excellent marker for molecular staging (55).  
Furthermore, recent studies have shown that the myc oncogene stimulates mitochondrial 
glutaminolysis resulting in reprogramming of mitochondrial metabolism to depend on 
glutamine catabolism to sustain cellular viability (56).  In support of this hypothesis, our 
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pathway analysis associated both upregulation of the Myc oncogene and alterations in 
mitochondrial oxidative phosphorylation with poor outcome. 
To identify the prognostic potential of these genes, we built several classification 
models to identify genes with the most predictive power.  Of the four models tested, all 
classified the samples with 100% accuracy when the model was built from all 20 
samples.  However, when stratified cross-validation was used, the two SVMs and the 
linear regression model were 90% correct whereas the J48 decision tree was only 75% 
correct.  These stratified cross-validation results are generally thought to more accurately 
reflect results in subsequent applications of the model. The two SVM models classified 
with the same success rate regardless of whether  built with all fifteen genes or the three 
most heavily weighted contributors, suggesting that CCDC3, ADHFE1 and FBP1 are 
highly predictive in this data set and are likely to be robust classifiers in future OSA 
studies. 
While biomarker identification can be successful using traditional fold change 
methodology, as evidenced by our gene hits above, understanding of the processes of 
metastasis and chemoresistance can be furthered by all-inclusive pathway analysis.  Thus, 
to eliminate some of the arbitrary nature of traditional fold change analysis, we also 
examined our microarray data via this methodology.  Over 4,000 probesets were selected 
from microarray data using the J5 metric, annotated and converted to human identifiers 
using public-access tools including DAVID, and assigned to pathways with the GeneGo 
MetaCore program.  This program assigns pathway significance based upon the number 
of genes represented within a pathway and the direction of change.  The overwhelming 
benefit to this methodology is that change in a single gene will be ignored unless related 
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genes also demonstrate altered expression.  Thus, the downstream impact of chip 
anomalies, probeset inefficiencies and differences in preprocessing algorithms can be 
dramatically reduced.  This type of analysis allows integration of the typical microarray 
methodology examining highly expressed genes with the systems biology approach of 
examining large numbers of genes, some of which may be expressed only at low levels 
despite their importance to a given pathway (28).  One pertinent example is PTEN 
deletion which was identified as a chromosomal aberration in 40 % of canine OSA (9). 
However, loss of PTEN was not detected in our fold change analysis, but was associated 
with poor outcome by pathway analysis (Additional File 2). 
Although discussing each of the modulated pathways is beyond the scope of this 
study, some notable generalizations can be addressed. Cell adhesion and cytoskeletal 
remodeling are both strongly represented in pathways we have identified as significantly 
altered between our two cohorts; this suggests that the aggressiveness of tumor cells with 
regard to these two elements of metastasis may be just as important as chemoresistance 
mechanisms in this population.  Bone-related developmental and immune-response 
pathways are also represented, much as one would expect in these osteoblastic/osteolytic 
tumors. Finally, cAMP/PKA signaling pathways also have strong representation in these 
analyses. Similar alterations in cAMP/PKA signaling with upregulation of the PKA 
regulatory subunit 1α have been described in other cancers (57).  However, the 
differences between good and poor responders are notable and provide evidence for 
variation in molecular phenotype contributing to aggressiveness within the same 
histologic subtype of tumor. 
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The pathway analysis converged with the traditional fold change analysis at the 
hedgehog signaling pathway.  The hedgehog signaling pathway appears to act upstream 
of Wnt/β-catenin signaling during bone development and aberrant hedgehog signaling 
has been associated with cancer development and progression (58). As a result, we 
decided to examine other genes in the hedgehog pathway with qRT-PCR.  Of the eight 
hedgehog-related genes examined, three were significantly down regulated in the poor 
responder cohort.  These three genes, SMO, PTCH2 and DHH, where not identified on 
traditional fold change analysis and this is likely due to two factors.  First, DHH is not 
annotated in the canine genome so primers were designed based on a region of the canine 
genome homologous to the gene in other species.  Considering this, the Canine 2.0 
microarray does not have a probe for this gene.  Probes were present for the SMO and 
PTCH2 genes, however, in this study, raw array expression values for these genes were 
very low suggesting that the signal may be nearing the detection limit of the microarrays. 
Hedgehog interacting protein (HHIP) was identified by fold change criteria in 
both RMA and PLIER preprocessed arrays.  The up-regulation in the poor responder 
cohort was also observed as a trend in qRT-PCR but did not meet significance criteria.  
HHIP antagonizes all three of the hedgehog family of ligands (SHH, DHH and IHH) and 
has been shown to be down-regulated in numerous epithelial tumor types (59) with the 
notable exception of basal cell carcinoma where it is upregulated (60).  HHIP is also 
abundant in endothelial cells but is suppressed during angiogenesis through a VEGF 
mediated pathway (61).  The up-regulation of HHIP observed in our poor-responders 
likely has some causative relationship to the down-regulation of DHH and, through 
feedback loops, SMO and PTCH2 in the same cohort. 
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Three studies have examined gene expression in primary human OSA to identify 
chemotherapy-resistance signatures by comparing good and poor responders (62-64).  
Among them, they identified over 200 differentially regulated genes but each gene set 
was unique to each study (i.e. there was no overlap in expression signatures).  More 
recently, Walters and colleagues (65) assayed expression patterns in OSA cell lines with 
differing aggressiveness and identified 252 differentially regulated genes, four of which 
overlapped with the Mintz et al. study’s gene signature (63).  This lack of similarity in 
expression patterns is observed in array analyses of various tumor types and is not at all 
surprising when one contemplates the differences in array preprocessing algorithms.  
Considering the disparity between the heat maps presented in Figure 1A and 1B, it is 
plausible that the exact same data processed in two different ways may yield two very 
different sets of candidate genes.  Thus, in addition to traditional fold change analysis of 
microarray data for biomarker identification, a broader, unbiased systems-biology 
approach, such as we have done here, is likely to identify biological changes that can be 
reliably verified in multiple data sets.  In fact, this approach was used to analyze multiple 
independent data sets to show that genes involved in the oxidative phosphorylation 
pathway were reduced in metastases compared to primary solid carcinomas (28).  
Interestingly, in the current comparison of primary sarcomas, increased expression of 
genes in the oxidative phosphorylation pathway was associated with a poor outcome, 
suggesting that different metabolic factors may contribute to the initiation of metastasis 
from a primary tumor and the implantation and successful growth of metastasis at a 
distant site.   
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Given the small sample size of the study, we acknowledge that this data serves 
primarily as a road map for future studies.  Our sample size was small primarily due to 
the stringent selection criteria set forth in Methods limiting our samples to dogs that had 
appendicular osteosarcoma, undergone amputation and received chemotherapy.  
Furthermore, we limited our samples to those from dogs with either very low or very high 
DFIs; the 100 and 300-day cutoffs were intended to straddle our facility’s average DFI of 
200 days.  Selvarajah and colleagues recently studied gene expression in a group of dogs 
with OSA with good and poor outcome (66).  They utilized a larger sample size (n=32) 
but included dogs with axial OSA as well as dogs that did not receive adjuvant 
chemotherapy.  Although they did not observe differences in outcome due to these 
factors, previous studies have established an effect on DFI (2, 3, 5, 7).  They also based 
their good and poor responder groups on survival time instead of DFI:  this can greatly 
affect outcome groups in a field of medicine where euthanasia is practiced.  Beyond 
study-design differences, we applied a systems-based model for biomarker/pathway 
discovery by using the J5 metric to enrich for high to medium expressing genes that are 
most appropriate for selection as diagnostic/prognostic biomarkers, as opposed to fold-
change based input.  Hand annotation of many probesets based upon sequence homology 
allowed us to input a very large and complete data set into the MetaCore pathway 
analysis.  Despite these differences in study design and analysis methods, we identified 
some pathways with similarity to those they identified in their PANTHER analysis, 
including hedgehog signaling, WNT signaling and chemokine signaling.  Considering the 
differences in chemotherapy requirements between the two studies, these pathways may 
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be most indicative of increased metastatic potential as opposed to chemotherapeutic 
resistance.   
Work by Paoloni and colleagues provides strong evidence for the validity of dogs 
as a model for human OSA.  They found that canine and human OSA are more similar to 
each other than to normal tissues from the same species (10).  This, in concert with our 
growing body of knowledge regarding gene and pathway derangements in canine OSA 
provides insights into the mechanisms of OSA progression and chemoresistance. 
 
CONCLUSIONS 
The present study has examined gene expression in primary canine OSA via both 
traditional fold change analysis and systems-based pathway analysis and found 
significant differences between dogs that responded poorly to chemotherapy following 
definitive treatment and dogs that responded well as evidenced by a long disease-free 
interval.  This study has identified candidate biomarkers of aggressive tumors as well as 
pathways that are deranged in poor responders relative to good responders, opening the 
door for molecular prognostic screening in canine OSA and further molecular 
comparison between the human and canine disease.  Although further studies, such as 
protein expression analysis will be necessary to solidify the role of these genes and 
pathways in OSA, targets identified here provide a strong foundation from which to 
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Gaining perspective:  Gene expression analysis of canine 
osteosarcoma in relation to normal bone. 
 
SYNOPSIS 
 Osteosarcoma (OSA) is the most common primary bone tumor in humans and 
dogs.  The genomic and transcriptomic nature of the disease is best characterized as 
chaotic with aneuploidy and inconsistent gene expression patterns frequently observed 
among samples.  Technological advances allowing screening of an ever-increasing 
number of genes and chromosome regions offer the opportunity for identification of new 
molecular contributors to the disease.  Thus, we compared microarray expression profiles 
of primary canine OSA tumors to normal bone samples to gain insight into genes that 
contribute to tumorigenesis as well as disease progression and chemoresistance.  We also 
investigated genomic copy number status in primary tumors relative to matched normal 
tissue via array comparative genomic hybridization.  Microarray profiling identified over 
2,000 genes that were dysregulated in tumors relative to normal bone and aCGH studies 
identified regions of copy number alterations that may contribute to some of this 
dysregulation.  This integrated screening approach provides insight into the complex 
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mechanisms of OSA tumorigenesis and progression and may help to identify new gene 
targets for treatment and prognostic purposes. 
 
INTRODUCTION 
 Osteosarcoma (OSA) is the most common primary bone malignancy in both dogs 
and humans.  Roughly 800 new human cases occur annually and greater than 10-times 
that many occur in dogs (1, 2).  The disease in dogs is increasingly recognized as an 
excellent model for the human disease; thus, we previously sought to identify biomarkers 
of disease progression and chemotherapeutic resistance in canine patients (3).  Having 
identified several promising gene and pathway signatures, we next sought to gain 
perspective on this dysregulation by comparing OSA gene expression signatures to those 
of normal bone tissue. 
 A number of gene expression profiling studies aimed at identifying molecular 
features of OSA have been performed in humans (4-6).  Similarly, human OSA-derived 
in vitro models and mouse model systems have been used to seek out gene expression 
signatures that may identify the most aggressive or chemoresistant OSA types (7-10).  
Although several genes of importance in OSA progression have been identified (e.g. 
Ezrin), the greatest unifying factor of these studies is the lack of concordance between the 
resulting lists of prognostic or chemoresistance-related genes.  This is due, partly, to the 
multifactorial nature of OSA but also to very limited numbers of sample tissues available.  
The large number of dogs affected by this cancer as well as new initiatives by nationwide 
tumor archiving consortia to bank veterinary tumors offer unique study opportunities for 
biomarker identification (1, 11-14). 
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 Studies have examined OSA gene expression relative to normal tissues other than 
bone yet expression studies involving normal bone are lacking due to the low cellularity 
of this tissue and resulting difficulty of RNA extraction (14).  Thus, we set out to devise 
an effective method for high quality RNA extraction from bone and to analyze gene 
expression in this tissue via microarray and quantitative RT-PCR.  Additionally, we 
performed array comparative genomic hybridization (aCGH) studies on genomic DNA 
from tumors and normal muscle tissue to determine to what extent copy number 




 Canine tissues used in these studies were obtained from animals presenting to 
Colorado State University (CSU) for treatment of OSA.  Owner consent for tissue 
archiving was obtained prior to definitive surgical treatment.  Good- and poor-responder 
primary tumors were archived at the Animal Cancer Center between 1996 and 2006 - 
snap frozen tissues and formalin-fixed paraffin embedded (FFPE) tissues were archived.  
Good and poor responder groups were defined based upon patient disease-free-interval 
(DFI):  good-responders had a DFI greater than 300 days and poor-responders had a DFI 
less than 100 days following amputation of the affected limb and chemotherapy with 
doxorubicin and/or a platinum-based drug .  Normal bone and matched tumor samples 
were obtained from limbs post-amputation and harvested so that “normal” bone included 
in the study was distant from the tumor site and separated from the tumor by a joint (e.g. 
a femoral tumor would have matched distal tibia bone collected).  A one to two 
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centimeter section of normal bone was collected for each sample; marrow and medullary 
fat was removed at collection.  Tissue was snap frozen in liquid nitrogen and stored at -
80ºC until processing.  Inclusion in good and poor responder studies required limb 
amputation followed by doxorubicin and/or platinum drug adjuvant therapy whereas 
inclusion in normal bone studies required limb amputation.  Patient details are provided 
in Tables 2.1 and 3.1  
RNA Extraction 
 As many researchers are skeptical about the possibility of obtaining high quality 
RNA from normal bone tissue, we first set out to devise a method for efficient RNA 
isolation from normal bone.  Normal bone samples were collected as above then returned 
to liquid nitrogen immediately prior to extraction.  Bone samples were freeze fractured 
and powdered in a liquid-nitrogen cooled Biopulverizer (RPI Corp., Mount Prospect, IL).  
Up to 1 cm3 of the resulting powder was then added to 3 mL Trizol (Invitrogen, Cat# 
15596-026) and homogenized with a mechanical homogenizer for 60 s.  The resulting 
slurry was centrifuged at 2000 rpm in a swinging bucket rotor for 15 s to remove osseous 
particulates.  The supernatant was transferred to a new tube and was subjected to phase 
separation RNA extraction per the manufacturer's instructions.  RNA pellets were 
resuspended in nuclease free water, pre-treated with the RNase-Free DNase Set (Qiagen, 
Cat# 79254) then purified with the RNeasy cleanup protocol per the manufacturer's 
instructions (Qiagen, Cat# 74104).  Tumor samples were purified in a similar fashion, 
only with significantly less tissue input.  RNA was quantified via spectrophotometry and, 
prior to microarray, tissue and tumor RNA was bioanalyzed for quality at the Rocky 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































quality RNA with RNA Integrity Numbers (RINs) greater than 8 were used in microarray 
studies. 
Microarray 
 Eight normal bone samples were analyzed with Affymetrix Canine 2.0 GeneChips 
as previously described (3).  Resultant data was compiled with data from 15 good and 
poor-responder primary tumor samples obtained previously and analyzed with 
ArrayTrack (15).  Data was preprocessed with the Probe Logarithmic Intensity Error 
(PLIER) estimation algorithm with a Log2 transformation then analyzed for fold change 
based on two scenarios:  normal bone versus all tumors or normal bone versus good 
responders versus poor responders.  The first scenario was analyzed with a Bonferroni 
adjusted unpaired 2-tailed t-test, thresholds of corrected p-value <0.05 and fold-change 
>3 were applied.  The second scenario was analyzed with pairwise t-test comparisons and 
the same p-value and fold-change thresholds.  Heat maps were generated with the 
ArrayTrack software using average Euclidean distance estimators and unsupervised 
clustering for all axes. 
Array Comparative Genomic Hybridization 
 Genomic DNA was extracted from patient-matched normal tissue (muscle, skin) 
using the DNeasy (Qiagen, Cat# 69504) kit per the manufacturer's instructions.  Array-
CGH was performed by Dr. Matthew Breen's laboratory at North Carolina State 
University as previously described (16).  Amplification of each probe region was 
expressed as Log2 tumor tissue relative to normal tissue.  gDNA hybridization intensities 
were compared to microarray expression data from good and poor responder groups as 
well as all tumors relative to normal bone. 
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RESULTS AND DISCUSSION 
Gene Expression Profiling in Normal Bone: A Valuable Reference for OSA Studies 
 Having previously identified a number of genes that were dysregulated between 
good and poor-responder canine patients' primary OSA tumors, we sought to determine 
the degree of dysregulation of these genes relative to an applicable baseline:  normal 
bone.  Using the methods described here, ample quantities of RNA were obtained from 
non-tumor-bearing bone; Affymetrix Canine 2.0 expression arrays were then performed 
on these samples to provide perspective for tumor gene expression profiles.  Comparing 
all tumors as a group (n=15) to all normal bone samples yielded 2,549 differentially 
expressed probesets (FC>3, p<0.05, unpaired, 2-tailed t-test).  Hierarchical unsupervised 
clustering of these probesets grouped all normal bone samples together and all tumor 
samples together (Figure 3.1a).  Principal components analysis of this data also clustered 
tumors together, separated from normal bone, on the basis of one principal component 
(Figure 3.1b). 
 Pairwise comparisons of the three groups (good responders, poor responders and 
normal bone) yielded 4,587 significant probesets when comparing normal bone to good 
responders, 4,982 differentially regulated probesets when comparing normal bone to poor 
responders, and 114 significantly different probesets when comparing good and poor 
responders.  Intersection of these gene groups was visualized with a Venn diagram based 
upon gene IDs (Figure 3.2).  Multiple probesets were often present for one gene ID and 
probesets without an assigned ID were excluded, reducing the total number of probesets 






















(middle segment) flagging these genes as those that have progressively altered expression 
patterns with increasing tumor aggressiveness.  2,401 significant genes were shared when 




Figure 3.1 – Heat map and principal components analysis of gene expression in 
canine OSA compared to normal bone.  A) Heat map was generated using ArrayTrack 
software on Log2-transformed PLIER pre-processed expression data from Affymetrix 
Canine 2.0 microarrays.  The 2,549 probe sets included were selected by traditional fold-
change analysis (FC>3, p<0.05).  Both axes were unsupervised during average Euclidian 
clustering.  Normal bone samples are denoted with “N#” and primary tumor samples are 
denoted with unique 6-digit numbers.  B)  Principal components analysis of the samples 
separated normal bone from tumor samples based on one principal component.  Tumors 

















demonstrated no differences between good and poor responders, they are not likely to be 
related to progression but are tumor-specific and may contribute to tumorigenesis and 
maintenance of the primary tumor.  Nineteen genes were identified in the comparisons 
between poor responders vs. normal bone and good responders vs. poor responders (left 
wedge).  These genes are unchanged in good responders relative to normal bone but have 
altered expression in the worst tumors, suggesting they may play a role as mediators of 
invasion, metastasis and/or chemoresistance.  Fourteen genes were shared in the 
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Figure 3.2 – Venn diagram displaying overlapping features from pairwise 
comparisons of microarray expression data.  Log2-transformed PLIER pre-processed 
array intensities from Affymetrix Canine 2.0 chips were subjected to pairwise 
comparisons.  Venn diagram was constructed on gene identity.  The three cohorts 
were:  normal bone (n=8), good responder primary tumors (DFI>300 days, n=7), and 
poor responder primary tumors (DFI<100 days, n=8).  Gene lists extracted for each 
overlapping segment are presented in Appendix B. 
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responders (right wedge).  As these genes were dysregulated in good responders but not 
poor, it suggests they may be positive prognostic indicators or merely incidental findings.  
Gene lists generated by the intersection of these pairwise comparisons are provided in 
Appendix B. 
 Fold change values were extracted for several previously-identified genes of 
interest; additionally, bad-flag calls were examined to interpret their relevance to the 














"bad," gene expression differences were verified by qRT-PCR (Figure 2.2). Thus, even at 
low hybridization signal, this platform offers excellent sensitivity.  This method of 






















































































































































































































Figure 3.3 – Extracted microarray expression data for previously identified genes of 
interest.  Log2-transformed PLIER pre-processed Affymetrix Canine 2.0 expression 
data for eight genes highlights the perspective gained by including normal bone in the 
study.  Expression for each gene and cohort is expressed as fold change relative to the 
good-responder cohort (middle bar of each cluster).  Cross bars represent significance 
(p<0.05).  “Bad Flags” indicates the number of samples identified by processing 
software as too low for detection.
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in only good and poor responder groups.  For instance, the targets fructose 1,6 
bisphosphatase (FBP1) and insulin-like growth factor 2 (IGF2) were less-attractive as 
biomarkers following inclusion of normal bone expression in the analysis.  While normal 
bone and poor responders both demonstrated significant expression differences from 
good responders for these two genes, no differences between normal bone and poor 
responders were observed.  This finding suggests that the observed dysregulation may be 
natural variance or unrelated to tumor progression.  Other targets, however, became even 
more promising following this analysis.  The oncofetal gene IGF2 mRNA binding protein 
1 (IGF2BP1) was overexpressed in all tumors relative to normal bone and significantly 
more so in poor-responder tumors relative to good-responder tumors.  All normal bone 
samples were denoted as bad flags by the analysis software but, as this gene is wholesale 
suppressed in most normal tissues, this is to be expected.  Exclusion of these "bad" flags 
would have truncated valuable data.  Additionally, the putative tumor suppressor gene n-
Myc downstream regulated gene 2 (NDRG2) demonstrated a similar stair-step pattern of 
regulation but progressing from highest expression in normal bone to least expression in 
poor-responder tumors.  Finally, this study identified several genes that demonstrate a 
progressive downregulation similar to NDRG2 yet have received limited or no attention 
in cancer:  alcohol dehydrogenase, iron-containing 1 (ADHFE1), sodium channel, 
voltage-gated, type I, beta (SCN1B) and coiled coil domain containing 3 (CCDC3). 
  
Array Comparative Genomic Hybridization Highlights the Chaotic Nature of OSA 
 Copy number alterations (CNAs) are a well-established means of genetic 
dysregulation and OSA is often described as having a high degree of aneuploidy (12, 17, 
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18).  Thus, aCGH was used to assay a subset of good and poor-responder tumors relative 
to paired normal tissue to determine the extent of CNAs and related expression 
alterations in this system.  A total of eight primary tumors with paired muscle samples 
(n=4 from each cohort) where analyzed.  No software capable of comparing one-color 
microarrays (e.g the Affymetrix array used here) to the employed aCGH platform in the 
context of the canine genome is currently available.  Thus, individual chromosome maps 
were generated to compare aCGH relative hybridization intensities to microarray 
expression data.  Appendix C presents each chromosome as an aCGH intensity figure 
paired with a fold-change of tumor relative to normal bone microarray expression figure.  
Appendix D presents each chromosome as an aCGH intensity of good and poor 
responder cohorts figure paired with a fold-change of poor responders relative to good 
responders microarray expression figure.  These chromosome profiles provide a visual 
means by which to assess regions in which gene over- or under-expression may be related 
to chromosomal amplification or deletion. 
 Locus regions that were identified in previous studies as important to OSA 
tumorigenesis or progression as well as several other regions identified in the pairwise 
comparison conducted here have been labeled with green boxes in Appendix C figures.  
Ezrin, found on Cfa 1, is associated with invasion and metastasis and only shows one 
case of amplification whereas several samples show deletion (19).  The tumor suppressor 
tumor protein p53 (TP53) is located on Cfa 5: several samples show deletion in the 
region of this locus and two samples show amplification.  Deletion of portions of the 
TP53 gene have been observed in several systems although dominant negative mutations 
unrelated to CNAs are also common tumorigenic events (20-22).  The oncofetal gene 
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IGF2BP1 is located on Cfa 9 in close proximity to the breast cancer associated oncogene 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2/ HER2).  IGF2BP1 
was identified in the pairwise comparison analysis above, but demonstrates no CNAs in 
the eight samples examined here.  Previous studies of these two genes have determined 
that amplification often occurs in this region in human breast cancers, but, despite the 
proximity of these two loci, they are often amplified independently of each other (23).   
 Mouse double minute 2 (MDM2), located on Cfa 10, is often amplified in human 
OSA; overexpression of the gene product results in inappropriate down-regulation of the 
p53 tumor suppressor protein (24-26).  Two cases of amplification and three cases of 
deletion were observed in the region of this locus.  The cyclin-dependent kinase inhibitor 
2A (CDKN2A, Cfa 11) locus encodes two alternate gene products, both of which serve as 
tumor suppressors by interacting with the p53 and retinoblastoma (Rb) pathways (27-30).  
Deletion at this locus was observed in a majority of samples and has previously been 
identified as contributing to tumorigenesis in a number of different tumor types.  
Similarly, the RB tumor suppressor gene, found on Cfa 22, demonstrates copy number 
loss in three samples tested.  Thus, while genes involved in p53 and Rb control are not 
uniformly experiencing CNAs in this population, amplification or deletion at one of 
many related loci in different tumors are likely contributing to OSA development (31). 
 The runt-related transcription factor 2 (RUNX2) gene is a bone-development-
specific gene often observed to be upregulated in OSA (32-35).  The precise location of 
this gene has not been defined in dogs but a BLAST search of the human homolog coding 
sequence suggests that Cfa 12 is the likely chromosome.  The locus in question is 
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LOC474923 and demonstrates amplification in the majority of samples analyzed here.  
Corresponding overexpression of nearby mRNAs is also observed. 
 Previous work by Thomas and colleagues identified a number of common 
karyotypic aberrations in canine OSA (17).  These include loci of some genes already 
discussed as well as oncogenes such as v-myc myelocytomatosis viral oncogene homolog 
(c-Myc), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) and the 
rat sarcoma viral oncogene homologs (HRAS and KRAS).  They also identified CNAs in 
the tumor suppressor genes Wilms tumor 1(WT1) and phosphatase and tensin homolog 
(PTEN).  The current study supports their findings:  c-Myc and KIT both occupy regions 
of Cfa 13 and amplification in multiple samples is seen at each locus.  Similarly, 
microarray probes for these genes demonstrated significant two- and four-fold 
upregulation, respectively, when comparing all tumors to normal bone.  NDRG2, a gene 
identified in pairwise analysis as common to all three test groups, is regulated by c-Myc 
and also shows copy number loss in two samples tested here (Cfa 15)(36).  Thus, 
dysregulation of c-Myc targets may be caused by amplification at the c-Myc locus or 
deletion of one of its downstream targets, such as NDRG2.  PTEN and WT1 also show 
evidence of copy number loss in the current study (Cfa 26 and Cfa 18, respectively). 
 
 CONCLUSIONS 
 The chromosome maps generated here highlight the extreme variance in CNAs 
among individuals' tumors.  Despite this variance, amplification of oncogenes and 
deletion of tumor suppressor genes is a recurrent theme.  Furthermore, CNAs in genes 
involved in these pathways can cause the same phenotypes even when the oncogene or 
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tumor suppressor loci are unaffected.  Comparison of aCGH plots to microarray 
expression plots has provided further insight:  in some cases, gene expression tracks with 
CNAs, however, in others it does not, suggesting that, for these genes, other mechanisms 
of gene regulation are at work.  One such gene is NDRG2; mechanisms of its regulation 
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Validation of in vitro models for canine osteosarcoma 
SYNOPSIS 
 Canine osteosarcoma is an excellent model for the disease in humans and an 
increasing amount of research is being pursued in both primary tumors and immortal cell 
lines derived from these tumors.  Previously, we analyzed gene expression in canine 
osteosarcoma (OSA) with the intent of identifying biomarkers of tumor aggressiveness 
and chemoresistance; here we pursue validation of in vitro models prior to embarking on 
further mechanistic studies of biomarkers.  Cell line cross-contamination as well as 
genetic drift during passaging have been acknowledged as widespread problems since the 
1960s.  Thus, a highly sensitive polymerase chain reaction (PCR)-based approach and 
short tandem repeat (STR) profiling were used to examine the prevalence of inter- and 
intraspecies cell line contamination and to verify that canine cell lines to be used in future 
studies were canine and unique.  Furthermore, the availability of anti-canine antibodies is 
limited, thus, we have tested anti-human antibodies to ADHFE1 and SCN1B for 
specificity to canine proteins via both western blot and immunohistochemistry.  Sixty cell 
lines from six laboratories were tested with multiplex species-specific PCR capable of 
identifying six commonly used species.  Of these, three were determined to be 
misidentified by species.  To identify intraspecies contamination among canine cancer 
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cell lines, 29 canine lines from three different laboratories were analyzed with STR 
fingerprinting.  Using this methodology, three canine cell lines were determined to be 
misidentified or cross-contaminated by other canine cell lines and genetic drift was 
observed within one cell line.  These findings emphasize the importance of cell line 
validation as a critical component of “good cell culture practice”  and add detail to the 
body of knowledge regarding two canine genes that may be important in the 
tumorigenesis and progression of osteosarcoma.  
INTRODUCTION 
Osteosarcoma (OSA) is the most common primary bone malignancy in both 
humans and dogs affecting roughly 800 adolescents and 8,000 companion dogs annually 
(1, 2).  Diseases in veterinary patients, including OSA, are becoming widely 
acknowledged as valid translational models for similar diseases in humans and, as such, 
veterinary research facilities are performing an increasing number of in vitro and in vivo 
clinical trials using models from a variety of species (3).  Thus, it is crucial for the 
veterinary community to possess the resources to fully study these models and to 
undertake the necessary steps to validate all cell lines in use.  Prior studies by our 
laboratory identified several genes that may contribute to cancer progression and 
chemoresistance in canine OSA (4).  Following up that study with investigations into the 
roles of identified genes required validation of in vitro models with regard to species and 
tumor of origin as well as validation of the specificity of anti-human antibodies in canine 
samples.   
 Cell lines are widely used in biomedical research as in vitro models for disease.  
HeLa cells were established in 1952 and, as early as 1958, interspecies cross-
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contamination between these cells and other lines was observed (5).  In the 1960’s, 
karyotyping, examination of biochemical polymorphisms and immunological approaches 
were developed to test cell line identity (6) within and between species but the early 
pioneers of cell line validation generally met with resistance from the  scientific 
community (5).  More recently, it has been estimated that 18% to 36% of cell lines may 
be contaminated or misidentified (7).  With the advent of relatively simple PCR-based 
DNA fingerprinting techniques, a new drive for cell line validation was initiated, aimed 
at providing a solution for eradication of cell line misidentification (8).   
 In addition to misidentification, problems with excessive sub-culturing of cells 
have also been identified (9).  As cell lines are maintained in culture for long periods of 
time, selective pressures are being exerted on them and, thus, lines are subject to genetic 
drift, especially at higher passage numbers.  Therefore, even when a cell line has not been 
contaminated, it can take on new attributes, skewing experimental data.  Currently, an 
increasing number of journals require cell-line validation prior to publication as examples 
emerge of cell lines with false identities being used and published about long after they 
have been identified as problematic (10).  
With the recent sequencing of the canine genome, in-depth gene expression  
studies have become more-feasible in canine models; however, many resources specific 
to canine samples are relative to those available for humans and mouse and rat models 
(11).  In order to investigate mechanisms of disease and progression, antibodies need to 
be generated or validated for the canine model and expressed sequences need to be 
confirmed. 
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Researchers at the Colorado State University (CSU) Animal Cancer Center 
(ACC) use a variety of cell lines from a number of different species, including a panel of 
canine cancer cell lines.  Because of this diversity, it was determined that testing for both 
inter- and intraspecies cell line contamination was necessary.  Multiplex polymerase 
chain reaction (PCR) has been demonstrated to be effective at determining species 
contamination (12) and short tandem repeat (STR) profiling is commonly used in animal 
breed detection and parentage testing as well as human forensics to differentiate between 
individuals of the same species.  Utilizing these relatively simple and robust methods, the 
current study has identified instances of both inter- and intraspecies cell line 
contamination.  Sixty cell lines from multiple species of origin, 29 of which were canine, 
were tested via PCR.  Subsequent STR screening of the 29 canine cell lines has allowed 
development of a database of canine STR profiles for comparison to other investigators’ 
cell lines and periodic cell line revalidation.  Additionally, presumptive OSA cell lines 
were assayed for  expression of the osteoblast differentiation factor, runt-related 
transcription factor 2 (RUNX2), to verify they were truly OSA derived.  Finally, anti-
human antibodies to Alcohol Dehydrogenase Iron Containing 1 (ADHFE1) and Sodium 
Channel, Voltage-Gated Type I β (SCN1B) have been validated for use in canine 
samples.   
METHODS 
Canine Tissues 
 Canine tissues in this study were collected from dogs presenting to CSU or other 
veterinary teaching hospitals for treatment of OSA.  Owner consent for tissue archiving 
was obtained prior to definitive treatment.  Good- and poor-responder primary tumors 
 117
were archived at the Animal Cancer Center between 1996 and 2006 - snap frozen tissues 
and formalin-fixed paraffin embedded (FFPE) tissues were archived.  Good and poor 
responder groups were defined based upon patient disease-free-interval (DFI):  good-
responders had a DFI greater than 300 days and poor-responders had a DFI less than 100 
days. This is the same primary tumor sample set used in a previous publication (4).  
Samples of each primary tumor were collected at the time of limb amputation, flash 
frozen for nucleic acid extraction and/or formalin fixed and paraffin embedded for 
histology and IHC. 
Mammalian Cell Lines 
 Cell lines used in this study were graciously provided by several 
laboratories in the CSU ACC.  They were received either as a cryopreserved vial or 
phosphate-buffered-saline-washed pellets. Cryopreserved cells were cultured in "C10" 
media:  DMEM high glucose with 6 mM L-glutamine, 1x each of sodium pyruvate, 
MEM vitamins, MEM non-essential amino acids and antibiotic-antimycotic, 10% fetal 
bovine serum (FBS) and Plasmocin prophylactic (Invivogen, Cat# ant-mpp). Cell cultures 
were detached from plates with 3 mM ethylenediaminetetraacetic acid (EDTA) in 
phosphate-buffered saline (PBS) or 0.25% trypsin in PBS with EDTA, pelleted by 
centrifugation for 5 minutes at 500 x g and extracted as described below. 
Polymerase Chain Reaction Species Validation 
Considering the variety of species of cell lines currently in use at the ACC, a 
multiplex PCR test was adapted from previous work to differentiate among cell lines 
from dogs, cats, mice, rats, Chinese hamsters, and humans (12).  Genomic DNA from 60 
cell lines from six laboratories with multiple presumed species of origin was extracted 
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with the DNeasy kit per the manufacturer’s protocol (Qiagen, 69504) from cells grown to 
90% confluency on 10 cm culture dishes or from pelleted cells.  For the purposes of 
comparison, this screen tested cell line duplicates from different laboratories.  PCR 
reactions were performed using 1 µL (50-400 ng) of genomic DNA in a reaction mixture 
adapted from previous work (12) containing 20 mM Tris-HCl pH 8.4, 50 mM KCl, 6 mM 
MgCl, 0.5% glycerol, 0.006% NP40/Tween 20 (1:1 v:v), 500 μM dNTPs, primers and 
1.25 U GoTaq polymerase (Promega, M5005).  Primers were synthesized by Integrated 
DNA Technologies; sequences and concentrations were as previously published (12) 
except for the Chinese hamster antisense primer which was adapted to 5’-GCG TAG 
GCG AAC AGG AAG TAT C-3’ to match the currently published genomic sequence.  
Internal control primers that detect a 70 bp amplicon in all species were also included.  
Thermal cycling conditions were:  95oC for 5 minutes followed by 30 cycles of 95oC for 
30 s, 60oC for 15 s and 72oC for 30 s and completed with a 7 minute final elongation at 
72oC.  PCR products were run on a 2% agarose gel in TBE at 100 v for 60 minutes and 
visualized under ultraviolet light by ethidium bromide staining.  A ladder containing PCR 
of gDNA from all six species was run concurrently.  To validate the sensitivity of the 
multiplex PCR, each species’ DNA was artificially contaminated with 10% and 1% of 
another species’ DNA and tested. 
Short Tandem Repeat Profiling of Canine Cell Lines 
Short tandem repeat (STR) profiling was performed on cell lines that PCR testing 
identified as canine in origin to assess the frequency of intraspecies contamination among 
cell lines.  One µL of genomic DNA prepared as above was input into multiplex STR 
PCR reactions using the StockMarks kit (Applied Biosystems, PN 4307481) per the 
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manufacturer’s protocol.  Two separate runs were performed to test a total of 29 cell lines 
(20 presumed unique lines, 9 duplicates from different laboratories).  A positive control 
sample from the kit was included in each run.  Thermal cycling conditions were as 
recommended by the manufacturer without controlled ramping.  PCR products were 
analyzed via capillary electrophoresis (Applied Biosystems, Genetic Analyzer 3130xl)  
per manufacturer’s protocols except as follows: 1 uL of PCR product was mixed with  
9 μL water to lower signal intensity during the run and 1.5 μL of diluted PCR product 
was then mixed with 0.5 μL size standardf  and 10 μL highly deionized formamide.  
Additionally, POP7 polymer was used instead of POP4 and the array length was 50 cm.  
Run conditions were identical to the default run module except the injection time was 
increased from 15 to 24 seconds and the scan number was shortened from 1800 scans to 
1750.  Data interpretation was performed by manually binning alleles into size groupings 
and assigning allele designations.   
RNA Extraction and qRT-PCR 
Following pelleting of cells, RNA was extracted using the RNeasy kit (Qiagen, 
Cat# 74104) per the manufacturer's instructions.  Resultant RNA was quantified via 
spectrophotometry and 1μg was added to reverse transcription (RT) reactions using the 
Quantitect Reverse Transcription kit (Qiagen, Cat# 05313).  Quantitative RT-PCR was 
performed as previously described using previously published primers (4) for ADHFE1, 
SCN1B and HPRT1 (hypoxanthine phosphoribosyltransferase 1, housekeeping gene).  
RUNX2 primer sequences were as follows:  forward - 5'- TGT TTA GCC CTG CAG 
TGA AGA CGA -3', reverse - 5'- ACT GAG GCG GTC AGA GAA CAA ACT -3'.  
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Gene expression data from canine tissues was previously published (4).  Fold change was 
calculated using the 2(-ΔΔCt) method (13). 
Western Blot Validation of Antibodies 
 Western blot analysis was performed on whole-cell lysates obtained by 
repeatedly passing cell pellets through a 26-guage needle in Tris pH 7.5 buffer with 
cOmplete™, EDTA-free Protease Inhibitor Cocktail Tablets (Roche, Cat# 04693132001).  
Total protein was quantified with a BCA Assay kit (Pierce, Cat# 23227) and 25 μg 
protein denatured in 1x Laemli Buffer was loaded for each sample.  Proteins were 
electrophoresed on 12% SDS-PAGE gels with 5% stacking gels at 180 v for 50 minutes 
and were then transferred to PVDF membranes with a semi-dry transfer unit.  Membranes 
were dried with methanol then blocked in 5% milk in Tris-buffered saline with Tween-20 
(TBST) for one hour at room temperature.  Membranes were incubated with primary 
antibody in blocking buffer over night at 4°C, washed in TBST and incubated with 
secondary antibody in blocking buffer for one hour at room temperature.  Following an 
additional wash step, SuperSignal West Pico Chemiluminescent Substrate (Pierce, Cat# 
34078) was used for development and images were captured on a Bio-Rad ChemiDoc 
XRS system.  α-tubulin was used as a loading control:  primary antibody (Sigma Cat# 
T5168 mouse monoclonal anti-human) incubation was performed for one hour at a 
1:5,000 dilution in 5% milk/TBST, secondary antibody (BioRad Cat# 170-6516, HRP-
conjugated goat anti-mouse IgG) incubation was performed for one hour at room 
temperature at a 1:10,000 dilution in 5% milk/TBST.  Western blotting was performed on 
a selection of canine OSA cell lines:  Abrams, D17, Gracie, McKinley, Moresco, Vogel 
and Yamane. 
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Specificity of the primary antibodies was verified using blocking peptides per 
standard protocols.  Briefly, primary antibody was incubated with 10x (by mass) blocking 
peptide in blocking buffer overnight at 4°C with agitation before being applied to the 
membrane.  In parallel, unblocked primary was applied to a second, identical membrane.  
The western blot was completed as above and membrane signals were compared between 
the two membranes.   
The anti-human primary antibodies tested here were both generated in rabbit and 
were polyclonal to the targets, ADHFE1 and SCN1B.  The ADHFE1 antibody was 
obtained from Abcam (Cat# ab84313), the blocking peptide from Aviva Systems Biology 
(Cat# ARP52720_P050), and was targeted to an epitope that was 98% homologous to the 
equivalent canine peptide.  The SCN1B antibody was obtained from Sigma (Cat# 
AV35028), the blocking peptide from Aviva Systems Biology (ARP35028_P050), and 
was targeted to an epitope that was 100% homologous to the equivalent canine peptide.  
Goat anti-rabbit IgG secondary was obtained from Sigma (Cat# 170-6516) 
Immunohistochemsitry 
Immunohistochemistry (IHC) was performed on canine kidney sections and a 
pilot group of FFPE OSA tissues (n=17) to optimize antibody and assess staining 
patterns.  The primary antibodies were the same as used for western blotting.  The 
secondary antibody and ABC reagents used were components of the Vectastain Elite 
Rabbit kit (Vector Laboratories, Cat#PK-6101).  Final development was performed with 
ImmPACT DAB Peroxidase Substrate (Vector Laboratories, Cat# SK-4105).  Slides with 
5 μm thick sections were deparaffinized and rehydrated in serial alcohol baths.  Antigen 
retrieval was performed in a pressure-cooker with citric acid-based antigen unmasking 
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solution (Vector Laboratories, Cat# H-3300):  the unit was brought to boiling, slides were 
added and the lid was secured.  After five minutes of full-pressure heating, slides were 
allowed to cool to room temperature before washing in deionized water.  Endogenous 
peroxidase activity was quenched in 3% hydrogen peroxide followed by water and TBST 
washes.  Sections were isolated with a hydrophobic pen and blocking was performed with 
1.5% goat serum in TBST for one hour at room temperature.  Blocking buffer was 
aspirated and primary antibody was applied at a 1:500 to 1:10,000 dilution (depending on 
the antibody) in blocking buffer; sections were incubated overnight at 4°C in a 
humidified chamber.  Slides were washed 3 times for 3 minutes in TBST before 
application of secondary antibody.  Secondary antibody was diluted 1:1,000 in blocking 
buffer, applied to all sections and incubated for 1 hour at room temperature.  Slides were 
again washed and ABC reagent was applied per the manufacturer's instructions.  
Following a 30-minute incubation, the ABC reagent was washed off the slides and DAB 
reagent was applied.  Development was allowed to proceed for one minute.  Slides were 
washed and counterstained with hematoxylin, dehydrated and mounted per standard 
protocols.  Negative controls lacking primary antibody as well as blocking-peptide 
blocked primary controls were included.   
RESULTS 
Multiplex PCR Species Validation 
The multiplex PCR was successfully able to identify all six tested species and the 
internal control amplicon at previously published amplicon sizes (Fig. 4.1) (12).  
Furthermore, when each species of interest was contaminated with 10% and 1% gDNA 
from a different species, the PCR detected this contamination with 100% success rate.  
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Figure 4.1B demonstrates this contamination study with canine gDNA as the primary 
input alone (lane 1) and contaminated with 10% (even lanes) and 1% (odd lanes) of 
human (lanes 2-3), cat (lanes 4-5), Chinese hamster (lanes 6-7), rat (lanes 8-9) and mouse 
(lanes 10-11) DNA.  Lane 12 is a negative control with no input gDNA and the final two 



















Figure 4.1 – Multiplex PCR agarose gel electrophoresis.  (A) A species ladder was 
developed to test six species (lane 1).  In descending size order:  human (391 bp), cat 
(341 bp), Chinese hamster (315 bp), rat (196 bp), dog (172 bp) and mouse (150 bp) 
species bands were successfully detected. Lane 2: 100 bp ladder.  (B) Genomic DNA 
from canine cell lines was experimentally contaminated with 10% (Lanes 2, 4, 6, 8 
and 10) and 1% (Lanes 3, 5, 7, 9 and 11) gDNA from human, cat, Chinese hamster, rat 
and mouse cell lines respectively.  Lane 12 is a negative control and Lanes 13 and 14 
are the species ladder and 100 bp ladder respectively.  Composite image of single gel 
with two sets of wells.  (C) Mistaken identity in a “canine melanoma” cell line:  four 
cell lines were tested, one was determined to have become human (Lane 2) but the 
other three remained canine (Lanes 3-5).  Lane 1:  100 bp ladder, Lane 6:  negative 
control, Lane 7:  100 bp ladder.
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Multiplex PCR testing of a total of 60 cell lines yielded three cases of mistaken 
identity.  The first, a slow-growing canine osteosarcoma cell line “Yamane” was 
identified by PCR as murine in origin.  A sample of this cell line from a different 
laboratory tested as canine indicating that the first laboratory had experienced a previous 
mislabeling or contamination event.  The second case of mistaken identity was observed 
in another slow-growing canine cell line:  the “Parks” melanoma tested as human in 
origin by PCR (Figure 4.1C).  The investigator working with this line had noticed a 
change in morphology and proliferation rate and, thus, requested the validation.  As with 
the “Yamane” cell line, a different laboratory’s stock of the “Parks” cell line tested as 
canine.  Finally, another presumed canine osteosarcoma line, “Grey,” was identified by 
PCR as human in origin.  None of these three samples demonstrated any evidence that the 
original species was still present in the sample. This result was not surprising as previous 
studies have shown that contaminating cell lines can completely overgrow cultures in as 
few as four or five passages (5). 
Table 4.1 – Observed allele sizes in 29 canine cell lines. 
 
 Allele Designation 
 A B C D E F G H I J K 
PEZ 1 107 115 119 123 127       
PEZ 3 112 115 118 121 124 127 128 131 134 136 139 
PEZ 5 103 107 111 115        
PEZ 6 171 175 179 180 183 184 187 188 191 199  
PEZ 8 227 228 229 232 233 236 238 240 245 249  
PEZ 12 263 267 270 274 277 285 288 290 297 301  
PEZ 20 172 176 180         
FHC 2010 227 231 235 239        
FHC 2054 147 151 156 160 164 168 172 176    
FHC 2079 272 275 279 287 291       
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Short Tandem Repeat Profiling of Canine Cell Lines 
Short tandem repeat analysis of verified canine cell lines yielded three additional 
cases of mistaken identity.  The STR kit tested ten different loci; up to 11 different alleles 
were observed among the samples (Table 4.1).  Alleles were designated by sequential  
lettering because a set nomenclature utilizing allelic ladders for canine STRs has not yet 
been established.  This tactic allows comparisons between different cell lines or multiple 
samples from the same cell line to validate identity within a species.  Cancer cell lines 
can contain many genetic alterations including loss of heterozygosity or the gain or loss 
of allele copies, thus, sub-lines of the same cell line may not have identical STR profiles.   
Considering this, looser criteria are required for the comparison of cancer cell line STR 
profiles.  Previous work comparing STR alleles in human cell lines determined that a 
threshold of 75% identity was sufficient to identify all cell lines known to derive from a 
single source.  Virally transformed and drug-resistant sublines also conformed to this 
threshold (14).  Cell lines isolated from different individuals showed no greater than 50% 
identity (14). 
In the first case of mistaken identity, two samples of the widely-used D17 canine 
osteosarcoma cell line had vastly different STR profiles (Figure 4.2).  In order to 
determine the correct STR profile, two additional samples of the D17 cell line were 
analyzed, including a sample obtained from the supplier (ATCC).  Comparisons of the 
STR profiles between multiple samples obtained from a total of 8 osteosarcoma cell lines 
allowed the determination that the STR profile of one of these “D17” cell lines matched 
that of another canine osteosarcoma line, the Moresco line (Table 4.2).  The other “D17” 
cell line matched the STR profile of the D17 sample obtained from the supplier (ATCC).   
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Figure 4.2 – Abbreviated STR profile of two cell lines originally presumed to both 
be D17.  A) Three STR loci from the sentinel D17 cell line from one laboratory 
compared to the same 3 loci (B) of the original D17 cell line from the provider 
(reference cell line)g.  The lines share the same FHC2054 allele but the other two loci 
do not match.  Four additional loci from the sentinel (C) and reference (D) D17 cell 
lines do not share alleles.  Further testing demonstrated that the sentinel line (A&C) 
was identical to the “Moresco” cell line and that a D17 line from another laboratory 
matched the reference D17 line (B&D). 
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Table 4.2 – Allele distribution in 29 cell lines as determined by STR analysis. 
 




2010 PEZ5 PEZ20 PEZ12 PEZ3 PEZ6 PEZ8 
FHC 
2079 
C2(1195)b A A,C B C B C C,K* E,H C,D A 
           
Morescob A C A A 0 A,I H A,F G A 
D17b A C A A 0 A,I H,I A,F G A 
           
Abrams[r]1,b A,C D,H A,C A B D,J E C,G B,G D,E 
Abramsa A,C D,H A,C A B D,J E C,G B,G D,E 
Abrams2,b A,C D,H A,C A B D,J E C B,G D,E 
           
CMT27b B B,C C A B E A,D B I,J A 
CMT12b B B C A B E A,D B E,I A 
CML6Mb B B C A B E A,D* B E,I A 
           
Gracieb B C,G B,C C C C,D F,G C,E H B,C 
           
Vogela B,C C,G C,D A B D B,H B,F C,F A,B 
Vogelb B,C C,G C,D A B D B,H B,F C,F A,B 
           
OSWb B,D C D A C C,G E,J B,E H C 
OSWb B,D C D A C C,G E,J B,E H C 
           
DEN-HSA1,b B,D F,G B,C A B,C F,G E E,G C,H B,C 
DEN-HSA2,b B,D F,G B,C A 0 F,G E E,G C,H B,C 
Fitz-HSAb B,D F,G B,C A B,C F,G E E,G C,H B,C 
           
CTACb C E A,B D B E H,I E A B 
           
McKinleya C,D B,C B,C A B D,F G,H G,J B A,B 
McKinleyb C,D B,C B,C A B D,F G,H G,J B A,B 
           
Dog Control C,D B,G C A A,C A,I B,E D,G D,H B 
           
Yamanea C,D B A A B C E,H A C B 
           
DH82b C,D C,F B B B C,F E C D,H B 
           
K9TCCb C,D H B D B B C E F C 
           
1771[r]b C,E B B A 0 D,E K I F,J A 
           
CML6Mc C,E B C,D A 0 E,I G,I C F,H B 
           
CML10C2b D C B D B C,D C C,E B,H A,E 
CML84-
10C2c D C B D B C,D C C,E B,H A,E 
           
D17a E C B,D A 0 A,H G C D B 
D173,b E C B,D A A,C A,H G C D B 
* = allele call missed by analysis software, a = “Laboratory 1”, b = “Laboratory 2”, c = “Laboratory 3”,  
1 = Oldest passage of cell line, 2 = Recent passage of cell line, 3 = Sentinel cell line from supplier 
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In the second case, the STR profile for the canine Fitz-HSA hemangiosarcoma cell line 
exactly matched both early and late passage number samples from the DEN-HSA 
hemangiosarcoma line, indicating the three samples are derived from the same source.   
A third case of mistaken identity occurred when two separate samples of a 
putative canine melanoma cell line, CML6M, did not have similar STR profiles.  
However, one sample shared an identical STR profile with the mammary tumor cell line, 
CMT12, indicating contamination or mislabeling. Interestingly, the CMT12 and CMT27 
cell lines had STR profiles that were 90% conserved, showing differences in only two 
alleles, indicating that they were likely derived from the same donor.  This change in 
alleles may represent genetic drift of a single cell line or the difference between a primary 
tumor and a metastatic site.  Additional information regarding the derivation of these cell 
lines or comparisons to earlier passages will help to resolve these questions. The other 
CML6M sample had a unique STR 
profile when compared to all the 
canine cell lines tested to date and is 
presumed to be correct.  
Short tandem repeat profiling 
is also useful for the detection of 
genetic drift among different passages 
of the same cell line.  In the current 
study, one such case of genetic drift 
was observed.  Comparison of three 
Abrams canine osteosarcoma cell line 
 
 
Figure 4.3 – PEZ 6 locus of early (A) and 
late passage (B) number samples of the 
canine osteosarcoma cell line “Abrams”.  
Note the loss of the second allele (arrow) in 
the later passage sample. 
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samples indicated that one later passage sample had lost one PEZ 6 allele resulting in 
95% identity with the other two samples (Figure 4.3).  In all, seven of 60 cell lines tested 
(12%) were misidentified or altered.  Although this is lower than suggested averages (7), 
it still validates the necessity of good cell culture practices including periodic cell line 
validation.  The observed misidentifications may be due to contamination or accidental 
mislabeling.  Thus, it is imperative to practice excellent cell culture techniques and 
regular testing to prevent cases of misidentification from wasting valuable time and 
money. 
RUNX2 Expression as a Means to Validate OSA Origin of Cell Lines 
 In order to validate that all canine OSA cell lines used in this study were, indeed, 
derived from OSA, we tested expression of the bone/OSA marker, RUNX2.  RUNX2 is a 
well-established marker of OSA and typically shows strong up-regulation in these tumors 
[see (15) for review].  Via qRT-PCR, we determined that RUNX2 was, indeed, detectable 
in all presumed OSA cell lines (Ct < 37 cycles, data not shown). 
ADHFE1 Expression in Canine OSA Cell Lines 
 ADHFE1 was previously identified as a dysregulated gene in canine OSA and it 
was determined to be an attractive target for model generation.  Thus, we analyzed 
protein and mRNA expression of this gene in cell lines for future in vitro studies.  qRT-
PCR in the Abrams, McKinley, Vogel and Yamane (verified canine) cell lines identified 
a range of expression levels spanning those observed in good and poor responder dogs 
(Figure 4.4A).  The ADHFE1 antibody tested successfully probed the target protein:  the 
expected band size of 40-45 kD was observed as was a larger band, roughly 80 kD in size 
(Figure 4.4B).  Blocking peptide blocked signal from both of these bands, and the 
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information from the supplier indicates that this larger band is present in human samples 
as well.  However, it is worth noting that only the intensity of the smaller band tracks 
with observed mRNA expression levels. 
 
SCN1B Expression in Canine Cell Lines 
SCN1B expression levels were also examined relative to good and poor responder 




























































































Figure 4.4 - Validation of ADHFE1 expression in canine cell lines.  A) Relative 
expression of ADHFE1 mRNA in four cell lines compared to primary tumors from a 
previous study.  All bars represent fold change relative to good-responder primary 
tumors (Good Resp.) B) Membrane was probed with rabbit polyclonal anti-human-
ADHFE1.  Both the ~40 kD and the ~80 kD bands seen here were observed by the 
supplier on human samples.  Lanes 1-4 - cell lines, lane 5 - molecular weight markers. 
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expressing far greater quantities of SCN1B mRNA than observed in any primary tumors 
tested thus far (Figure 4.5A).  The SCN1B antibody that was tested also successfully 
probed the target protein but, again, generated two bands.  The expected band size was 
observed at 29 kD as was a 50 kD band that was also observed by the supplier (Figure 
4.5B).  HeLa cells (Lane 4) were included in this blot as a positive control and 
demonstrated similar banding patterns to the canine samples.  Blocking peptide 


















































































































Figure 4.5 - Validation of SCN1B expression in canine cell lines.  A) Relative 
expression of SCN1B mRNA in three cell lines compared to primary tumors from a 
previous study.  All bars represent fold change relative to good responder primary 
tumors (Good Resp.).  B) Membrane was probed with rabbit polyclonal anti-human-
SCN1B antibody.  Both the ~29 kD and the ~50 kD bands seen here were observed by 




Immunohistochemical Validation of Antibodies in Canine Samples 
To determine if antibody functionality observed in western blots translated to IHC 
procedures, primary canine tumors as well as control tissues were stained using the 
antibodies that had been determined to be specific above.  Blocking peptide and negative 
controls lacking primary antibody were used to optimize antibody concentrations.  The 
ADHFE1 antibody was optimized in canine kidney sections.  Initial staining with 1:1,000 







Figure 4.6 - Immunohistochemical staining of canine kidney sections with anti-
ADHFE1 antibody.  All images are 400x.  5 μm sections of primary tumor tissue 
were stained for ADHFE1 using the same polyclonal antibody used for western 
blotting.  Positive signal is indicated by brown staining (DAB development), 
hematoxylin (blue) counter-stain (A-D). Primary antibody concentrations of 1:1,000 
(A,C) and 1:10,000 (B,D) were tested.  Blocking peptide blocking of primary 
antibody specific activity (C,D) indicated that 1:1,000 was too high of a concentration 
as it produced non-specific nuclear staining (C).  1:10,000 dilution, however, yielded 
specific staining as all staining was blocked by the blocking peptide (D).  
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staining (Figure 4.6A).  Staining with a 1:10,000 dilution of primary antibody, however, 
abolished all nuclear staining yet maintained membranous staining (Figure 4.6B).  To 
determine which pattern was specific, blocking peptide was used to block specific 
binding of primary antibody to the targeted epitope.  This experiment determined that the 
nuclear staining observed with the more concentrated primary antibody was non-specific 
as only membranous staining was blocked by blocking peptide (Figure 4.6C-D). 
 SCN1B antibody staining of control tissues (kidney and skin) indicated that 
SCN1B is localized to a subpopulation of tubule cells (Figure 4.7A) and is present in 
sebaceous glands and hair follicles (Figure 4.7B).  Staining of primary OSA tumors 
indicated that the protein was localized to the cytoplasm and was present in the vast 
majority of tumors (Figure 4.7C,E).  Blocking peptide studies indicated that slight 
background staining was present in those tumors demonstrating the strongest staining 
(Figure 4.7D) but not in tumors with less-intense or less-frequent staining (Figure 4.7F). 
DISCUSSION 
In the current study, we have validated canine species, STR identity and RUNX2 
expression for seven canine OSA cell lines to be used in future studies and validated two 
anti-human antibodies for use in canine samples.  Additionally, we have tested a variety 
of other cell lines for species identity and STR genotype, in the process, establishing a 
database of these findings as a resource for other researchers. 
The pet dog population is a uniquely ideal model group for many diseases in 
humans, especially cancers.  Their large body size and similar metabolic rate make for 









Figure 4.7 - Immunohistochemical staining of canine kidney, skin and tumor 
sections with anti-SCN1B antibody.  All images are 400x.  5 μm sections of primary 
tumor tissue were stained for ADHFE1 using the same polyclonal antibody used for 
western blotting.  Positive signal is indicated by brown staining (DAB development), 
hematoxylin (blue) counter-stain (A-F). Canine normal tissues: (A) Canine kidney 
tubules, (B) canine skin section with sebaceous gland and hair follicle.  Canine OSA 
sections:  C) unblocked SCN1B staining, D) blocked SCN1B antibody used for 
staining in a sample from the same dog.  E&F)  Same as C & D but with tumor from a 
different patient. 
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they share a living environment with humans and are more closely genetically related to 
people than are mice.  Compared to humans, dogs are a relatively inbred population; this 
may lend itself to successful identification of disease-causing genetic factors that are 
otherwise obscured in the human population.  Finally, unlike mouse models, diseases in 
dogs are spontaneous and more likely to reflect similar human diseases (1, 3, 16, 17).  
Multiplex PCR testing using species specific primers is a simple and inexpensive 
way to begin the species validation process in any facility where multiple species of cell 
lines are used.  Following species validation, PCR-based STR profiling is the current 
“gold standard” for cell line validation within a species.  Commercial microsatellite kits 
are not currently available for all species.  However, the increased use of STR analysis in 
forensics and parentage testing for breed registries has resulted in the development of 
STR panels for a growing variety of species.(18-25)  Both forensic and parentage testing 
require the STR panels to be sufficiently complex to allow for the identification of 
individuals in a population and within specific breeds.  The selected loci must also 
exhibit efficient, repeatable amplification in and between laboratories.  Typically, 
tetranucleotide repeats have proven to be the least susceptible to error.(23)  The STR 
panel used in this study exceeded 99% power of exclusion for canine parentage 
verification in 61% of the breeds tested in a previous study.(26)  
For the effective development of searchable databases, a standardized 
nomenclature for a consistent set of microsatellite markers is required.  For such 
nomenclature to be developed, allelic ladders for each locus must be generated so that 
allele size can be standardized across different facilities.  As these are not currently 
available for the canine species, the allele sizes presented in Table 1 are specific to the 
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capillary electrophoresis instrument and methodology used at CSU.  The control canine 
DNA (Table 2) that was included with the STR kit may, to a limited extent, be used as an 
inter-facility reference point.  However, the control DNA is not sufficiently precise to 
supplant an allelic ladder because DNA migration in capillary electrophoresis is 
dependent upon both size and sequence. Thus, the use of an allelic ladder would greatly 
enhance size measurement accuracy (23).   
The average standard deviation in allele size for this control was ±0.176 bp 
between runs indicating that there was a high degree of repeatability when the same 
instrument was used. However, different instruments and polymers may result in as much 
as a 4 bp shift. As a consequence, most laboratories conducting parentage testing require 
that the samples for offspring and all possible parents are tested concurrently to minimize 
error. The consistency in allele size between runs suggests that this will not be a problem 
for cell line validation within CSU’s core facility; however, control samples will be 
monitored to detect deviations in the observed allelic sizes.  
Standard cell culture practices that should be implemented to avoid contamination 
include maintenance of separate culture media stocks for each cell line, never having 
multiple cell lines in the hood at the same time, and thoroughly cleaning the hood and 
associated cell culture equipment between cell lines.  Beyond these basic practices, 
validation of cell lines before beginning a new study is highly recommended.  To further 
the precision of cell line validation, it is recommended that, whenever a new cell line is 
cultured from tissue, a sample from the tissue donor be analyzed with STR profiling so 
that all future passages of the resulting cell line may be compared against the donor’s 
profile.  Furthermore, to avoid genetic drift, it is advantageous to maintain low passage 
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number stocks to which an experimenter can return when cultured cell lines reach a high 
passage number or show evidence of genetic drift on STR analysis. 
Despite these current limitations, STR analysis provides a simple, inexpensive 
method to validate cell line consistency and identity. The development of a database of 
STR profiles and comparison of cell line profiles from multiple sources including early 
passage samples or donor tissues will improve the quality, consistency, and validity of 
research studies utilizing canine cell lines.  
Quantitative RT-PCR for the RUNX2 gene was a fast and effective method of 
verifying that OSA cell lines were, indeed, derived from OSA.  Up-regulation of this 
gene is not unique to OSA but the only other system in which it is commonly observed is 
acute myeloid leukemia.  Thus, RUNX2 expression must be evaluated in the context of 
cell morphology - as OSA cells are adherent and spindloid and leukemic cells are, 
generally, non-adherent and round, they are easy to differentiate.  Using this 
methodology, the seven OSA cell lines addressed in this study have been validated as 
OSA-derived. 
Only a very limited number of anti-canine antibodies are commercially available 
as the dog model system is only recently gaining acceptance.  Thus, short of generating 
new antibodies, the only way to study protein expression in canine samples is to validate 
currently available antibodies.  Many of these are anti-human antibodies and, considering 
the high degree of homology between dogs and humans, have a good chance of working 
in the canine system.  We approached antibody validation by first verifying that there was 
a significant amount of conservation between the target epitope and the canine protein 
sequence.  This, undoubtedly, contributed to the validation success rate shown here. 
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The importance of blocking peptides for optimization of IHC is often omitted in 
standard protocols.  The false background staining observed in canine kidney sections 
stained with anti-ADHFE1 (Figure 4.6) emphasizes that having a blocking peptide for 
every antibody is crucial if one wishes to generate true and correct data.  An additional 
two antibodies were validated for use in canine samples; data for these are presented in 
the chapters focused on the genes IGF2BP1 (Ch. 5) and NDRG2 (Ch. 6). 
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Expression of the oncofetal protein IGF2BP1 contributes to an 




 Background:  Osteosarcoma (OSA) is a highly aggressive bone malignancy that 
affects both dogs and humans.  Previous identification of IGF2BP1 as a negative 
prognostic indicator in canine OSA led us to investigate possible mechanisms of control 
for this gene as well as the effects of modulating its expression in this system.  Methods:  
Normal bone mRNA expression of IGF2BP1 was compared to that of tumors using 
microarrays and qRT-PCR.  Intracellular localization of IGF2BP1 protein was examined 
via immunohistochemistry and in vitro invasion was assayed following siRNA-mediated 
knockdown.  Genomic DNA was analyzed to determine if amplification of the IGF2BP1 
locus was amplified and 3' UTR analysis was performed to determine if UTR shortening 
was responsible for over-expression of this gene.  Results:  IGF2BP1 transcript was 
found to be virtually undetectable in normal bone with microarray and qRT-PCR but up-
regulated in the vast majority of tumor samples tested.  Protein was localized to the 
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cytoplasm in many tumor samples but extended into the nucleus in others.  siRNA-
mediated knockdown was successful and reduced invasion in the Abrams canine OSA 
cell line.  Genomic amplification of the IGF2BP1 locus does not appear to be a 
mechanism of over-expression in this system but 3' UTR truncation may contribute to 
increased mRNA half life.  Conclusions:  IGF2BP1 is up-regulated in canine OSA, 
most-so in dogs that respond poorly to definitive treatment and adjuvant chemotherapy.  
When modulated in vitro, IGF2BP1 contributes to invasion in canine OSA and over-
expression of the gene is likely influenced by 3' UTR shortening in vivo. 
INTRODUCTION 
 Osteosarcoma (OSA) is the most common primary bone malignancy in both 
humans and dogs affecting roughly 800 adolescents and 8,000 companion dogs annually 
(1, 2).  Standard of care in both species involves resection of the tumor either by 
amputation or limb sparing surgery followed by adjuvant chemotherapy.  Neoadjuvant 
chemotherapy is commonly utilized in human medicine but less-so in canine patients.  
The majority of OSA tumors in both dogs and humans occur in the metaphyseal regions 
of long bones in the appendicular skeleton.  Histological classifications are shared 
between species as are many molecular characteristics of the disease (1, 3-6).  Metastatic 
disease of the lungs is the most common cause of morbidity and mortality and is a strong 
negative prognostic indicator (1, 2, 7).  Roughly 10-15% of patients of both species 
present with clinically detectable metastases and it is estimated that over 80% of patients 
may have undetectable micrometastatic disease at presentation. Thus, systemic 
chemotherapy aimed at diminishing distant disease is included in most protocols.   
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 Considering the similarities between canine and human living environments, their 
genomes and the pathology of OSA, this disease in dogs is increasingly recognized as a 
valuable model for the human disease (3, 8).   Previous studies by our laboratory 
identified Insulin-Like Growth Factor II (IGF2) mRNA Binding Protein I (IGF2BP1) as a 
gene that was highly expressed in primary OSA tumors from dogs that rapidly developed 
metastatic disease following  definitive treatment when compared to dogs that exhibited 
slower disease progression (9).  IGF2BP1 has been identified in a number of different 
systems and, as such, is known by many names including Zipcode-Binding Protein 1 
(ZBP1), Coding Region Determinant Binding Protein (CRD-BP) and IMP-1, an alternate 
acronym for its IGF2 binding capability (10-13).  The genomic DNA encoding this 
protein is located on human chromosome 17q21 and on canine chromosome 9; in both 
species, the promoter region has extensive CpG islands.  A 15-exon transcript has been 
identified in both dogs and humans and an additional 13-exon splice variant has been 
identified in humans.  The gene has an extensive 3' untranslated region (6.7 kb) with 
three highly conserved poly-adenylation signals and five highly-conserved Let-7 binding 
sites (14).  Additional miRNA binding sites are also present.  The translated protein is 
577 aa long with 6 conserved domains:  two K-homology (KH) domains and four RNA 
recognition motifs (RRM) (Figure 5.1).  This gene has been termed "oncofetal" as it is 
only expressed in cancer and fetal tissues, expression is extremely limited in normal adult 
tissues (12, 15). 
 A number of studies have identified IGF2BP1 as a poor prognostic factor in 
several different cancer types.  Doyle and colleagues identified chromosomal 
amplification of the IGF2BP1 region in human breast carcinomas; this was particularly  
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notable as this gene is near Her-2 yet they found amplification of the two genes to be 
independent of each other.  They also found that IGF2BP1 amplification correlated with 
increased tumor grade, projecting a poor outcome (16).  Ioannidis and colleagues 
supported this finding in breast carcinomas (17) and found this gene to be overexpressed 
in brain and lung cancers (18).  This latter group did note that upregulation is not unique 
to malignancy as it was also observed in some benign masses.  From this, they 
hypothesized that activation of IGF2BP1 may be an early step in tumorigenesis.  
IGF2BP1 has been linked to progression in lung, colorectal and ovarian carcinomas (19-
22) and was found to be expressed in 72% of malignant mesenchymal tumors tested in 
one study as compared to 40% of benign masses (23). 
 As an mRNA binding protein, IGF2BP1 interacts with and modulates the 
expression of a number of different targets.  CRD-BP was first discovered by Jeffrey 
Ross's group at UW Madison when they were investigating the stability of c-myc mRNA.  










Figure 5.1 - Schematic of IGF2BP1 genomic DNA.  IGF2BP1 is a 15-exon gene with 
a small 5’ UTR and a 3’ UTR over 6kb in length.  UTRs are represented by hashed 
boxes and exons by wide solid bars.  Introns are represented by narrow lines and are 
not drawn to scale.  Large CpG islands populate the 5’ end of the coding sequence and 
promoter region and are represented by stippled boxes.  Three highly conserved poly-
adenylation sites and five Let-7 binding sites are indicated by vertical bars.  Ampilicon 
locations for coding sequence and constitutive and distal UTR regions (CDS, cUTR 
and dUTR, respectively) are indicated by brackets.  Adapted in part from Mayr & 
Bartel, 2009 (14). 
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disrupted, decreased the half life of this mRNA by 4 to 8 fold (10).  From this, they 
determined that a protein (CRD-BP) binds to this region and protects it from 
endonucleolytic cleavage.  ZBP1 was first discovered by Robert Singer's group in the 
context of its binding to and localization of β-actin mRNAs in chick embryo fibroblasts 
(13).  In a number of elegant mRNA trafficking studies, they determined that ZBP1 plays 
a crucial role in cell polarization and lamelapodia formation  by directing localization of 
β-actin mRNAs (24-26).  Additionally, they determined that the interaction of β-actin and 
ZBP1 is controlled by Src-mediated phosphorylation of a tyrosine residue of ZBP1 
causing cargo release at the periphery of the cell (27).  In 1999, Nielsen and colleagues 
coined yet another acronym for this protein, IMP-1, after they discovered it associating 
with the insulin-like growth factor II leader 3 mRNA (11, 12).  In this initial study, they 
determined that multiple IMP-1 proteins bind to and repress translation of the IGFII 
leader 3 mRNA during key stages of embryonic development.  With so many potential 
regulatory targets, it is unsurprising that dysregulation of IGF2BP1 could play a major 
role in tumorigenesis and cancer progression. 
 As the body of knowledge regarding miRNAs has dramatically increased in 
recent years, IGF2BP1 has gained more attention due to its lengthy 3' UTR with multiple 
Let-7 and other miRNA binding sites.  Let-7 has been identified as tumor suppressor 
miRNA capable of suppressing oncogene expression as well as cell-cycle factors.  Recent 
literature indicates it also downregulates IGF2BP1 which, in turn, may actually be a 
master regulator of cell-cycle-progression factors that are downstream of MYC including 
Cyclin D2 (CCND2), Cyclin-Dependent Kinase 6 (CDK6) and Cyclin-Dependent Kinase 
(CDC2) among others (28, 29).  In a 2009 publication, Mayr & Bartel identified one 
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possible mechanism by which IGF2BP1 can escape Let-7 regulation:  alternative 
cleavage and polyadenylation of the 3' UTR that removes all Let-7 binding sites from the 
transcript (14).  Thus, dysregulation of Let-7 can lead to a release of IGF2BP1 expression 
and/or early cleavage of the UTR can be favored by conditions in the cell, effectively 
removing the ability of Let-7 to suppress the half-life of IGF2BP1.  In either scenario, 
massive disruption in the normal control cascades of the cell ensues and the diverse 
IGF2BP1 downstream targets are released from their normal regulation. 
 The current study compares previously determined OSA primary tumor 
expression patterns of IGF2BP1 with those of normal bone via both microarray and 
quantitative reverse transcription PCR (qRT-PCR) as well as exploring IGF2BP1 
expression in canine OSA cell lines.  Array CGH analysis comparing normal tissue 
(muscle, skin) to a subset of OSA primary tumors was also performed to investigate if 
IGF2BP1 dysregulation was caused by gene amplification.  Immunohistochemical 
staining of primary OSA sections was utilized to determine if staining of this factor could 
be used as a prognostic indicator.  Additionally, we sought to elucidate the effect of 
IGF2BP1 expression in these cells with respect to invasion and migration.  Finally, we 
examine relative expression levels of different 3' UTR segments to determine if 




 Canine tissues used in microarray and PCR studies were obtained from animals 
presenting to Colorado State University (CSU) for treatment of OSA.  Owner consent for 
tissue archiving was obtained prior to definitive surgical treatment.  Good- and poor-
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responder primary tumors were archived at the Animal Cancer Center between 1996 and 
2006 - snap frozen tissues and formalin-fixed paraffin embedded (FFPE) tissues were 
archived.  Good and poor responder groups were defined based upon patient disease-free-
interval (DFI):  good-responders had a DFI greater than 300 days and poor-responders 
had a DFI less than 100 days.  Normal bone and matched tumor samples were obtained 
from limbs post-amputation and harvested so that “normal” bone included in the study 
was distant from the tumor site and separated from the tumor by a joint (i.e. a femoral 
tumor would have matched distal tibia bone collected).  Tissue was collected, snap frozen 
in liquid nitrogen and stored at -80ºC until processing.  Tumor tissues for an independent 
data set used for immunohistochemistry (n=64) were collected at various veterinary 
teaching hospitals and archived at CSU as FFPE blocks.  Inclusion in these studies 
required limb amputation followed by doxorubicin and/or platinum drug adjuvant 
therapy. 
Canine Cell Lines 
 Canine cell lines used in this study were graciously provided by Dr. Douglas 
Thamm and all cell lines were validated for species and short-tandem-repeat identities as 
previously described (30).  Abrams cells were derived from metastatic OSA nodules 
whereas McKinley, Vogel and Yamane were derived from primary tumors.  Cells were 
cultured in C10 media (DMEM high glucose with 6mM L-glutamine, 1x each of sodium 
pyruvate, MEM vitamins, MEM non-essential amino acids and antibiotic-antimycotic, 
10% fetal bovine serum (FBS) and Plasmocin prophylactic (Invivogen, ant-mpp)).  C0.1 




 Tumor and normal tissues were freeze-fractured, homogenized, extracted in 
Trizol per the manufacturer’s instructions and purified with the RNeasy cleanup protocol.  
Cell cultures were detached from plates with 3mM ethylenediaminetetraacetic acid 
(EDTA) in phosphate-buffered saline (PBS) or 0.25% trypsin in PBS with EDTA, 
pelleted by centrifugation for 5 minutes at 500 x g and extracted using the RNeasy kit per 
the manufacturer’s protocol.  RNA was quantified via spectrophotometry and, prior to 
microarray, tissue RNA was bioanalyzed for quality at the Rocky Mountain Regional 
Center for Excellence (RMRCE) Genomics Core at CSU.  Only high quality RNA with 
RNA Integrity Numbers (RINs) greater than 8 were used in microarray studies. 
Microarray 
 Eight normal bone samples were analyzed with Affymetrix Canine 2.0 GeneChips 
as previously described (9).  Resultant data was compiled with data from 15 good and 
poor-responder primary tumor samples obtained previously and analyzed with 
ArrayTrack (31).  Data was preprocessed with the Probe Logarithmic Intensity Error 
(PLIER) estimation algorithm with a log2 transformation then analyzed for fold change 
based on two scenarios:  normal bone versus all tumors or normal bone versus good 
responders versus poor responders.  The first scenario was analyzed with a Bonferroni 
adjusted unpaired 2-tailed t-test, thresholds of corrected p-value <0.05 and fold-change 
>3 were applied.  The second scenario was analyzed with pairwise t-tests and the same p-
value and fold-change thresholds.  Log2-transformed PLIER IGF2BP1 expression values 




 Reverse transcription (RT) was performed on RNA samples with the QuantiTect 
Reverse Transcription kit (Qiagen, 05313) per the manufacturer's instructions with 1μg 
RNA input, a ten-minute gDNA digest incubation and a 30-minute RT incubation.  No-
RT controls were included for each sample as was one no-transcript control per RT 
reaction.  Real-time quantitative PCR was performed using the iQ SYBR Green 
Supermix (Bio-Rad, 170-8880) in 25 μL reactions with 25 ng equivalent cDNA input.  
IGF2BP1 and housekeeping gene (HPRT-1) primers were as previously published (9) 
and were included in the reactions at 100 nM forward and 300 nM reverse primer 
concentrations.  Standard curves for the two primer sets over two orders of magnitude 
were within 5% efficiency of each other.  Thermal cycling was performed on the 
Mx3000p instrument (Stratagene) with the following parameters:  95°C for 10 m 
followed by 40 cycles of 95°C for 30 s and 60°C for one minute.  Data collection was 
performed at the end of the 60°C step.  Dissociation curve ramps were performed at the 
end of the cycle to verify that only a single product was generated.  Data analysis was 
performed with the Mx3000p software.  IGF2BP1 expression was normalized to HPRT-1 
and fold change was calculated using the 2(-ΔΔCt) method (32). 
Western Blotting 
 Western blotting was performed on whole-cell lysates obtained by repeatedly 
passing cell pellets through a 26-gauge needle in Tris pH 7.5 buffer with cOmplete™, 
EDTA-free Protease Inhibitor Cocktail Tablets (Roche, 04693132001).  Total protein was 
quantified with a BCA Assay kit (Pierce, 23227) and 25 μg protein was loaded for each 
sample.  Proteins were electrophoresed on 12% SDS-PAGE gels with 5% stacking gels at 
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180 v for 50 minutes and were then transferred to PVDF membranes with a semi-dry 
transfer unit.  Membranes were dried with methanol then blocked in 0.5% milk in Tris-
buffered saline with Tween-20 (TBST) for one hour at room temperature.  The primary 
antibody was obtained from Abcam (ab82968 - rabbit polyclonal to human); the targeted 
epitope is 100% homologous to the canine protein (Figure 5.2).  Membranes were  
 
incubated overnight at 4°C with primary antibody diluted 1:1,000 in 0.5% milk/TBST 
and were then washed 3 times for five minutes each in TBST.  Secondary antibody 
(HRP-conjugated goat anti-rabbit IgG, Bio-Rad, 172-1019) was applied at a dilution of 
1:10,000 in 5% milk/TBST for a one-hour, room-temperature incubation followed by 
TBST washes.  SuperSignal West Pico Chemiluminescent Substrate (Pierce, 34078) was 
used for development and images were captured on a Bio-Rad ChemiDoc XRS system.  
Specificity of the primary antibody was verified using a blocking peptide (Abcam 
ab100852) per standard protocols.  Briefly, primary antibody was incubated with 10x (by 
mass) blocking peptide in blocking buffer overnight at 4°C with agitation before being 
applied to the membrane.  In parallel, unblocked primary was applied to a second, 
identical membrane.  The western blot was completed as above and membrane signals 
were compared between the two membranes.  α-tubulin was used as a loading control:  
primary antibody (Sigma Cat# T5168 mouse monoclonal anti-human) incubation was 
Epitope    (aa1) KSGYAFVDCPDEHWAMKAIETFSGKVELQGKRLEIEHSVPKKQRSRKIQI  (aa50)    
KSGYAFVDCPDEHWAMKAIETFSGKVELQGKRLEIEHSVPKKQRSRKIQI
IGF2BP1 (aa36) KSGYAFVDCPDEHWAMKAIETFSGKVELQGKRLEIEHSVPKKQRSRKIQI  (aa85 )
 
 
Figure 5.2 – Alignment of IGF2BP1 antibody epitope and canine IGF2BP1.  The 
region probed by the antibody shares 100% of identities between the canine and 
human genes.  The matching blocking peptide is identical in sequence to the epitope. 
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performed for one hour at a 1:5,000 dilution in 5% milk/TBST, secondary antibody 
(BioRad Cat# 170-6516,  HRP-conjugated goat anti-mouse IgG) incubation was 
performed for one hour at room temperature at a 1:10,000 dilution in 5% milk/TBST with 
washing and development steps as above. 
Immunohistochemistry 
 Immunohistochemistry (IHC) was first performed on the good and poor responder 
groups (n=17) then in the expanded, independent data set.  The primary antibody was the 
same as used for western blotting.  The secondary antibody and ABC reagents used were 
components of the Vectastain Elite Rabbit kit (Vector Laboratories PK-6101).  Final 
development was performed with ImmPACT DAB Peroxidase Substrate (Vector 
Laboratories, SK-4105).  Slides with 5 μm thick sections were deparaffinized and 
rehydrated in serial alcohol baths.  Antigen retrieval was performed in a pressure-cooker 
with citric acid-based antigen unmasking solution (Vector Laboratories, H-3300):  the 
unit was brought to boiling, slides were added and the lid was secured.  After five 
minutes of full-pressure heating, slides were allowed to cool to room temperature before 
washing in deionized water.  Endogenous peroxidase activity was quenched in 3% 
hydrogen peroxide followed by water and TBST washes.  Sections were isolated with a 
hydrophobic pen and blocking was performed with 1.5% goat serum in TBST for one 
hour at room temperature.  Blocking buffer was aspirated and primary antibody was 
applied at a 1:500 dilution in blocking buffer; sections were incubated overnight at 4°C in 
a humidified chamber.  Slides were washed 3 times for 3 minutes in TBST before 
application of secondary antibody.  Secondary antibody was diluted 1:1,000 in blocking 
buffer, applied to all sections and incubated for 1 hour at room temperature.  Slides were 
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again washed and ABC reagent was applied per the manufacturer's instructions.  
Following a 30-minute incubation, the ABC reagent was washed off the slides and DAB 
reagent was applied.  Development was allowed to proceed for one minute.  Slides were 
washed and counterstained with hematoxylin, dehydrated and mounted per standard 
protocols.  Negative controls lacking primary antibody were included.  Slides were 
scored by two blinded individuals on several criteria:  presence of sufficient tissue to read 
four or more 400x fields, percent and intensity of cytoplasmic staining and percent and 
intensity of nuclear staining.  Scorers were instructed to avoid tissue edges to decrease 
artifactual findings.  Good- and poor-responder scores were analyzed with Fisher's Exact 
Test; the larger, independent dataset was analyzed by generating Kaplan-Meier survival 
curves followed by log-rank analysis to compare groups. 
Array Comparative Genomic Hybridization 
 Genomic DNA was extracted from tumors and patient-matched normal tissue 
(muscle, skin) using the DNeasy (Qiagen, Cat# 69504) kit per the manufacturer's 
instructions.  Low yield tissue samples were digested overnight in proteinase K, salt 
extracted per standard protocols and precipitated in ethanol prior to DNeasy cleanup.  
Array-CGH was performed by Dr. Matthew Breen's laboratory at North Carolina State 
University as previously described (33).  Relative amplification of the IGF2BP1 region 
was determined by dividing signal of each tumor sample by its matched normal sample. 
IGF2BP1 Knockdown 
 Transient knockdown with siRNA was pursued in the Abrams cell line.  Stealth 
pre-annealed siRNAs were designed with the BLOCK-iT RNAi design software and 
purchased from Invitrogen; sequences were: Scrambled, 5’-CAG GUG UGU GGU ACC 
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UUA CGA UGC A-3’ with complement 5’-UGC AUC GUA AGG UAC CAC ACA 
CCU G; si1, UUC CCU UGC AAU UCG ACU UUC CCG G-3’ with complement 5’-
CCG GGA AAG UCG AAU UGC AAG GGA A-3’;  si2, 5’-UGC CAA UGA UGG 
CAC CCA CAU ACU G-3’ with complement 5’-CAG UAU GUG GGU GCC AUC 
AUU GGC A-3’.  Cells were split onto 24-well, 6-well or 6cm plates and allowed to 
adhere overnight.  The following day, HiPerFect transfection reagent (0.86 μL/cm2 plate 
surface area, Qiagen, 301705)  was mixed with siRNA duplexes (0.33 μL/cm2 of a 20 μM 
solution) in DMEM and allowed to incubate for 15 minutes at room temperature for 
complex formation.  This solution was then added, dropwise, to the plates and gently 
mixed.  A Cy3 labeled siRNA (10 nM) was used as a transfection control (Integrated 
DNA Technologies - IDT).  Cells were incubated for 6-72 hours with the siRNA before 
being harvested or split for further experiments.  Knockdown was verified with qRT-PCR 
and western blot. 
Invasion and Migration Assays 
 Abrams cells that had been transfected with either scrambled or targeted siRNAs 
were split onto 24-well FluoroBlok BioCoat Matrigel invasion or FluoroBlok migration 
plates (BD Biosciences, 354166 and 351158) 24 or 48 hours following transfection at a 
density of 2,000 cells/chamber in 500 μL C0.1 media.  750 μL C10 media 
(chemoattractant) was added to the bottom chamber of half of the wells whereas C0.1 
was added to the other half.  24 hours following plating, media from the chambers was 
removed and 4 μg/mL Calcein AM (BD Biosciences, 354216) in Hank's Buffered Salt 
Solution was added to the bottom chamber.  Plates were incubated at 37°C in 5% CO2 for 
1 hour then read on a fluorescence plate reader at 494/517 nm (Excitation/Emission).  
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Three replicates of each treatment were performed.  Net invasion was determined by 
dividing invasion signal by migration signal. 
3' Untranslated Region Analysis 
 In order to determine the prevalence of 3' untranslated region (UTR) shortening in 
IGF2BP1 transcripts, primers were designed for qRT-PCR to generate amplicons in the 
constitutive UTR (cUTR) and the distal UTR (dUTR).  Amplicon locations are 
diagrammed in Figure 5.1.  Primer sequences were:  cUTR Fwd 5'-AAG GAC AAC 
GGG CTG AAA TCG AGA-3', Rev 5'-CAA GCA AGT GGG CAA ACC TGA TCT-3' 
and dUTR  Fwd 5'-TGA GAG AGG CCG CTT CTG AAT CAA-3', Rev 5'-TCA GAA 
GGG AAG GGA CGC ATC TTT-3'.  qRT-PCR was performed as above with reactions 
for both UTR amplicons, the translated-region amplicon and the housekeeping gene 
performed concurrently to minimize inter-run variability.  Expression relative to HPRT-1 
was calculated and expressed as 2(-ΔCt); fold-chage was calculated using the 2(-ΔΔCt) 
method. 
RESULTS 
Microarray and qRT-PCR Analysis 
 IGF2BP1 has been identified as an oncofetal protein and, thus, we wished to 
compare previously-observed tumor expression levels to that of normal bone.  Toward 
this end, we performed microarray and qRT-PCR analysis of normal bone and compared 
it to the DFI cohorts and to matched tumor samples.  IGF2BP1 transcript was virtually  
undetectable on microarray, with all 8 samples being flagged as "bad" by standard 
analysis procedures.  When this small expression was compared to DFI cohorts, a 
greather-than 70-fold down regulation was observed relative to both tumor sets (Figure  
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5.3A).  We validated this with qRT-PCR and observed a similar stair-step pattern with 
normal bone having virtually no IGF2BP1 expression, good-responder tumors having 
increased expression and poor-responder tumors demonstrating dramatically increased  

































































































































Figure 5.3 - IGF2BP1 expression from microarray and qRT-PCR studies.  A) Mean 
fold change from Canine 2.0 microarrays.  IGF2BP1 was first identified as a potential 
biomarker in microarrays comparing DFI>300 (good responder) to DFI<100 (poor 
responder) canine patients.  Addition of normal bone microarrays indicates strong 
upregulation in tumors relative to normal bone and a greater increase in poor responders.  
Normal bone n=8, DFI>300 n=7, DFI<100 n=8.  B)  IGF2BP1 expression relative to 
HPRT-1 as assayed via qRT-PCR.  Error bars represent standard deviation, * = p<0.05, 
*** = p<0.001. Datasets are expanded compared to microarray study.  C) Fold change of 
IGF2BP1 in primary OSA tumors relative to matched normal bone for nine dogs. 
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expression (Figure 5.3B).  When we compared normal bone samples to matched tumors 
via qRT-PCR, we observed a dramatic upregulation in 6 of 9 tumors, exceeding 400-fold 
in one case (Figure 5.3C).  The other three tumors demonstrated no or limited 
upregulation of IGF2BP1 indicating that dysregulation of this gene may not be an 
important factor in those individuals. 
Immunohistochemical Analysis 
 Considering the observed mRNA expression pattern of IGF2BP1 (i.e. highest in 
poor-responders) and previous reports indicating prognostic significance, we pursued 
immunohistochemical staining of tumor sections with the aim of developing a widely-
applicable prognostic screen.  As a pilot experiment, tumor sections from dogs included 
in the DFI cohorts were probed for IGF2BP1 staining.  Cellular localization of the protein 
varied between samples with some only demonstrating cytoplasmic staining while others 
demonstrated both cytoplasmic and nuclear staining (Figure 5.4A-D).  In this group of 
samples, presence of nuclear staining in greater than 25% of cells was predictive of 
outcome (Fisher's Exact Test, p=0.009).  Immunohistochemistry was then pursued in a 
larger, independent set of 80 primary tumors from dogs with known DFIs and treatment 
histories.  Neither cellular localization of IGF2BP1 nor intensity and frequency of 
staining were prognostic in this data set (Figure 5.4E-F). 
IGF2BP1 Expression in Canine Cell Lines 
 With the aim of examining mechanisms and results of IGF2BP1 dysregulation in 
vitro, mRNA and protein product expression of this gene were assayed in four canine 
OSA cell lines.  Using qRT-PCR, mRNA expression of IGF2BP1 was compared to 
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Figure 5.4 – Immunohistochemical staining of primary OSA sections for IGF2BP1 
and survival curves based on IHC scores.  (A & B) H&E and IGF2BP1 staining, 
respectively, of a representative tumor sample (#184844).  Note the strong cytoplasmic 
staining but lack of nuclear staining.  400x magnification.  (C & D) H&E and IGF2BP1 
staining of a tumor sample (#223986) representative of those with frequent nuclear 
staining.  400x magnification.  Initial study of DFI cohorts (n=17) indicated that nuclear 
staining in >25% of cells correlated with poor outcome (Fisher’s exact test, p=0.009).  
Considering these initial findings, the IHC study was expanded to an independent data 
set (n=64) and survival curves based upon cytoplasmic and nuclear staining were 
constructed (E & F).  No significant differences between staining patterns were found. 
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 from a metastatic nodule, demonstrated the highest expression at a 20-fold increase over 
good-responder primary tumors (Figure 5.5A).  The Vogel line expressed the least 
 
 IGF2BP1 mRNA with a 4-fold decrease relative to the DFI>300 cohort and a 10-fold 
decrease relative to the DFI<100 cohort.  Upon western blot, only the two highest  

























































Figure 5.5 – Expression of IGF2BP1 in canine OSA cell lines.  (A) qRT-PCR 
analysis of four OSA cell lines – fold change is expressed relative to the good-
responder cohort (DFI>300).  (B) Western blotting was able to detect protein 
product in the two highest expressing cell lines, Abrams and McKinley, whereas 
protein was not detected in the Vogel and Yamane lines (Lanes 1-4, left to right: 
Abrams, McKinley, Vogel and Yamane, respectively)  α-Tubulin loading control, 
below. 
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siRNA Knockdown of IGF2BP1 
 In order to examine what benefits IGF2BP1 overexpression may confer to OSA 
cells, we knocked down transcripts of this gene using siRNA methodology in the highest-
expressing cell line (Abrams).  Scrambled (negative control) and two targeted siRNAs 
were designed and introduced into Abrams cultures with lipid-based transient 
transfection.  qRT-PCR analysis of cells between 6 and 72 hours post-transfection 
indicated that IGF2BP1 was rapidly and effectively knocked down by this strategy with 
an observed 6-fold down-regulation of mRNAs after 24 hours and 10-fold down-
regulation after 72 hours relative to scrambled controls (Figure 5.6A & B). IGF2BP1-si1 
was most effective at knocking down the target and demonstrated the most long-lived 
effects.  IGF2BP1-si2 was also effective but not to the extent of IGF2BP1-si1 and mRNA 
expression began to recover 72 hours following transfection (Figure 5.6B).  Western blot 
was used to verify protein knockdown 48 to 116 hours following transfection.  As with 
mRNA expression, IGF2BP1-si1 was the most effective and lasting siRNA (Figure 
5.6C). 
Invasion & Migration Assays 
 To determine the effect of IGF2BP1 expression on tumor progression and 
metastasis, Abrams cells that had been transfected with siRNAs were assayed for 
invasion and migration capabilities.  Cells that had been transfected 24-hours previously  
were plated onto invasion or migration chambers and allowed to incubate for 24 hours.  
The resulting data showed little difference between scrambled and targeted siRNAs 
(Figure 5.6D, black bars).  A subsequent western blot of a sample of these cells indicated 















































































































































Figure 5.6 – IGF2BP1 knockdown and subsequent invasion and migration assays in 
the Abrams cell line.  Successful knockdown was confirmed at 6,12, 24, 48 and 72 
hours post transfection via qRT-PCR in two separate experiments (n=3 biological 
replicates per treatment, A & B, IGF2BP1 expression relative to HPRT1).  Knockdown 
was also confirmed via western blot of whole-cell lysates at 48, 72, 96 and 116 hours 
post transfection (C), α-Tubulin was used as a loading control.  Sc = scrambled siRNA, 
si1 = IGF2BP1-si1, si2 = IGF2BP1-si2, UT = untransfected.  D) Two separate 
invasion/migration assays were performed:  they were initiated either 24 h or 48 h 
following transfection and allowed to incubate for 24 hours prior to development 
(n=3/treatment, * = p<0.05).  Percent invasion was calculated as 
RFU(invasion)/RFU(migration) where RFU=Relative Fluorescence Units.  Western blot 
follow-up with samples of cells that had been transfected concurrently to experimental 
cells indicated that knockdown of IGF2BP1 was not apparent at the protein level 24h 
after transfection (E).  Knockdown was apparent at 48 h post-transfection (F). 
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 Thus, the experimental window was shifted so that cells were plated into invasion or 
migration chambers at 48 hours post transfection and incubated for 24 hours.  A 
significant reduction in percent invasive cells was observed for both targeted siRNAs 
relative to the scrambled control (Figure 5.6D, gray bars).  Furthermore, a trend showing 
fewer invasive cells in the IGF2BP1-si1 treated group relative to the IGF2BP1-si2 treated 
group correlated with the relative levels of knockdown between these two treatments.  
Subsequent western blotting of samples of these cells showed detectable knockdown with 
both targeted siRNA treatments relative to scrambled and untransfected cells (Figure 
5.6F). 
Array Comparative Genomic Hybridization 
 Array CGH was pursued as a methodology for determining genomic amplification 
in tumor tissues relative to normal tissues.  This assay was performed by Dr. Matthew 
Breen's laboratory with their 2 Mb resolution canine BAC array.  Genomic DNA was 
extracted from primary tumors and matched normal muscle tissue in a subset of the DFI 
cohort samples (n=4 from each group).  Intensity of tumor DNA relative to somatic DNA 
was calculated and plotted for a region surrounding the IGF2BP1 locus (Figure 5.7A).   
Thresholds for locus amplification or deletion relative to somatic DNA were: 
Log2>0.201 (amplification) and Log2<-0.234 (deletion).  In these 8 samples, no 
amplification was observed at any of the loci surrounding IGF2BP1, in fact, deletion was 
observed at several probe regions, however, not in the region closest to the IGF2BP1 
gene (Figure 5.7A, arrow).  mRNA expression  of IGF2BP1 for these 8 tumor samples 
was plotted to compare relative expression to locus intensity (Figure 5.7B).  Two of the 














respectively) also demonstrated higher aCGH signals but these did not meet thresholds 
for amplification.  Thus, although IGF2BP1 locus amplification has been observed in 
breast cancers, it does not appear to be the underlying cause of overexpression in these 
samples of canine OSA. 
3' Untranslated Region Analysis 
 Recent reports of miRNA interaction with and truncation of the extensive 
IGF2BP1 3'UTR in human samples led us to investigate whether this mechanism of 
transcript control is active in canine OSA.  Predicted sequences of the canine IGF2BP1 
3'UTR do not describe a region equivalent to that found in humans so an in silico 
investigation comparing human to canine genomic contigs was undertaken.  Alignment of 
the sequences following the stop codons in both species demonstrated a greater than 70% 

















































































Figure 5.7 – Array CGH analysis of the chromosomal region surrounding IGF2BP1.  
aCGH analysis was performed on normal and tumor genomic DNA from n=4 good and 
poor responder (DFI>300, open symbols and DFI<100, filled symbols) dogs (A).  
IGF2BP1 extends from ~28,525 kb to ~28,567 kb indicated by the arrow.  Individual 
values are tumor intensity relative to normal tissue intensity.  Threshold for locus 
amplification was Log2>0.201 and for deletion, Log2<-0.234.  qRT-PCR expression of 
IGF2BP1 mRNA relative to HPRT-1 is also shown for these 8 dogs (B).  Symbols are as in 
“A.” 
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homology with 100% conservation of the location and sequence of poly-adenlylation 
signals and Let-7 binding sites diagrammed in Figure 5.1.  Thus, primers were designed 
to interrogate canine constitutive UTR (cUTR) and distal UTR (dUTR) prevalence.  As 
the cUTR is expected to be present in every transcript, expression of the cUTR was first 
compared to coding sequence (CDS) expression to validate the qRT-PCR methodology.  
Indeed, expression of the cUTR precisely correlated to the CDS expression as evidenced 
by a linear regression with a slope that was not significantly different from 1 (Figure 
5.8A, R2=0.99).  Next, CDS expression (and cUTR by proxy) was compared to dUTR 
expression in the good- and poor-responder cohorts.  One "good-responder" sample 
(188084) was excluded from linear regression analysis following an outlier test 
(Grubb's).  Linear regression indicated that significantly less dUTR relative to CDS was 
present in the poor-responder cohort (slope = 0.07147 ± 0.009084, R2=0.89, Figure 5.8B, 
dashed line) than in the good-responder cohort (slope = 0.1056 ± 0.008824, R2=0.95, 
Figure 5.8B, solid line, slope difference p=0.02141).  Fold-change of dUTR relative to 
CDS was also calculated for all samples (Figure 5.8C); in general, far more IGF2BP1 
transcripts lack dUTR in poor-responders than in good-responders. 
DISCUSSION 
 Previously, via microarray, we identified overexpression of IGF2BP1 in primary 
tumors as a negative prognostic indicator for disease free interval in dogs with OSA (9).   
In this study, we examined expression levels of this oncofetal gene in canine OSA and 
normal bone as well as its contribution to invasion and migration in this system.  
Immunohistochemical staining patterns were investigated with the aim of providing a 








































preservation technology.  We also examined two possible mechanisms of dysregulation, 
one of which may, indeed, be a factor in the increased expression of IGF2BP1 common 
to the majority of tumors studied.   






































































































































































































Figure 5.8 – Analysis of IGF2BP1 3’ UTR via qRT-PCR.  First, the expression 
(Ct values) of the constitutive UTR (cUTR) was compared to the expression of the 
coding sequence (CDS) in the 20 dogs comprising the DFI cohorts (A).  As the 
cUTR should be present on every CDS transcript, a slope of 1 and strict linearity 
was expected and observed.  Comparison of CDS expression to distal UTR 
(dUTR) expression in the same samples (expression relative to HPRT-1, B).  
Filled circles represent good responders whereas open boxes represent poor 
responders.  Linear regression analysis after exclusion of one outlier (188084, 
Grubb’s test) indicated that poor responder transcripts possessed significantly less 
(p=0.02) dUTR than good responders, relative to total transcript. C)  Fold change 
of dUTR expression relative to CDS for individual animals.  The outlier excluded 
from linear regression is indicated by a hashed bar. 
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 Although IGF2BP1 expression has been assayed in a number of tumor (in vitro 
and in vivo) and normal tissue systems, its expression in the canine model or evaluation 
in osteosarcoma samples compared to normal bone had not been investigated prior to the 
current study (14, 17-19, 21, 23, 28, 34-40).  Our findings indicate that IGF2BP1 in 
canine bone is not expressed except in the case of transformation where it is expressed at 
high levels in the majority of tumors.  Expression is further elevated in dogs that respond 
poorly to definitive treatment as evidenced by shorter disease-free intervals.  Thus, in this 
system, IGF2BP1 displays an oncofetal expression pattern as has been observed in other 
systems.   
 Interestingly, protein localization patterns vary among samples with some tumors 
demonstrating cytoplasmic localization while others show both nuclear and cytoplasmic 
(but not nucleolar) localization.  Previous studies have identified primarily cytoplasmic 
localization of this protein, especially at the leading edge of cells where it is involved in 
actin mRNA localization (19, 25, 26, 38, 39, 41).  However it has also, rarely, been 
observed in the nucleus and possesses a canonical nuclear export signal (NES) (26, 42).  
It has been hypothesized that IGF2BP1 protein binds to target mRNAs in the nucleus 
and, thus, guides their export, final destination, longevity and translatability (42, 43).  
That being said, one can speculate about potential causes of the observed nuclear staining 
in some of the samples tested here.  Perhaps a mutation has damaged a subset of 
IGF2BP1 proteins' NES so that they inappropriately remain in the nucleus or perhaps it is 
simply a reflection of target mRNA upregulation and, hence, increased demand for 
IGF2BP1 transit services.  Future mechanistic studies could provide much insight into 
this inconsistent distribution pattern.  Based upon the current findings, 
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immunohistochemistry does not appear to be a feasible prognostic screen.  However, a 
previous study identified the related protein, IGF2BP2, as an auto-antigen in 21% of 
hepatocellular carcinomas (44).  Thus, development of an ELISA screen for IGF2BP1 
auto-antibodies may yet hold promise as a prognostic or early-detection screen. 
 Small interfering RNA-mediated knockdown of IGF2BP1 and subsequent 
invasion and migration assays indicate that IGF2BP1 promotes invasion relative to 
migration in this system.  Interestingly, the body of literature regarding IGF2BP1 and cell 
invasion is highly contradictory and likely reflects the different systems studied.  In HeLa 
cells, knockdown of IGF2BP1 has been shown to inhibit invadopodia formation through 
a CD44-dependent mechanism, indicating that IGF2BP1 is pro-metastatic in this system 
(38).  Similarly, in a colorectal carcinoma system, IGF2BP1 has been shown to promote 
lamellipodia and ruffle formation, encouraging invasion.  However, in a rat mammary 
adenocarcinoma model, increased polarity but reduced chemotaxis in response to 
IGF2BP1 overexpression was observed.  The authors hypothesize that IGF2BP1 
interacting with β-actin stabilizes the cells' polarity in an anti-metastatic fashion (34).  
Wang and colleagues also identified IGF2BP1 as an anti-metastatic factor in primary 
human breast cancers as well as the same rat adenocarcinoma model (45, 46).  In two 
recent papers, Gu and colleagues examined a positive feedback loop between IGF2BP1 
and β-catenin in additional breast cancer systems (28, 35).  They determined that β-
catenin can promote transcription of IGF2BP1 and, in turn, IGF2BP1 stabilizes β-catenin 
transcripts.  Furthermore they found that IGF2BP1 was suppressed by hypermethylation 
of the promoter region in highly metastatic cell lines yet was over-expressed in non-
metastatic lines.  Again, identifying IGF2BP1 as an anti-metastatic factor.  It has been 
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suggested that these different conclusions arise because the action of IGF2BP1 is highly 
system-centric and primarily acts through different targets in different tissue types (22, 
35).  Indeed, this is likely the case as a negative feedback loop between IGF2BP1 and β-
catenin via the intermediary F-box and WD repeats protein, β-TrCP, has been identified 
in colorectal carcinomas (47).  Thus, we have determined that IGF2BP1 promotes 
invasion in a canine OSA model but this finding does not necessarily extend to other 
systems. 
 Previous studies identified genomic amplification of the IGF2BP1 locus as one 
cause of over-expression of the protein in breast carcinomas (16, 17).  Here, we 
investigated genomic amplification via aCGH in eight primary tumors and matched 
muscle tissue and did not identify significant levels of gene amplification at the IGF2BP1 
locus in any of these samples despite clear increases in gene expression.  Based upon the 
recent findings of Mayr & Bartel, we also investigated 3' UTR shortening (14).  Their 
study found that this was a common event for the IGF2BP1 transcript in transformed 
cells and, as this region is a target for Let-7-based suppression, shortening may allow 
over-expression (28, 29).  The current findings indicate that this mechanism does 
contribute to IGF2BP1 regulation in the canine OSA model as our poor-responder cohort 
had significantly greater transcript relative to dUTR than our good responder cohort.  
Upon identifying the significant outlier in our good-responder group, we investigated 
why this sample appeared more similar to the poor-responder group.  Review of 
veterinary records indicated that this sample may be misclassified:  one radiologist 
identified a possible lung mass within 150 days of definitive treatment but this mass was 
not identified on a follow-up radiograph.  Within six months, metastatic disease was 
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diagnosed.  Thus, uncertainty regarding DFI for this patient encourages its exclusion 
from future studies. 
 Let-7 evasion certainly appears to be a mechanism of IGF2BP1 over-expression 
in this model and this encourages speculation as to whether de novo events lead to 3' 
UTR shortening in tumors or if specific individuals are predisposed due to other factors.  
Large body size and rapid growth have been identified as factors in the development of 
OSA in both dogs and man, indeed, the Lin28/Let-7/IGF2BP1 signaling axis may 
contribute to both large body size and the pathenogenesis of OSA.  In one recent study, 
Lin28a transgenic mice (with resultant Let-7 suppression, and presumably increased 
IGF2BP1 expression) demonstrated increased body size and endocrine phenotypes 
including delayed puberty and increased glucose utilization (48).  Similarly, IGF2BP1-
deficient mice demonstrate a dwarf phenotype with impaired gut development.  Taken 
together, these studies suggest that Lin28a may be acting through IGF2BP1 to modulate 
size phenotypes (15).  Thus, one may speculate that individuals with even slightly 
overactive Lin28 genes will have less-active Let-7 signaling that directly translates into 
increased IGF2BP1 half life and larger body size.  Such a precarious balance in 
expression levels may be easily tipped into tumorigenesis by mutation or trauma to the 
system.  This axis deserves further investigation in OSA as targeted therapies aimed at 
IGF2BP1 may be able to right the system and prevent distant disease. 
 
ACKNOWLEDGEMENTS 
  We acknowledge Erin Petrilli and the Genomics Core at the Rocky 
Mountain Regional Center for Excellence at CSU for generating the microarray data.  We 
 170
would also like to thank Irene Mok and Kristen Grunerud at CSU’s Animal Cancer 
Center for coordinating sample retrieval from the tissue archive and amputees.  Deanna 
Dailey and Debra Kamstock deserve many thanks for their reading of IHC slides. This 
work was supported by grants to DLD from the Morris Animal Foundation (MAF 











1. Dernell WS, Ehrhart NP, Straw RC, Vail DM. Tumors of the skeletal system. In: 
Withrow SJ, Vail DM, editors. Withrow and MacEwen's Small Animal Clinical 
Oncology. 4th ed. St. Louis: Saunders Elsevier; 2007. p. 540-67. 
2. Jaffe N. Adjuvant chemotherapy in osteosarcoma:  An odyssey of rejection and 
vindication. In: Jaffe N, Bielack SS, Bruland OS, editors. Pediatric and 
Adolescent Osteosarcoma, Cancer Treatment and Research. New York: Springer; 
2009. 
3. Mueller F, Fuchs B, Kaser-Hotz B. Comparative biology of human and canine 
osteosarcoma. Anticancer Research 2007;27(1A):155-64. 
4. Paoloni M, Davis S, Lana S, Withrow S, Meltzer P, Khanna C. Comparative gene 
expression analysis of canine and human osteosarcoma.  Genes, Dogs & Cancer: 
4th International Canine Cancer Conference; 2006; Chicago, IL; 2006. p. 19. 
5. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, et al. Canine tumor 
cross-species genomics uncovers targets linked to osteosarcoma progression. 
BMC Genomics 2009;10(1):625. 
6. Thomas R, Wang H, Tsai P, Langford C, Fosmire S, Jubala C, et al. Influence of 
genetic background on tumor karyotypes: evidence for breed-associated 
cytogenetic aberrations in canine appendicular osteosarcoma. Chromosome 
Research 2009;17(3):365-77. 
7. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The 
effect of adjuvant chemotherapy on relapse-free survival in patients with 
osteosarcoma of the extremity. New England Journal of Medicine 
1986;314(25):1600-6. 
8. Sutter NB, Ostrander EA. Dog star rising:  the canine genetic system. Nature 
Reviews Genetics 2004;5(12):900-10. 
9. O'Donoghue LE, Ptitsyn AA, Kamstock DA, Siebert J, Thomas RS, Duval DL. 
Expression profiling in canine osteosarcoma: identification of biomarkers and 
pathways associated with outcome. BMC Cancer 2010;10(1):506. 
 172
10. Bernstein PL, Herrick DJ, Prokipcak RD, Ross J. Control of c-myc mRNA half-
life in vitro by a protein capable of binding to a coding region stability 
determinant. Genes & Development 1992;6(4):642-54. 
11. Nielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins 
(IMP) involved in RNA trafficking. Scandinavian Journal of Clinical and 
Laboratory Investigations 2001;61(Suppl 234):93-9. 
12. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen 
FC. A family of Insulin-Like Growth Factor II mRNA-binding proteins represses 
translation in late development. Molecular and Cellular Biology 1999;19(2):1262-
70. 
13. Ross AF, Oleynikov Y, Kislauskis EH, Taneja KL, Singer RH. Characterization 
of a β-actin mRNA zipcode-binding protein. Molecular and Cellular Biology 
1997;17(4):2158-65. 
14. Mayr C, Bartel DP. Widespread shortening of 3'UTRs by alternative cleavage and 
polyadenylation activates oncogenes in cancer cells. Cell 2009;138(4):673-84. 
15. Hansen TVO, Hammer NA, Nielsen J, Madsen M, Dalbaeck C, Wewer UM, et al. 
Dwarfism and impaired gut development in Insulin-Like Growth Factor II 
mRNA-Binding Protein 1-deficient mice. Molecular and Cellular Biology 
2004;24(10):4448-64. 
16. Doyle GA, Bourdeau-Heller JM, Coulthard S, Meisner LF, Ross J. Amplification 
in human breast cancer of a gene encoding a c-myc mRNA-binding protein. 
Cancer Research 2000;60(11):2756-9. 
17. Ioannidis P, Mahaira L, Papadopoulou A, Teixeira MR, Heim S, Andersen JA, et 
al. 8q24 Copy number gains and expression of the c-myc mRNA stabilizing 
protein CRD-BP in primary breast carcinomas. International Journal of Cancer 
2003;104(1):54-9. 
18. Ioannidis P, Kottaridi C, Dimitriadis E, Courtis N, Mahaira L, Talieri M, et al. 
Expression of the RNA-binding protein CRD-BP in brain and non-small cell lung 
tumors. Cancer Letters 2004;209(2):245-50. 
19. Dimitriadis E, Trangas T, Milatos S, Foukas PG, Gioulbasanis I, Courtis N, et al. 
Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical 
outcome in colon cancer. International Journal of Cancer 2007;121(3):486-94. 
20. Kato T, Hayama S, Yamabuki T, Ishikawa N, Miyamoto M, Ito T, et al. Increased 
expression of Insulin-like Growth Factor-II Messenger RNA Binding Protein 1 is 
associated with tumor progression in patients with lung cancer. Clinical Cancer 
Research 2007;13(2):434-42. 
 173
21. Kobel M, Weidensdorfer D, Reinke C, Lederer M, Schmitt WD, Zeng K, et al. 
Expression of the RNA-binding protein IMP1 correlates with poor prognosis in 
ovarian carcinoma. Oncogene 2007;26(54):7584-9. 
22. Vainer G, Vainer-Mosse E, Pikarsky A, Shenoy SM, Oberman F, Yeffet A, et al. 
A role for VICKZ proteins in the progression of colorectal carcinomas: regulating 
lamellipodia formation. The Journal of Pathology 2008;215(4):445-56. 
23. Ioannidis P, Trangas T, Dimitriadis E, Samiotaki M, Kyriazoglou I, Tsiapalis CM, 
et al. C-MYC and IGF-II mRNA-binding protein (CRD-BP/IMP-1) in benign and 
malignant mesenchymal tumors. International Journal of Cancer 2001;94(4):480-
4. 
24. Farina KL, Hüttelmaier S, Musunuru K, Darnell R, Singer RH. Two ZBP1 KH 
domains facilitate β-actin mRNA localization, granule formation, and cytoskeletal 
attachment. Journal of Cell Biology 2003;160(1):77-87. 
25. Oleynikov Y, Singer RH. Real-time visualization of ZBP1 association with β-
actin mRNA during transcription and localization. Current Biology 
2003;13(3):199-207. 
26. Pan F, Huttelmaier S, Singer RH, Gu W. ZBP2 facilitates binding of ZBP1 to β-
Actin mRNA during transcription. Molecular and Cellular Biology 
2007;27(23):8340-51. 
27. Hüttelmaier S, Zenklusen D, Lederer M, Dictenberg J, Lorenz M, Meng X, et al. 
Spatial regulation of β-actin translation by Src-dependent phosphorylation of 
ZBP1. Nature 2005;438(7067):512-5. 
28. Boyerinas B, Park S-M, Shomron N, Hedegaard MM, Vinther J, Andersen JS, et 
al. Identification of Let-7-regulated oncofetal genes. Cancer Research 
2008;68(8):2587-91. 
29. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, et al. 
Transcriptome-wide identification of RNA-binding protein and microRNA target 
sites by PAR-CLIP. Cell 2010;141:129-41. 
30. O'Donoghue LE, Rivest JP, Duval DL. Polymerase chain reaction-based species 
verification and microsatellite analysis for canine cell line validation. Journal of 
Veterinary Diagnostic Investigation 2011;23(4):780-5. 
31. Tong W, Cao X, Harris S, Sun H, Fang H, Fuscoe J, et al. ArrayTrack--
supporting toxicogenomic research at the U.S. Food and Drug Administration 
National Center for Toxicological Research. Environmental Health Perspectives 
2003;111(15). 
 174
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-
time quantitative PCR and the 2-Ct method. Methods 2001;25(4):402-8. 
33. Thomas R, Scott A, Langford CF, Fosmire SP, Jubala CM, Lorentzen TD, et al. 
Construction of a 2-Mb resolution BAC microarray for CGH analysis of canine 
tumors. Genome Research 2005;15(12):1831-7. 
34. Lapidus K, Wyckoff J, Mouneimne G, Lorenz M, Soon L, Condeelis JS, et al. 
ZBP1 enhances cell polarity and reduces chemotaxis. Journal of Cell Science 
2007;120(18):3173-8. 
35. Gu W, Pan F, Singer RH. Blocking beta-catenin binding to the ZBP1 promoter 
represses ZBP1 expression, leading to increased proliferation and migration of 
metastatic breast-cancer cells. Journal of Cell Science 2009;122(11):1895-905. 
36. Ross J, Lemm I, Berberet B. Overexpression of an mRNA-binding protein in 
human colorectal cancer. Oncogene 2001;20(45):6544-50. 
37. Tessier CR, Doyle GA, Clark BA, Pitot HC, Ross J. Mammary tumor induction in 
transgenic mice expressing an RNA-binding protein. Cancer Research 
2004;64(1):209-14. 
38. Vikesaa J, Hansen TVO, Jønson L, Borup R, Wewer UM, Christiansen J, et al. 
RNA-binding IMPs promote cell adhesion and invadopodia formation. The 
EMBO Journal 2006;25(7):1456-68. 
39. Hammer NA, Hansen TvO, Byskov AG, Meyts ER-D, Grøndahl ML, Bredkjær 
HE, et al. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and 
testicular cancer. Reproduction 2005;130(2):203-12. 
40. Ioannidis P, Mahaira LG, Perez SA, Gritzapis AD, Sotiropoulou PA, Kavalakis 
GJ, et al. CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells 
and affects c-myc and IGF-II expression in MCF-7 cancer cells. The Journal of 
Biological Chemistry 2005;280(20):20086-93. 
41. Nielsen FC, Nielsen J, Kristensen MA, Koch G, Christiansen J. Cytoplasmic 
trafficking of IGF-II mRNA-binding protein by conserved KH domains. Journal 
of Cell Science 2002;115(Pt 10):2087-97. 
42. Nielsen J, Adolph SK, Rajpert-De Meyts E, Lykke-Andersen J, Koch G, 
Christiansen J, et al. Nuclear transit of human zipcode-binding protein IMP1. 
Biochemical Journal 2003;376(Pt 2):383-91. 
43. Jønson L, Vikesaa J, Krogh A, Nielsen LK, Hansen Tv, Borup R, et al. Molecular 
composition of IMP1 ribonucleoprotein granules. Molecular & Cellular 
Proteomics 2007;6(5):798-811. 
 175
44. Zhang J-Y, Chan EKL, Peng X-X, Tan EM. A novel cytoplasmic protein with 
RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. The 
Journal of Experimental Medicine 1999;189(7):1101-10. 
45. Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E, et al. 
Identification and testing of a gene expression signature of invasive carcinoma 
cells within primary mammary tumors. Cancer Research 2004;64(23):8585-94. 
46. Wang W, Wyckoff JB, Frohlich VC, Oleynikov Y, Hüttelmaier S, Zavadil J, et al. 
Single cell behavior in metastatic primary mammary tumors correlated with gene 
expression patterns revealed by molecular profiling. Cancer Research 
2002;62(21):6278-88. 
47. Noubissi FK, Elcheva I, Bhatia N, Shakoori A, Ougolkov A, Liu J, et al. CRD-BP 
mediates stabilization of [beta]TrCP1 and c-myc mRNA in response to [beta]-
catenin signalling. Nature 2006;441(7095):898-901. 
48. Zhu H, Shah S, Shyh-Chang N, Shinoda G, Einhorn WS, Viswanathan SR, et al. 
Lin28a transgenic mice manifest size and puberty phenotypes identified in human 









Suppression of the putative tumor suppressor gene, n-Myc 
Downstream Regulated Gene 2 (NDRG2), contributes to 
doxorubicin resistance in canine osteosarcoma. 
 
SYNOPSIS 
Background:  Osteosarcoma (OSA) is a highly aggressive bone malignancy that affects 
both dogs and humans.  Previous identification of NDRG2 mRNA suppression as a 
negative prognostic indicator in canine OSA led us to investigate possible mechanisms of 
control for this gene as well as the effects of modulating its expression in this system.  
Methods:  Normal bone mRNA expression of NDRG2 was compared to that of tumors 
using microarrays and qRT-PCR.  Genomic DNA was analyzed to determine if copy 
number alterations of the NDRG2 locus caused loss of expression and demethylating 
agent effects on NDRG2 expression were explored.  Stable transfectants expressing 
NDRG2 were generated and tested for chemosensitivity to doxorubicin and carboplatin  
Results:  NDRG2 was dramatically downregulated in tumors relative to normal bone.  
Two different expressed isoforms of NDRG2 were identified and characterized and three 
possible mechanisms of this suppression were identified:  c-Myc overexpression, copy 
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number loss at the NDRG2 locus and gDNA methylation.  NDRG2 expressing clones 
demonstrated enhanced doxorubicin sensitivity. Conclusions:  NDRG2 is down-
regulated in canine OSA, most-so in dogs that respond poorly to definitive treatment and 
adjuvant chemotherapy.  This suppression may play a significant role in tumor invasion 
and metastasis as well as resistance to chemotherapy that leads to treatment failures. 
 
INTRODUCTION 
  Osteosarcoma (OSA) is a highly aggressive primary bone malignancy that 
affects both dogs and humans.  Roughly 800 adolescents and over ten times as many 
companion dogs are diagnosed annually (1, 2).  Standard of care in both species involves 
resection of the tumor either by amputation or limb sparing surgery followed by adjuvant 
chemotherapy.  Neoadjuvant chemotherapy is commonly utilized in human medicine but 
less-so in canine patients.  The majority of OSA tumors in both dogs and man occur in 
the metaphyseal region of long bones in the appendicular skeleton.  Histological 
classifications are shared between species as are many molecular characteristics of the 
disease (1, 3-6).  Metastatic disease of the lungs is the most common cause of morbidity 
and mortality and is a strong negative prognostic indicator (1, 2, 7).  Roughly 10-15% of 
patients of both species present with clinically detectable metastases and it is estimated 
that over 80% of patients may have undetectable micrometastatic disesease at 
presentation. Thus, systemic chemotherapy aimed at diminishing distant disease is 
included in most protocols.   
 Considering the similarities between canine and human living environments, their 
genomes and the pathology of OSA, this disease in dogs is increasingly recognized as a 
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valuable model for the human disease (3, 8).   Previous studies by our laboratory 
identified n-Myc Downstream Regulated Gene 2 (NDRG2) as a gene that was suppressed 
in primary OSA tumors from dogs that responded poorly to definitive treatment when 
compared to dogs that responded well (9).  NDRG2 maps to human chromosome 14q11.2 
and to the equivalent locus on chromosome 15 in dogs.  The gene encodes 16 exons with 
up to eight isoforms predicted in humans and seven in dogs.  The promoter region has a 
substantial CpG island and several studies have found genomic DNA methylation to be 
important in transcriptional control of this gene, especially in cancer (10, 11).  Mutations 
in the promoter region that presumably affect transcription factor assembly have also 
been identified and result in gene suppression.  Additionally, transcripts have an ~850 bp 
3' untranslated region with several conserved micro-RNA recognition sites that influence 
mRNA half life (10).  At least two protein isoforms have been identified in humans, dogs 
and mice; the protein contains a conserved alpha-beta hydrolase (ABH) domain but its 
precise function in cells is unknown .  The protein is typically localized in the plasma 
membrane and cytosol with a small nuclear population (12).  Enhanced nuclear 
translocation of the protein has been demonstrated in response to Hypoxia Inducible 
Factor 1 (HIF1) expression in hypoxic tumor cells but no nuclear import element was 
identified (13).  Three highly conserved phosphorylation sites are present in the translated 
protein (Thr 330, Ser 332 and Thr 348) and are substrates for multiple kinases (14).   The 
recent elucidation of the crystal structure of this protein has provided some clues as to its 
behavior in cells (12).  The catalytic residues common to most ABH proteins are not 
present in NDRG2, thus, it likely lacks enzymatic activity.  It does, however, appear to 
interact with other molecules and α-helix 6 is important in that role, notably in the 
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suppression of β-catenin signaling (12). Additionally, helix α6 may be responsible for the 
nuclear translocation of NDRG2 under hypoxic conditions.  Two studies have identified 
Matrix Metallopeptidase 9 (MMP9) inhibition as a downstream target of NDRG2; one of 
these determined that Bone Morphogenetic Protein 4 (BMP4) was an intermediate 
regulator in that activity, suggesting a role for NDRG2 in inhibition of invasion and 
metastasis (15, 16). 
 NDRG2 expression has been identified as a prognostic factor in a variety of 
tumors including breast, thyroid, colorectal, lung and brain cancer where it has been 
dubbed a tumor suppressor (17-22).  Furthermore, even patients with a good prognosis 
often have reduced NDRG2 expression in tumor samples when compared to normal 
tissue.  Although the name of the gene implies it is regulated by  n-Myc, it has been 
firmly established that it is, in fact, downstream of c-Myc in most tissues (10, 23, 24).   
 In this study, we sought to identify expression changes of NDRG2 in canine OSA 
and to further elucidate its role in these tumors.  NDRG2 has received only limited 
attention in sarcomas thus far but the current study determines that it does, indeed, play a 
role in mesenchymal tumors (15). We identify two cases of gene deletion as well as 
provide evidence that gDNA methylation is involved in NDRG2 downregulation.  




 Canine tissues used in microarray and PCR studies were obtained from animals 
presenting to Colorado State University (CSU) for treatment of OSA.  Owner consent for 
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tissue archiving was obtained prior to definitive surgical treatment.  Good- and poor-
responder primary tumors were archived at the Animal Cancer Center between 1996 and 
2006 - snap frozen tissues and formalin-fixed paraffin embedded (FFPE) tissues were 
archived.  Good and poor responder groups were defined based upon patient disease-free-
interval (DFI):  good-responders had a DFI greater than 300 days and poor-responders 
had a DFI less than 100 days.  Inclusion in these studies required limb amputation 
followed by doxorubicin and/or platinum drug adjuvant therapy.  Normal bone and 
matched tumor samples were obtained from limbs post-amputation and harvested so that 
“normal” bone included in the study was distant from the tumor site and separated from 
the tumor by a joint (e.g. a femoral tumor would have matched distal tibia bone 
collected).  Tissue was collected, snap frozen in liquid nitrogen and stored at -80ºC until 
processing.   
Canine Cell Lines 
 Canine OSA cell lines used in this study were graciously provided by Dr. Douglas 
Thamm and all cell lines were validated for species and short-tandem-repeat identities as 
previously described (25).  Abrams and D17 cells were derived from metastatic OSA 
nodules whereas Gracie, McKinley, Moresco and Vogel were derived from primary 
tumors.  Cells were cultured in "C10" media:  DMEM high glucose with 6 mM L-
glutamine, 1x each of sodium pyruvate, MEM vitamins, MEM non-essential amino acids 
and antibiotic-antimycotic, 10% fetal bovine serum (FBS) and Plasmocin prophylactic 





 Tumor and normal tissues were freeze-fractured, homogenized, extracted in 
Trizol (Invitrogen, Cat# 15596-026) per the manufacturer’s instructions and purified with 
the RNeasy (Qiagen, Cat# 74104) cleanup protocol.  Cell cultures were detached from 
plates with 3 mM ethylenediaminetetraacetic acid (EDTA) in phosphate-buffered saline 
(PBS) or 0.25% trypsin in PBS with EDTA, pelleted by centrifugation for 5 minutes at 
500 x g and extracted using the RNeasy kit per the manufacturer’s protocol.  RNA was 
quantified via spectrophotometry and, prior to microarray, tissue RNA was bioanalyzed 
for quality at the Rocky Mountain Regional Center for Excellence (RMRCE) Genomics 
Core at CSU.  Only high quality RNA with RNA Integrity Numbers (RINs) greater than 
8 were used in microarray studies. 
Microarray 
 Eight normal bone samples were analyzed with Affymetrix Canine 2.0 GeneChips 
as previously described (9).  Resultant data was compiled with data from 15 good and 
poor-responder primary tumor samples obtained previously and analyzed with 
ArrayTrack (26).  Data was preprocessed with the Probe Logarithmic Intensity Error 
(PLIER) estimation algorithm with a log2 transformation then analyzed for fold change 
based on two scenarios:  normal bone versus all tumors or normal bone versus good 
responders versus poor responders.  The first scenario was analyzed with a Bonferroni 
adjusted unpaired 2-tailed t-test, thresholds of corrected p-value <0.05 and fold-change 
>3 were applied.  The second scenario was analyzed with a 3-way ANOVA and the same 
p-value and fold-change thresholds.  Log2-transformed PLIER NDRG2 expression values 
were extracted for this study. 
 182
Quantitative RT-PCR 
 Reverse transcription (RT) was performed on RNA samples with the QuantiTect 
Reverse Transcription kit (Qiagen, Cat# 05313) per the manufacturer's instructions with  
1 μg RNA input, a ten-minute gDNA digest incubation and a 30-minute RT incubation.  
No-RT controls were included for each sample as was one no-transcript control per RT 
reaction.  Real-time quantitative PCR was performed in duplicate using the iQ SYBR 
Green Supermix (Bio-Rad, Cat# 170-8880) in 25 μL reactions with 25 ng equivalent 
cDNA input.  Any sample where duplicates were not within 0.5 Ct of each other was 
repeated.  NDRG2 and housekeeping gene (HPRT-1) primers were as previously 
published (9) and were included in the reactions at 100 nM forward and 300 nM reverse 
primer concentrations.  NDRG2 Exon-2 primers were as follows:  Fwd 5'-TGA GTT 
AGC TGC CCG AAT CCT CCT-3', Rev 5'-AGA GCG GCT GGA AGC AAG ACT 
TAT-3'.  Bone Morphogenetic Protein 4 (BMP4) primers were:  Fwd 5'-TTA CAT GCG 
GGA TCT TTA CCG GCT-3', Rev 5'-TGG TCC CTG GGA TGT TCT CCA AAT-3'.  
We also examined c-Myc mRNA expression in matched tumor and normal samples to 
determine what proportion of tumors with suppressed NDRG2 may overexpress Myc; 
primers were:  Fwd 5'-TCA ATG ACA GCA GCT CGC CCA A-3', Rev: 5'-TTC GTC 
CTC TTG TTC TTC CTC CGA-3'. Standard curves for the five primer sets over two 
orders of magnitude were within 5% efficiency of each other.  Thermal cycling was 
performed on the Mx3000p instrument (Stratagene) with the following parameters:  95°C 
for 10 m followed by 40 cycles of 95°C for 30 s and 60°C for one minute.  Data 
collection was performed at the end of the 60°C step.  Dissociation curve ramps were 
performed at the end of the cycle to verify that only a single product was generated.  Data 
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analysis was performed with the Mx3000p software.  NDRG2 expression was normalized 
to HPRT-1 and fold change was calculated using the 2(-ΔΔCt) method (27). 
Western Blotting 
 Western blot analysis was performed on whole-cell lysates obtained by repeatedly 
passing cell pellets through a 26-guage needle in Tris pH 7.5 buffer with cOmplete, 
EDTA-free Protease Inhibitor Cocktail Tablets (Roche, 04693132001).  For 
phosphorylation analysis, cell lysates were extracted in the presence of calf intestinal 
alkaline phosphatase (CIAP) with CIAP buffer (New England Biosystems, M0290S) per 
standard protocols (28). Total protein was quantified with a BCA Assay kit (Pierce, Cat# 
23227) and 25 μg protein was loaded for each sample.  Proteins were electrophoresed on 
12% SDS-PAGE gels with 5% stacking gels at 180 v for 50 minutes and were then 
transferred to PVDF membranes with a semi-dry transfer unit.  Membranes were dried 
with methanol then blocked in 5% milk in Tris-buffered saline with Tween-20 (TBST) 
for one hour at room temperature.  The primary antibody was obtained from Sigma (Cat# 
HPA002896, rabbit polyclonal anti-human); the targeted epitope is 99% homologous to 
the canine protein.  Membranes were incubated overnight at 4°C with primary antibody 
diluted 1:10,000 in 5% milk/TBST.  The following day, they were washed 3 times for 
five minutes each in TBST.  Secondary antibody (HRP-conjugated goat anti-rabbit IgG, 
Bio-Rad, Cat# 170-6515) was applied at a dilution of 1:10,000 in 5% milk/TBST for a 
one-hour, room-temperature incubation followed by TBST washes.  SuperSignal West 
Pico Chemiluminescent Substrate (Pierce, Cat# 34078) was used for development and 
images were captured on a Bio-Rad ChemiDoc XRS system.  Specificity of the primary 
antibody was verified using a blocking peptide isolated from mammalian cells expressing 
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cloned NDRG2 as described below and via western blotting of whole cell lysates from 
cells expressing this cloned NDRG2 protein.  Immunoblotting for the V5 epitope was 
performed to verify size and identity of cloned NDRG2 in transfected cells as above 
(Invitrogen, Cat# R960-25) with anti-mouse IgG secondary (BioRad Cat# 170-6516, 
HRP-conjugated goat anti-mouse IgG). For blocking experiments, primary antibody was 
incubated with 10x (by mass) blocking peptide in blocking buffer overnight at 4°C with 
agitation before being applied to the membrane.  In parallel, unblocked primary was 
applied to a second, identical membrane.  The western blot was completed as above and 
membrane signals were compared between the two membranes.  α-tubulin was used as a 
loading control:  primary antibody (Sigma Cat# T5168 mouse monoclonal anti-human) 
incubation was performed for one hour at a 1:5,000 dilution in 5% milk/TBST, secondary 
antibody (BioRad Cat# 170-6516, HRP-conjugated goat anti-mouse IgG) incubation was 
performed for one hour at room temperature at a 1:10,000 dilution in 5% milk/TBST with 
washing and development steps as above. 
Array Comparative Genomic Hybridization 
 Genomic DNA was extracted from tumors and patient-matched normal tissue 
(muscle, skin) using the DNeasy (Qiagen, Cat# 69504) kit per the manufacturer's 
instructions.  Low yield tissue samples were digested overnight in proteinase K, salt 
extracted per standard protocols and precipitated in ethanol prior to DNeasy cleanup.  
Array-CGH was performed by Dr. Matthew Breen's laboratory at North Carolina State 
University as previously described (29).  Relative amplification of the NDRG2 region 
was determined by dividing signal of each tumor sample by its matched normal sample. 
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Cloning and Transfection of Canine NDRG2 
 TOPO cloning into the pcDNA™3.2/V5-GW/D-TOPO® vector was used to 
generate plasmids containing the NDRG2 coding sequence per the manufacturer's 
protocol (Invitrogen, K2440-20).  Primers targeted to the start and stop codon regions, 
with additional sequence necessary for TOPO cloning, were designed based upon RefSeq 
mRNA sequence.  Reverse transcription of mRNA was performed as for qRT-PCR; 
NDRG2 targeted primers were:  Fwd 5'-CAC CAT GGC GGA GCT GCA GGA GGT-3', 
Rev minus stop codon 5'-GCA GGA GAC CTC CAT GGT ATG CCC-3', and Rev with 
stop codon 5'-TCA GCA GGA GAC CTC CAT GGT ATG CCC-3'.  Vogel and 
McKinley cell line cDNA was used as the template.  Specific cDNAs were amplified in 
50 μL reactions consisting of 5 μL Thermo Pol buffer (New England BioLabs, Cat# 
B9004S), 500 μM dNTPs, 660 nM MgSO4, 300 nM each forward and reverse primers 
and 1 u VentR® DNA polymerase (New England BioLabs, Cat# M0254S).  Thermal 
cycling parameters were: 95°C for 2 min followed by 35 cycles of 95°C for 30 s, 60°C 
for 30 s and 72°C for 90 s with a final elongation at 72°C for 5 min.  PCR product was 
electrophoresed on 1% agarose gels with GelGreen (Biotium, Cat# 41005) in 1x TBE 
buffer for 1 hour; bands were visualized under UV light, excised and purified using the 
QIAquick Gel Extraction Kit (Qiagen, Cat# 28704).  Purified product was combined with 
the vector and allowed to incubate at room temperature for 5 minutes before being 
transferred to ice.  2 μL of this reaction was then added to 50 μL of DH5α chemically 
competent cells (Invitrogen, Cat# 18263-012), incubated on ice for 30 m, heatshocked at 
37°C for 45 s, then returned to ice.  250 μL SOC medium was added and the reaction was 
incubated at 37°C for 1 h with 225 RPM shaking.  The resultant culture was plated onto 
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LB-Agar plates with 100 μg/mL ampicillin and incubated overnight at 37°C.  Individual 
colonies were picked and cultured in 3 mL LB broth with 100 μg/mL ampicillin at 37°C 
overnight.  The resultant cultures were pelleted and plasmid DNA was extracted using 
alkaline lysis and the QIAprep Spin Miniprep Kit (Qiagen, Cat# 27104).  Restriction 
digests and sequencing (CSU Proteomics and Metabolomics Facility) of the plasmids was 
performed to verify the presence and direction of the insert.  Plasmids were stably 
transfected into the Abrams cell line by electroporation of 2.5x105 cells in cold PBS with 
a one-pulse, 220 V, 20 μs protocol.  Cells were plated onto 15 cm plates and selected 
with 750 μg/mL G418 in C10 media for two weeks before selection of stable clones.  The 
same methodology was used to transfect the negative control plasmid, cDNA3.2/V5/GW-
CAT into Abrams cells for comparison.  No blocking peptide was available for the 
antibody used in this study so protein product from stable transfections was 
immunoprecipitated using a V5 tagged protein purification kit per the manufacturer's 
protocol (MBL International, Cat# 3315A) to use as a blocking peptide.   
Chemotherapy Sensitivity Assays 
 As doxorubicin (DOX) and carboplatin (Carb) are the two primary 
chemotherapeutic drugs currently used to treat canine OSA at Colorado State University, 
we assayed the sensitivity of Abrams cells to these drugs when expressing exogenous 
NDRG2.  Clones expressing exogenous NDRG2 or CAT were plated at a density of 2000 
cells/well on 96-well plates and allowed to adhere over night.  The following day, media 
was aspirated and replaced with C10 containing a range of drug concentrations:  DOX – 
200 ng/mL to 195 pg/mL, Carb – 300 μg/mL to 1.17 μg/mL (n=6 biological replicates per 
dose).  Cells were incubated for 72 hours with drug then assayed for viability with a 
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resazurin-based assay per standard protocols (30).  Dose-response curves were generated 
and analyzed with GraphPad Prism 5.0 software (31). 
5-Azacytidine Treatment  
 Untransfected Abrams cells were plated at 40% confluency and treated with  
10 μM 5-azacytidine in C10 media (n=5 biological replicates).  Vehicle controls (0.1% 
DMSO) were included (n=2 biological replicates).  Abrams cells were chosen specifically 
as, of all cell lines examined, they express the least endogenous NDRG2.  Forty-eight 
hours after treatment, cells were harvested, RNA was extracted and samples were assayed 
for NDRG2 expression via qRT-PCR. 
 
RESULTS 
NDRG2 mRNA Expression is Suppressed in OSA 
 Previous studies by our laboratory indicated that NDRG2 is down-regulated in 
dogs that respond poorly to definitive treatment compared to dogs that respond well (9).  
In order to gain perspective on this dysregulation, we performed microarray and qRT-
PCR studies on normal bone samples to compare expression to matched tumor samples 
as well as previously-analyzed tumor samples.  Signalment, tumor location and other 
details regarding the matched tumor-normal bone study population are outlined in Table 
3.1; good and poor responder patient details are as previously published (9).  Microarray 
findings indicate that NDRG2 is dramatically down-regulated in all OSA primary tumors 
studied relative to normal bone with the lowest levels of expression observed in primary 
tumors from the poor-responder cohort (DFI<100 days)(Figure 6.1a).  Normal bone 


































































































































































































































Figure 6.1 – Messenger RNA Expression of NDRG2 in primary OSA tumors, cell 
lines and normal bone. A)  Microarray analysis revealed significant progressive 
downregulation of NDRG2 in tumors from both good and poor responders relative to 
normal bone.  Normal bone n=8, Poor Resp. n=8, Good Resp. n=7, *=p<0.05.  B) 
qRT-PCR validation of microarray data with NDRG2 transcript expression relative to 
HPRT-1 expressed as 2(-ΔCt).  Fold change calculations are inset, n=10 for good and 
poor responder groups and n=9 for normal bone and matched tumor. C) NDRG2 
expression in tumors relative to matched normal bone from the same patient as 
measured by qRT-PCR. D) mRNA expression of c-Myc in tumors relative to matched 
normal bone as measured by qRT-PCR.  E) qRT-PCR analysis of NDRG2 transcript 
expression in three canine OSA cell lines expressed as fold change relative to good-
responder (DFI>300) primary tumor samples. 
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tumors (Figure 6.1a, left bar) which, in turn, express over 3-fold more NDRG2 than poor 
responders (Figure 6.1a, middle and right bars) indicating a 30-fold down-regulation in 
poor responders relative to normal bone.  To confirm these findings, we validated mRNA 
expression levels with qRT-PCR on an expanded sample set of poor- and good-responder 
primary tumors, normal bone and tumor samples matched to the normal bone samples.  
This study confirmed significant down-regulation of NDRG2 in all primary tumors 
relative to normal bone (Figure 6.1b).  On a patient-by-patient basis, NDRG2 was also 
down-regulated in tumor relative to normal bone (Figure 6.1c).  In two cases, NDRG2 
was down-regulated almost 40-fold in the primary tumor.  When comparing c-Myc 
mRNA expression in this same matched tumor and normal bone sample set, we observed 
c-Myc upregulation in only four of nine samples (Figure 6.1d, N1, N5, N8 & N10).  
Thus, while NDRG2 has been shown to be Myc responsive in tumor systems, it is not the 
only means of NDRG2 suppression in this sample set.  With the aim of identifying viable 
in vitro models for this dysregulation, we assayed NDRG2 expression in canine OSA cell 
lines.  Expression levels similar to those observed in both good- and poor-responders 
were identified in different lines with the Abrams line expressing very low amounts of 
NDRG2 mRNA, similar to poor-responders, and the Vogel and McKinley lines 
mimicking good-responder expression levels (Figure 6.1e). 
Two NDRG2 Isoforms are Expressed in Cell Lines and Primary Tumors 
 Initially, we performed immunoblotting on cell lines to determine if NDRG2 
protein expression correlated with mRNA expression.  This preliminary study resulted in 
the identification of two distinct protein products, one at ~40 kD and a slightly larger one 
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Figure 6.2 – Protein and isoform analysis of NDRG2 in canine OSA cell lines.  A) 
Western blot of whole cell lysates from six canine OSA cell lines yielded two specific 
bands.  25μg protein loaded per well.  B) Western blot analysis of NDRG2 lysates 
untreated (odd lanes), or treated with calf intestinal alkaline phosphatase (CIAP, even 
lanes).  C) Pre-cloning PCR yielded two distinct product sizes:  Lane 1 – McKinley 
cell line amplicon Lane 2 – 100 bp ladder, 1 kb band, Lane 3 – 1 kb ladder, 1 kb band, 
Lane 4 – Vogel cell line amplicon.  D)  Quantitative RT-PCR of NDRG2 using 
primers that amplify all isoforms or Exon 2-specific primers.  Expression is relative to 
HPRT1 and is expressed as 2(-ΔCt). N=2 technical replicates per expression value. 
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NDRG2 protein undergoes post-translational modification in some cell lines leading to 
the observed size shift or b) multiple NDRG2 protein isoforms are present in some OSA 
cell lines.  As NDRG2 has multiple conserved phosphorylation sites, we first investigated 
whether this size shift was due to phosphorylation by immunoblotting cell lysate that had 
been treated with calf intestinal alkaline phosphatase (CIAP).  This dephosphorylation 
method did not yield any changes in band distribution on western blot as untreated lysate 
(Figure 6.2b, odd lanes) ran no differently than CIAP treated lysate (Figure 6.2b, even 
lanes).  In order to determine if expression of multiple isoforms was the cause of the 
western banding pattern, full-length coding sequence NDRG2 cDNA was amplified using 
gene specific primers from McKinley and Vogel lines, the two lines with the strongest 
secondary bands.  Although the resulting PCR products were very similar in size, two 
distinct products were present upon gel electrophoresis (Figure 6.2c) 
 The resulting PCR products were cloned into the mammalian expression vector 
pDNA™3.2/V5-GW/D-TOPO® and sequenced with primers flanking the inserts.  Two 
inserts were obtained and the difference between them was the presence (long isoform) or 
absence (short isoform) of a 14 aa domain following AA 25 (Exon 2).  Insert sequences 
and alignments of encoded proteins are provided in Appendix E.  Proteins generated from 
these coding sequences are predicted to be 371 aa and 357 aa in size.  To assess the 
prevalence of the Exon 2-containing isoform of NDRG2 in canine OSA cell lines, Exon 2 
specific primers were designed and qRT-PCR was performed to compare total NDRG2 
expression to long isoform expression.  In all cell lines examined, the short NDRG2 
isoform was predominant, but in some lines (i.e. D17, McKinley, Moresco) the long 
isoform approached 1/3 to 1/2 of total NDRG2 transcripts (Figure 6.2D). 
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 Having identified this splice variant, we hypothesized that Exon 2-containing 
transcript expression may relate to the prognostic value of NDRG2 expression in canine 
primary tumors.  Thus, exon-specific qRT-PCR expression analysis was performed on 
the good- and poor-responder primary tumor cohorts.  A slight trend demonstrating a 
smaller proportion of exon 2-containing long isoform transcripts (y-axis) relative to total 
NDRG2 (x-axis)  in good-responder tumors was observed following linear regression 












Gene Deletion and Methylation:  Two Mechanisms of NDRG2 Suppression 
 Copy number aberrations (CNAs) at the NDRG2 locus have been previously 
identified in tumors (11), thus, array CGH was performed to examine this possible 
mechanism of NDRG2 suppression in canine OSA.  Array CGH was performed on four 





































Figure 6.3 – Isoform analysis of NDRG2 mRNA comparing primary canine OSA 
tumors from good and poor-responder cohorts.  qRT-PCR relative expression of the 
Exon 2-containing isoform (y-axis) is plotted against total NDRG2 relative 
expression (x-axis).  Lines indicate linear regression analysis for each group (n=10 
per group). 
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tumors were compared to matched normal tissue to identify tumor-specific CNAs.  Two 
samples, one from each cohort, demonstrated gene deletion at the probe location closest 
to the NDRG2 gene (Figure 6.4a, arrow).  Upon comparing chromosomal hybridization  

































































































































Figure 6.4 – Mechanisms of NDRG2 dysregulation in canine OSA.  A)  Array 
CGH analysis of the chromosomal region surrounding the NDRG2 locus identified 
two samples with locus deletion. Individual values are tumor intensity relative to 
normal tissue intensity.  Threshold for locus amplification was Log2>0.201 and for 
deletion, Log2<-0.234. Probe region closest to the NDRG2 gene locus is indicated 
with an arrow.  B) NDRG2 relative expression as measured by qRT-PCR for the 
same samples.  Symbols are as in (A). C) NDRG2 expression in Abrams cell lines 
was measured via qRT-PCR following 48-hour treatment with the demethylating 
agent 5-Azacytidine (n=5) or a vehicle control (n=2).  Significant upregulation of 
NDRG2 transcription was observed following treatment (p=0.046, one-tailed, 
unpaired t-test). 
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intensities to observed mRNA expression levels, however, it was notable that the extent 
of mRNA suppression did not correlate with deletion (i.e. tumors without deletion had 
equal or less NDRG2 mRNA than tumors with CNAs) (Figure 6.4b).  Thus, it was clear 
that additional mechanisms must be involved in NDRG2 suppression, especially in 
tumors without CNAs. 
 To investigate whether methylation influences NDRG2 expression in this system, 
the cell line with the most-suppressed NDRG2 (Abrams) was subjected to 5-Azacytidine 
treatment.  Following 48-hour treatment with this demethylating agent, NDRG2 
expression was significantly up-regulated compared to vehicle controls (Figure 6.4c).  
These findings indicate that methylation may, indeed, suppress transcription of NDRG2 
in OSA. 
Exogenous NDRG2 Modulates BMP4 Expression in Transfected Cells 
 Abrams cells were stably transfected with either short isoform or long isoform 
expression constructs to further investigate the role of NDRG2 in this system.  Resulting 
short isoform clones were denoted with numbers (i.e. Clone 2) and long isoform clones 
were denoted with letters (i.e. Clone C).  Bone Morphogenetic Protein 4 (BMP4) was 
previously identified as a downstream target of NDRG2 (16), thus, BMP4 expression was 
assayed via qRT-PCR to determine if exogenous NDRG2 was active in the cells.  This 
was deemed especially important as all transfected NDRG2 was also expressing a linker 
and V5 tag at the C-terminus of the protein and it was unknown how this would affect 
protein functionality.  BMP4 expression tracked with NDRG2 expression independent of 
which NDRG2 isoform was transfected suggesting that exogenous NDRG2 was, indeed, 
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Figure 6.5 – NDRG2 mRNA and protein expression in Abrams transfectants.  A) 
qRT-PCR expression analysis of total NDRG2 expression (black bars), Exon 2-
containing NDRG2 isoforms (stipled bars) and BMP4 expression (gray bars). “Short 
Pool” and numbered clones denote cells transfected with the isoform lacking Exon 2, 
lettered clones are cells transfected with the Exon 2-containing isoform. n=2 technical 
replicates per sample, total NDRG2 expression is the mean of two separate 
experiments, error bars represent SEM. B) Relative mRNA expression of BMP4 (y-
axis) plotted against total NDRG2 mRNA expression (x-axis) expressed as 2(-ΔCt) 
relative to HPRT1 in Abrams-NDRG2 clones and short pool.  Line indicates linear 
regression analysis, slope is significantly non-zero (p=0.03).  C) Relative mRNA 
expression of BMP4 (y-axis) plotted against total NDRG2 mRNA expression (x-axis) 
in untransfected Abrams cells and Abrams-CAT clones.  Line indicates linear 
regression analysis which was not significantly different from zero. D) Western blots of 
NDRG2 transfectants.  UT=untransfected, SP=short pool, numbered clones are 
transfected with the short isoform and lettered clones with the long isoform. Figure is a 
composite of two blots, each stripped and re-probed with the noted antibodies. 
 196
2 expression was only up-regulated in clones that were specifically transfected with that 
isoform (Figure 6.5a, stippled bars).  Linear regression analysis of total NDRG2 
expression versus BMP4 expression in Abrams-NDRG2 transfectants yielded a 
significantly non-zero slope (p= 0.0305), suggesting the interconnection of these two 
genes (Figure 6.5b).  However, untransfected Abrams cells and Abrams-CAT clones 
demonstrated inordinately high and variable levels of BMP4 transcript that did not 
correlate with NDRG2 expression (Figure 6.5c). 
 To further evaluate the nature of the protein product generated in transfectants, 
western blotting was performed on whole cell lysates of various clones.  Anti-V5 probing 
identified no bands in untransfected cells, one band in short isoform transfected cells and 
two bands in long isoform transfected cells (Figure 6.5d, top panel).  Similarly, Anti-
NDRG2 probing identified the same banding pattern in transfected cells in addition to 
endogenous NDRG2 (Figure 6.5d, middle panel).  Exogenous NDRG2 is notably larger 
than endogenous NDRG2 due to the attached V5 tag and linker which total an additional 
33 aa.  Abrams-NDRG2-Clone 5 demonstrated fainter bands than expected from mRNA 
assays but this was due to insufficient protein loading as evidenced by the α-Tubulin 
loading control (Figure 6.5d, bottom panel).  The distinct doublet observed in long-
isoform transfected cells (Figure 6.5d, far right panel) cannot be explained by isoform 
differences as Exon 2 isoform expression makes up the vast majority of total NDRG2 in 
these clones (Figure 6.5a, final bars).  Thus, this isoform likely undergoes preferential 
post-translational modification as compared to the short isoform. 
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NDRG2 Suppression Confers Doxorubicin Resistance 
 Stable Abrams-NDRG2 clones and control Abrams-CAT clones were assayed for 
both DOX and Carb sensitivity to determine if NDRG2 modulates this aspect of tumor 
aggressiveness.  Overexpression of NDRG2 did not modulate sensitivity to Carb (data 
not shown), however, sensitivity to DOX was significantly increased in all short-isoform 
expressing transfectants as evidenced by reduced half maximal inhibitory concentration 
values (IC50) (Figure 6.6a-e, Table 6.1).  The heterogeneous pool of short-isoform 
transfected Abrams cells demonstrated the smallest increase in sensitivity relative to 
Abrams-CAT clones, supporting the idea that this heterogeneous population is likely to 
have a proportion of low NDRG2 expressing cells still contributing to resistance.  Long 
isoform transfectants demonstrated a range of DOX sensitivities, with two of the clones 
demonstrating heightened sensitivity while the third, highest expressing clone (Abrams-
NDRG2-Clone C), was as resistant as the Abrams-CAT pool (Figure 6.6f-h, Table 6.1). 
 Four stable clonal Abrams-CAT populations were also generated to determine the 
extent of inherent variability in DOX resistance for clones selected from this cell line.  
Three of four of these clones ( Table 6.1 Abrams-CAT clones 1, 4, and 6) demonstrated 
significantly different resistance compared to the pool, however, in all cases, IC50 values 
were greater than those observed for the Abrams-CAT pool (Table 6.1).  Thus, while the 
Abrams cell line demonstrates some natural variability in sensitivity to DOX, 















































































































































































































 Previously, we identified underexpression of NDRG2 mRNA in primary tumors 
as a negative prognostic indicator for disease free interval in dogs with OSA (9).  
Although NDRG2 expression had been assayed previously in a number of different tumor 
Figure 6.6 (Preceding Page) – Resazurin-based viability assays of Abrams-NDRG2 
and Abrams-CAT cells following DOX treatment.  Stable clones of NDRG2 
expressing Abrams cells were selected and subjected to 72-hour DOX treatment after 
which cell viability was measured.  From this, half maximal inhibitory concentration 
values (IC50) were determined as a measure of drug sensitivity.  A-D) Four clonal 
isolates expressing the short isoform of NDRG2.  E) The heterogeneous pool of short 
isoform transfectants.  F-H) Three clonal isolates expressing the long isoform of 
NDRG2. 




b IC50 vs. CAT Pool IC50
c
Abrams-NDRG2-Short Poold 16.09 12.91 to 20.06 P<0.0001
Abrams-NDRG2-Clone 2 6.487 5.557 to 7.573 P<0.0001
Abrams-NDRG2-Clone 3 9.771 8.761 to 10.90 P<0.0001
Abrams-NDRG2-Clone 6 4.077 3.263 to 5.094 P<0.0001
Abrams-NDRG2-Clone 8 7.396 6.109 to 8.954 P<0.0001
Abrams-NDRG2-Clone Ae 14.54 11.95 to 17.69 P<0.0001
Abrams-NDRG2-Clone C 32.79 23.46 to 45.82 0.9173
Abrams-NDRG2-Clone D 6.259 5.186 to 7.555 P<0.0001
Abrams-CAT Poolf 32.18 27.23 to 38.03 NA
Abrams-CAT Clone 1 64.74 54.32 to 77.15 P<0.0001
Abrams-CAT Clone 2 35.47 27.91 to 45.09 0.4117
Abrams-CAT Clone 4 50.14 37.18 to 67.62 0.0082
Abrams-CAT Clone 6 72.25 56.03 to 93.17 P<0.0001
a – Half maximal inhibitory concentration values for DOX, b – 95% confidence interval for IC50, c –
significance values for nonlinear regression analysis comparing clone IC50s to CAT Pool IC50, d –
“Short Pool” and numbered clones denote transfectants with NDRG2 lacking Exon 2, e – lettered 
clones denote transfectants with NDRG2 including Exon 2, f – CAT Pool and clones are negative 
control samples
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systems, this is the first report of dysregulation in OSA relative to normal bone and the 
first examination of expression in the canine model  (10, 11, 15-23, 32-34).  We 
examined expression levels of this tumor suppressor gene in canine OSA and normal 
bone as well as its contribution to chemotherapeutic resistance in this system.  We have 
identified two expressed isoforms of the mRNA and protein in canine samples.  
Furthermore, it is likely that one of these isoforms undergoes post-translational 
modification in the in vitro system.  We also examined three possible mechanisms of the 
observed mRNA suppression, all of which may, indeed, be factors in the NDRG2 
dysregulation common to all of the tumors studied.   
 Although its precise mechanism of action remains a mystery, previous association 
studies have linked NDRG2 to a variety of downstream targets important in cancer 
progression.  For instance, NDRG2 protein has been found to directly interact with β-
catenin protein and affect downregulation of TCF/β-catenin transcriptional targets such as 
Cyclin D1 and fibronectin (12, 21).  Similarly, cells expressing transfected NDRG2 have 
been shown to secrete enhanced levels of BMP4 which then suppresses matrix 
metallopeptidase 9 (MMP9) activity and cell invasion (16).  Alteration in MMP9 
expression in response to NDRG2 has also been shown to involve nuclear factor of kappa 
light polypeptide gene enhancer in B-cells (NFκB) as an intermediary (15).  Additionally, 
NDRG2 transfection led to activation of suppressor of cytokine signaling 1 (SOCS1) in 
breast cancer cells which then reduced phosphorylation and activity of Janus tyrosine 
kinase 2 (JAK2) and signal tranducer and activator of transcription 3 (STAT3) resulting in 
decreased cellular proliferation (35).  Finally, studies have shown that NDRG2 can 
enhance apoptosis mediated by hypoxia, p53 and Fas (13, 33, 36).   
 201
 The role of BMP4 in OSA has typically been viewed as a negative one:  increased 
expression tends to correlate with less-differentiated tumors and worse outcomes (37).  
Despite this, even benign bone tumors can express and secrete BMP4, implying that 
BMP4 is not strictly a marker of aggressive malignancy but may indicate activation of 
non-tumorous osteoblasts (38).  Our findings may provide a clue as to how BMP4 is 
(dys-)regulated in OSA:  untransfected Abrams cells and CAT-transfected Abrams clones 
with extremely low levels of NDRG2 demonstrated variable but high BMP4 mRNA 
expression.  However, when NDRG2 was transfected into these cells, BMP4 expression 
was expressed in an NDRG2-positively-responsive fashion.  From this, one may 
hypothesize that, upon NDRG2 suppression, BMP4 is released from this controlling 
factor and behaves in a tumorigenic, pro-proliferative manner.  However, restoration of 
even a small amount of functional NDRG2 signaling restores proper BMP4 control, 
reducing the influence of this signaling molecule on reactive bone formation and 
proliferation.  Furthermore, NDRG2 expression has been linked to a BMP4-dependent 
repression of MMP9 expression in breast cancer, suggesting a role for NDRG2 and 
BMP4 in invasion and metastasis suppression (16).   
 NDRG2 and BMP4 have also been identified as upstream regulators and 
downstream targets, respectively, of NFκB (15).  NDRG2 transfection of murine 
melanoma cells resulted in suppression of NFκB and a resultant decrease in metastatic 
potential (15).  Increased NFκB activity in OSA has been strongly correlated with 
proliferation and invasion (39, 40).  Furthermore, knockdown of NFκB induced BMP4 
expression in OSA cells (39) and suppressed vascular endothelial growth factor (VEGF) 
and intercellular adhesion molecule 1 (ICAM-1) resulting in reversion of the metastatic 
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phenotype of the murine OSA cell line LM8 (40).  Thus, multiple lines of evidence 
suggest that, via interactions with NFκB and its downstream targets, NDRG2 serves as 
both a tumor suppressor and a metastasis suppressor. 
 Our findings confirm that NDRG2 is widely suppressed in OSA primary tumors.  
Similarly, we have confirmed that both NDRG2 gene deletion as well as methylation can 
serve as mechanisms for suppression of this gene (10, 11, 41).  Furthermore, c-Myc-
dependent repression of the NDRG2 gene via direct binding of the core promoter has 
been identified in a number of different cell types and it has been determined that this 
repression is dependent on Myc-interacting zinc finger 1 (ZBTB17 aka Miz-1) 
association with Myc (24).  c-Myc and n-Myc have both been identified as oncogenes 
that can be overexpressed in OSA and copy number gains of c-Myc have been observed 
in canine OSA (6, 42-45).  Additionally c-Myc expression has been associated with 
methotrexate and cisplatin resistance in OSA (46, 47) and mouse models of Myc 
alteration have demonstrated that reduction of Myc expression can cause tumor 
regression (48).  Thus, dysregulation in either of these upstream factors can inhibit 
NDRG2 expression.  Here, we have observed upregulation of c-Myc mRNA relative to 
normal bone in four of nine matched tumors indicating that over-expression of this 
oncogene may suppress NDRG2 in a portion of OSA primary tumors.  Other gene 
regulation mechanisms not yet addressed in this system may also be at work.  For 
instance, microRNA regulation of NDRG2 has also been observed (10).  As our 
transfectants lack 3'UTR, they also, undoubtedly lack some of the control mechansims 
that may contribute to NDRG2 suppression in OSA.  Thus, generation of luciferase-
3'UTR constructs may be very informative in future studies aimed at more closely 
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defining mechanisms of post transcriptional NDRG2 regulation.  As mentioned 
previously, NDRG2 is also a known phosphorylation target for several kinases, thus, 
modulation in kinase activity or mutation in phosphorylation sites can alter downstream 
effects without altered transcriptional activity of NDRG2 (14).   
 For the first time, we have linked NDRG2 suppression to chemoresistance; to 
date, no other studies have examined this important feature of cancer progression with 
regard to NDRG2.  Interestingly, while our short isoform expressing cells consistently 
demonstrated enhanced DOX chemosensitivity, long isoform expressing cells were 
inconsistent.  The structure and function of Exon 2 is currently unknown as crystal 
structure analyses have not included it, thus, it is worth exploring in the future because 
the short isoform may be far more therapeutically beneficial than the long isoform (12).  
Our finding that restoration of NDRG2 short isoform expression induces DOX 
chemosensitivity in OSA makes sense if one considers the interconnection between 
NDRG2 and NFκB.  NFκB overexpression has been shown to induce chemoresistance 
through pro-survival/anti-apoptotic mechanisms, thus, its suppression by NDRG2 may 
very well be the mechanism of sensitivity induction we see here (49-51).  However, as 
NFκB responsiveness to NDRG2 has not yet been assessed in this system, future 
identification of new NDRG2 gene targets and modulators of chemoresistance may yet be 
possible. 
 In conclusion, we have identified NDRG2 as a potential prognostic biomarker in 
canine OSA and followed that up with investigations into mechanisms of its suppression 
in these tumors.  Myc oncogene expression, CNAs and methylation of the NDRG2 locus 
likely contribute to gene suppression but other mechanisms may also be identified that 
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contribute to the profound reduction in mRNA observed in all tumors tested here.  
NDRG2 involvement with the NFκB pathway may contribute to both metastases and 
chemoresistance in OSA, thus, further evaluation of this link will be of great value.  
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 The studies presented in this dissertation describe molecular analyses of 
osteosarcoma (OSA) in canine patients with the aim of identifying novel factors that 
contribute to disease progression and chemotherapeutic resistance.  As OSA is the most 
common primary bone tumor in both dogs and man, and current treatments provide only 
a limited cure rate, new therapeutic targets are sorely needed.  The high incidence of this 
cancer in the canine population as well as their genetic and environmental similarities to 
humans make them an ideal translational study model.  Thus, new discoveries in the field 
of canine OSA research can benefit both veterinary and human patients. 
 In Chapter 2, we profiled gene expression using Affymetrix Canine 2.0 
microarrays in primary tumors taken from two cohorts of canine OSA patients:  those 
with good responses and those with poor responses following definitive treatment by 
amputation of the affected limb followed by adjuvant therapy with doxorubicin and/or a 
platinum-based drug.  Patients were selected for these cohorts on the basis of disease free 
intervals (good responders = DFI>300 days, poor responders = DFI<100 days) which 
were determined from the medical record.  The aim of this study was to identify genes 
and pathways that were dysregulated between the tumors of the two cohorts and 
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determine a gene signature that predicted the most aggressive or chemoresistant tumors.  
Microarray analysis and subsequent qRT-PCR validation of this data led to the 
development of four predictive models that were based on a selection of differentially 
regulated genes.  Additionally, pathway analysis of microarray data identified several 
dysregulated pathways including hedgehog signaling.  This broad survey study laid the 
groundwork for future investigations into the molecular pathogenesis of OSA. 
 Having identified several genes of interest in the outcome-based study, we wished 
to establish applicable baseline data for the dysregulation observed in tumors.  Thus, in 
Chapter 3, we pursued gene expression profiling of normal bone as well as array 
comparative genomic hybridization (aCGH) to determine what portion of gene 
(dys)regulation was due to gene copy number alterations (CNAs).  Comparing normal 
bone gene expression to that of primary tumors was strikingly informative as only a 
subset of previously-identified progression-related genes were significantly altered from 
normal in all tumors.  Furthermore, aCGH analysis of primary tumors relative to normal 
tissue identified many regions of CNA in primary tumors and emphasized the chaotic 
nature of OSA chromosome derangements.  As a general theme, many tumors 
demonstrated copy number gain of oncogenes, copy number loss of tumor suppressors 
and/or CNAs in genes associated with those pathways.  These survey experiments 
provided much-needed perspective on the studies in Chapter 2 and allowed us to move 
forward with the most-robust targets. 
 Cell line contamination has gained much attention in recent years and many 
funding agencies and journals are beginning to require validation of cell lines.  Thus, with 
the aim of generating vigorous and correct data in future in vitro work, we pursued 
 212
validation of cell lines with respect to species, short tandem repeat (STR), and tissue of 
origin identities.  In Chapter 4, we verified that all cell lines to be used in future studies 
were derived from different canine individuals and that they had been generated from 
OSA.  Additionally, we identified several instances of cell line contamination in the 
Animal Cancer Center and generated a database of STR profiles to be used in future 
validation studies.  Finally, we also validated anti-human antibodies for use in canine 
samples for western blotting and immunohistochemsitry. 
 Having verified the sanctity of the canine in vitro models, we next pursued in-
depth examination of two genes that had been identified in our outcome-based survey 
experiments.  The first, insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) 
is explored in Chapter 5.  Previous work had identified IGF2BP1 as an oncofetal gene:  
expressed during embryonic development and in some cancers but suppressed in normal 
adult tissues.  Our analysis confirmed this relative to normal bone:  mRNA expression 
was virtually undetectable in normal bone but increased in good-responder primary 
tumors and was even further elevated in poor-responder primary tumors.  
Immunohistochemical evaluation of IGF2BP1 expression in primary tumors from our 
study cohorts revealed increased nuclear localization of IGF2BP1 as a prognostic 
indicator for poor outcome but application of this screen to a large, independent data set 
demonstrated no relationship between nuclear or cytoplasmic staining frequency/intensity 
and outcome.  Analysis of CNAs in the region around the IGF2BP1 locus indicated that 
gene amplification was not the cause of enhanced expression in tumors.  Thus, we 
investigated an additional mechanism of IGF2BP1 dysregulation:  3' untranslated region 
(UTR) shortening.  Transcript of this gene can possess a 3' UTR of up to 7 kb in length 
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with multiple micro-RNA response elements.  Previous studies identified shortening of 
this region as a possible mechanism of escape from normal regulation.  Our analysis 
determined that primary tumors from poor outcome patients have a significantly smaller 
proportion of IGF2BP1 transcripts with full-length 3'UTR compared to patients with 
good outcomes.  Next, we set out to explore functional consequences of IGF2BP1 
expression in an in vitro model.  Knockdown of this gene in the Abrams canine OSA cell 
line was accomplished with siRNA and resulted in decreased invasive capacity of the cell 
line.  Thus, we determined that truncation of the IGF2BP1 3' UTR can contribute to its 
overexpression in OSA and this overexpression may result in enhanced metastatic 
capacity of the tumor. 
 Finally, in Chapter 6, we investigated the functional role of the putative tumor 
suppressor gene n-Myc downstream regulated gene 2 (NDRG2) in OSA.  Expression 
analysis of the NDRG2 mRNA identified suppression in good-responder primary tumors 
and significantly stronger suppression in poor-responder primary tumors relative to 
normal bone.  As this gene has been shown to be downregulated in response to c-Myc, c-
Myc expression in matched normal bone and tumor samples was assayed.  This study 
identified upregulation of c-Myc in 4/9 tumors relative to normal bone.  NDRG2 
expression, however, was suppressed in 9/9 tumors relative to normal bone indicating 
that other mechanisms were also causing suppression.  aCGH analysis of the region 
surrounding the NDRG2 locus identified copy number loss in 2/8 primary tumors (25%) 
which was unrelated to outcome.  Additionally, treatment with the demethylating agent 5-
azacytidine increased NDRG2 mRNA expression in an in vitro system.  These findings 
highlighted the importance of multiple factors in the (dys)regulation of NDRG2 in this 
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system.  To examine the functional role of this gene, we cloned the two expressed 
NDRG2 isoforms into a mammalian expression construct and generated stable Abrams-
NDRG2 expressing cell line clones.  Resultant clones demonstrated enhanced sensitivity 
to doxorubicin compared to negative-control transfected cell lines.  Thus, we determined 
that multiple mechanisms of gene regulation control suppression of NDRG2 in canine 
OSA and tumors with reduced NDRG2 may exhibit resistance to one of the most 
common therapeutic agents used to treat this disease. 
 In conclusion, the work presented in this dissertation defines a pyramid of 
investigations into the molecular factors in OSA that contribute to disease progression 
and chemoresistance.  We used broad survey experiments to identify novel factors related 
to outcome then fine-tuned those findings in order to select genes for in-depth 
investigation.  The initial pursuit of a prognostic factor or factors developed, instead, into 
more-thoroughly defining the roles of two genes that may contribute to outcome:  
IGF2BP1 and NDRG2.  These two genes likely contribute to metastasis and 
chemotherapeutic resistance yet are not adequate, by themselves, to serve as prognostic 
indicators.  They do, however, emphasize the likely importance of MYC-related genes in 
the pathogenesis of OSA.  IGF2BP1 has been shown to be upstream of MYC in some 
systems whereas NDRG2 has been shown to be downstream of it.  In this system, we 
observed altered expression of these genes as well as copy number alterations and 
dysregulation in MYC; these changes were most robustly demonstrated by poor 
responders.  Thus, dysregulation of MYC and related genes likely contributes to an 
aggressive OSA phenotype.  This contribution, however, cannot account for all observed 
cases with short time to metastases or limited response to chemotherapy.  Therefore, 
 215
more work remains to be done to identify molecular features of OSA that contribute to 
metastasis and chemotherapeutic resistance.  
 
Future Directions 
 There are a number of additional studies that could be performed to further 
investigate the roles of IGF2BP1 and NDRG2 in OSA.  For instance, mammalian 
expression vectors containing shRNAs specific to IGF2BP1 have already been generated 
by our laboratory.  Stable transfection of IGF2BP1 expressing cell lines with these 
knockdown vectors would allow long-term chemosensitivity and proliferation assays as 
well as other studies of tumor aggressiveness (e.g. colony formation, growth in soft agar) 
to be performed.  Similarly, full length IGF2BP1 coding sequence has been generated for 
cloning and transfection.  Stable overexpression of this gene in low IGF2BP1-expressing 
cell lines may provide further insights into its role in OSA.  Additionally, further 
investigation of the 3' UTR shortening phenomenon in independent sets of primary 
tumors may lead to the development of prognostic screens or treatment modalities based 
around this method of dysregulation.  Finally, locked nucleic acid technology provides a 
means by which to knock down gene expression in vivo.  As this gene is unexpressed in 
normal tissues, one could hypothesize that systemic knockdown of IGF2BP1 in cancer 
patients would have only limited side effects and may prove an effective method of 
limiting tumor cell invasion and metastasis.  Assessment of this methodology in mouse 
models of OSA may provide an excellent platform for development of a new anti-OSA 
treatment. 
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 There is much work yet to be done with regards to NDRG2 suppression in OSA.  
Our findings herein indicate that methylation of NDRG2 may silence this gene in tumors 
but further investigation with methylation-specific-PCR or sodium bisulfite sequencing 
would provide definitive evidence to this effect.  Also, it has been suggested that NDRG2 
pathways control matrix metallopeptidase expression.  It would be interesting to 
determine if these downstream targets are affected in our stable clones through the use of 
zymography and subsequent invasion assays.  Additionally, the means by which NDRG2 
regulates its downstream targets is currently unknown.  As we have validated an anti-
NDRG2 antibody and generated V5-tagged NDRG2 constructs, immunoprecipitation 
experiments followed by MALDI-TOF identification of NDRG2-associated targets 
would provide much needed information regarding its interaction network. 
 Our broad survey experiments also identified several other gene targets of 
interest:  coiled coil domain containing 3 (CCDC3), alcohol dehydrogenase iron 
containing 1 (ADHFE1) and sodium channel, voltage-gated, type I, beta (SCN1B) to 
name a few.  Our laboratory has already initiated investigations into two of these targets 
but as there is only a limited body of knowledge regarding these genes, there is much 
work yet to be done.  Similarly, there is much additional knowledge that can be mined 
from our large survey datasets.  One potential application of this data would be to obtain 
microarray data that has been performed on human samples and examine the intersections 
of this data with our canine data.  Further elucidation of the shared molecular 
characteristics between human and canine OSA may identify new gene targets that would 







































Figure A.1 - Signal transduction - cAMP signaling. Top scored pathway map in the 
analysis of gene targets common to both PLIER and RMA processing. Red symbols 
indicate degree of upregulation of gene target in DFI < 100 days relative to DFI > 300 
days, blue symbols indicate relative down-regulation. Numbers in symbols indicate 






































Figure A.2 - Cell Adhesion - Chemokines and Adhesion. Second scored pathway for 
the analysis of gene targets common to both PLIER and RMA processing. Red symbols 
indicate degree of upregulation of gene target in DFI < 100 days relative to DFI > 300 
days, blue symbols indicate relative down-regulation. Numbers in symbols indicate 








































Figure A.3 - Cell adhesion - ECM remodeling. Fifth scored pathway for the analysis 
of gene targets common to both PLIER and RMA processing. Red symbols indicate 
degree of upregulation of gene target in DFI < 100 days relative to DFI > 300 days, 
blue symbols indicate relative down-regulation. Numbers in symbols indicate specific 










Lists of genes obtained from pairwise t-test intersections of three study cohorts:  Poor 
Responder Primary Tumors (DFI<100 days, G1), Good Responder Primary Tumors 
(DFI>300 days, G2) and Normal Bone (G3).  Refer to Chapter 3 for discussion. 
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Chrosomal Expression Maps: 
Array Comparative Genomic Hybridization versus 














X-axes = chromosomal location of probe 
 
Y-axis (aCGH, top half of page) = hybridization intensity tumor (n=8) relative to normal 
tissue (n=8).  Thresholds for amplification and deletion are represented by dashed lines 
intersecting the Y axis at 0.201 and -0.234 respectively.  Each sample is represented by a 
point at each probe.  Mean intensities are represented by the continuous red line. 
 
Y-axis (Affymetrix, bottom half of page) = fold change tumors (n=15) relative to normal 
bone (n=8). 
 
Some locus regions of interest outlined in the text are indicated on figures with boxes and 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chrosomal Expression Maps: 
Array Comparative Genomic Hybridization versus 











X-axes = chromosomal location of probe 
 
Y-axis (aCGH, top half of page) = hybridization intensity poor-responder tumor 
(DFI<100, n=4, red circles) relative to paired normal tissue and good responder tumor 
(DFI>300, n-4, blue squares) relative to paired normal tissue.  Thresholds for 
amplification and deletion are represented by dashed lines intersecting the Y axis at 0.201 
and -0.234 respectively.  Means of four samples per group are plotted. 
 
Y-axis (Affymetrix, bottom half of page) = fold change poor-responder primary tumors 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































DNA sequencing results and translated protein sequence alignments for the two 
expression constructs used to generate stable Abrams-NDRG2 clones in Chapter 6.  The 
short clone lacks coding sequence Exon 2, a 14-amino acid domain that follows the first 
25 amino acids of the protein.  Stop codons were excluded in both constructs to attach V5 
tags to the resultant proteins.
 320
NDRG2 short clone sequence - Blue letters indicate the first base of each exon, red letters 
indicate the last base of each exon.  Lower-case letters highlighted in yellow indicate 
silent mutations present in the plasmid sequence.  Numbers to the right of each line 
indicate base position relative to CDS start codon 
 
ATGGCGGAGC TGCAGGAGGT GCAGATCACA GAGGAGAAGC CGCTGTTGCC  50 
AGGGCAGACG CCCGAGACGG CCAAGACTCA CTCTGTGGAG ACACCGTATG  100 
GCTCTGTCAC TTTTACTGTC TATGGGACCC CCAAGCCCAA ACGCCCAGCG  150 
ATACTCACCT ACCATGATGT AGGACTCAAC TATAAGTCTT GCTTCCAGCC  200 
GCTCTTTCAG TTCGGGGACA TGCAGGAAAT CATTCAGAAC TTCGTGCGGG  250 
TTCATGTGGA TGCCCCTGGA ATGGAAGAGG GGGCTCCCGT GTTCCCTTTG  300 
GGGTATCAGT ACCCGTCTCT GGACCAGCTC GCGGACATGA TCCCTTGCAT  350 
TCTGCAGTAC CTGAATTTCT CCACAATAAT TGGAGTTGGT GTTGGAGCTG  400 
GAGCCTACAT CCTGTCACGA TATGCTCTGA CCCACCCGGA TACAGTCGAG  450 
GGGCTTGTCC TCATCAACAT TGATCCCAAT GCCAAGGGTT GGATGGACTG  500 
GGCGGCCCAC AAGCTAACAG GTCTCACCTC TTCCATTCCG GAGATGATCC  550 
TCGGACATCT TTTCAGCCAG GAGGAGCTGT CTGGAAACTC GGAGCTGATA  600 
CAGAAGTACA GAAACATCAT CACACATGCG CCCAACCTGG AGAACATTGA  650 
ACTGTACTGG AACAGCTACA ACAATCGCCG AGACCTGAAC CTGGAGCGTG  700 
GCGGTGCCGT CACCCTCAGG TGCCCTGTGA TGCTGGTGGT GGGAGACCAA  750 
GCACCCCATG AAGATGCAGT GGTGGAGTGT AACTCAAAGC TGGACCCCAC  800 
CCAGACCTCT TTTCTCAAGA TGGCCGACTC TGGAGGTCAG CCCCAGCTGA  850 
CGCAGCCAGG CAAGCTGACC GAGGCCTTCA AGTACTTCCT GCAAGGCATG  900 
GGCTACATGG CCTCGTCCTG CATGACTCGC CTGTCGCGAT CGCGCACGGC  950 
CTCGCTGACC AGTGCGGCGT CCATTGATGG CAACCGGTCC CGCTCCCGCA  1000 
CCCTaTCGCA GGGCAGCGAG TCTGGGACTC TCCCTTCAGG GCCGCCaGGG  1050 
CATACCATGG AGGTCTCCTG C 
 
NDRG2 long clone sequence - Colors are as above, CDS Exon 2 is dark blue. 
 
ATGGCGGAGC TGCAGGAGGT GCAGATCACA GAGGAGAAGC CGCTGTTGCC  50 
AGGGCAGACG CCCGAGACGG CCAAGGAGGC TGAaTTAGCT GCCCGAATCC  100 
TCCTGGACCG GGGACAGACT CACTCTGTGG AGACACCGTA TGGCTCTGTC  150 
ACTTTTACTG TCTATGGGAC CCCCAAGCCC AAACGCCCAG CGATACTCAC  200 
CTACCATGAT GTAGGACTCA ACTATAAGTC TTGCTTCCAG CCGCTCTTTC  250 
AGTTCGGGGA CATGCAGGAA ATCATTCAGA ACTTCGTGCG GGTTCATGTG  300 
GATGCCCCTG GAATGGAAGA GGGGGCTCCC GTGTTCCCTT TGGGGTATCA  350 
GTACCCGTCT CTGGACCAGC TCGCGGACAT GATCCCTTGC ATTCTGCAGT  400 
ACCTGAATTT CTCCACAATA ATTGGAGTTG GTGTTGGAGC TGGAGCCTAC  450 
ATCCTGTCAC GATATGCTCT GACCCACCCG GATACAGTCG AGGGGCTTGT  500 
CCTCATCAAC ATTGATCCCA ATGCCAAGGG TTGGATGGAC TGGGCGGCCC  550 
ACAAGCTAAC AGGTCTCACC TCTTCCATTC CGGAGATGAT CCTCGGACAT  600 
CTTTTCAGCC AGGAGGAGCT GTCTGGAAAC TCGGAGCTGA TACAGAAGTA  650 
CAGAAACATC ATCACACATG CGCCCAACCT GGAGAACATT GAACTGTACT  700 
GGAACAGCTA CAACAATCGC CGAGACCTGA ACCTGGAGCG TGGCGGTGCC  750 
GTCACCCTCA GGTGCCCTGT GATGtTGGTG GTGGGAGACC AAGCACCCCA  800 
TGAAGATGCA GTGGTGGAGT GTAACTCAAA GCTGGACCCC ACCCAGACCT  850 
CTTTTCTCAA GATGGCCGAC TCTGGAGGTC AGCCCCAGCT GACGCAGCCA  900 
GGCAAGCTGA CCGAGGCCTT CAAGTACTTC CTGCAAGGCA TGGGCTACAT  950 
GGCCTCGTCC TGCATGACTC GCCTGTCGCG ATCGCGCACG GCCTCGCTGA  1000 
CCAGTGCGGC GTCCATTGAT GGCAACCGGT CCCGCTCCCG CACCCTGTCG  1050 





NDRG2 short clone protein alignment - NCBI blastx alignment of translated nucleotide 
sequence for the short construct with NDRG2 isoform protein sequence.  100% of 
residues align with transcript variants 6 and 7.  These two isoforms share identical coding 
sequences but differ in untranslated region sequence.  Mutations identified in coding 
sequence do not result in residue changes. 
 
ref|XP_863342.1| PREDICTED: similar to N-myc downstream-regulated gene 
2 isoform b isoform 6 [Canis familiaris] 
 
ref|XP_863366.1| PREDICTED: similar to N-myc downstream-regulated gene 




GENE ID: 609390 NDRG2 | NDRG family member 2 [Canis lupus familiaris] 
 
Score =  672 bits (1733),  Expect = 0.0 
Identities = 357/357 (100%), Positives = 357/357 (100%), Gaps = 0/357 (0%) 
Frame = +1 
 
Query  1     MAELQEVQITEEKPLLPGQTPETAKTHSVETPYGSVTFTVYGTPKPKRPAILTYHDVGLN  180 
             MAELQEVQITEEKPLLPGQTPETAKTHSVETPYGSVTFTVYGTPKPKRPAILTYHDVGLN 
Sbjct  1     MAELQEVQITEEKPLLPGQTPETAKTHSVETPYGSVTFTVYGTPKPKRPAILTYHDVGLN  60 
 
Query  181   YKSCFQPLFQFGDMQEIIQNFVRVHVDAPGMEEGAPVFPLGYQYPSLDQLADMIPCILQY  360 
             YKSCFQPLFQFGDMQEIIQNFVRVHVDAPGMEEGAPVFPLGYQYPSLDQLADMIPCILQY 
Sbjct  61    YKSCFQPLFQFGDMQEIIQNFVRVHVDAPGMEEGAPVFPLGYQYPSLDQLADMIPCILQY  120 
 
Query  361   LNFSTIIGVGVGAGAYILSRYALTHPDTVEGLVLINIDPNAKGWMDWAAHKLTGLTSSIP  540 
             LNFSTIIGVGVGAGAYILSRYALTHPDTVEGLVLINIDPNAKGWMDWAAHKLTGLTSSIP 
Sbjct  121   LNFSTIIGVGVGAGAYILSRYALTHPDTVEGLVLINIDPNAKGWMDWAAHKLTGLTSSIP  180 
 
Query  541   EMILGHLFSQEELSGNSELIQKYRNIITHAPNLENIELYWNSYNNRRDLNLERGGAVTLR  720 
             EMILGHLFSQEELSGNSELIQKYRNIITHAPNLENIELYWNSYNNRRDLNLERGGAVTLR 
Sbjct  181   EMILGHLFSQEELSGNSELIQKYRNIITHAPNLENIELYWNSYNNRRDLNLERGGAVTLR  240 
 
Query  721   CPVMLVVGDQAPHEDAVVECNSKLDPTQTSFLKMADSGGQPQLTQPGKLTEAFKYFLQGM  900 
             CPVMLVVGDQAPHEDAVVECNSKLDPTQTSFLKMADSGGQPQLTQPGKLTEAFKYFLQGM 
Sbjct  241   CPVMLVVGDQAPHEDAVVECNSKLDPTQTSFLKMADSGGQPQLTQPGKLTEAFKYFLQGM  300 
 
Query  901   GYMASSCMTRLSRSRTASLTSAASIDGNRSRSRTLSQGSESGTLPSGPPGHTMEVSC  1071 
             GYMASSCMTRLSRSRTASLTSAASIDGNRSRSRTLSQGSESGTLPSGPPGHTMEVSC 
Sbjct  301   GYMASSCMTRLSRSRTASLTSAASIDGNRSRSRTLSQGSESGTLPSGPPGHTMEVSC  357 
 322
NDRG2 long clone protein alignment - NCBI blastx alignment of translated nucleotide 
sequence for the long construct with NDRG2 isoform protein sequence.  100% of 
residues align with transcript variant 1.  Mutations identified in coding sequence do not 
result in residue changes.  Exon 2 is denoted by dark blue font. 
 
ref|XP_851185.1|PREDICTED: similar to NDRG2 protein (Syld709613 




GENE ID: 609390 NDRG2 | NDRG family member 2 [Canis lupus familiaris] 
 
Score =  697 bits (1798),  Expect = 0.0 
Identities = 371/371 (100%), Positives = 371/371 (100%), Gaps = 0/371 (0%) 
Frame = +1 
 
Query  1     MAELQEVQITEEKPLLPGQTPETAKEAELAARILLDRGQTHSVETPYGSVTFTVYGTPKP  180 
             MAELQEVQITEEKPLLPGQTPETAKEAELAARILLDRGQTHSVETPYGSVTFTVYGTPKP 
Sbjct  1     MAELQEVQITEEKPLLPGQTPETAKEAELAARILLDRGQTHSVETPYGSVTFTVYGTPKP  60 
 
Query  181   KRPAILTYHDVGLNYKSCFQPLFQFGDMQEIIQNFVRVHVDAPGMEEGAPVFPLGYQYPS  360 
             KRPAILTYHDVGLNYKSCFQPLFQFGDMQEIIQNFVRVHVDAPGMEEGAPVFPLGYQYPS 
Sbjct  61    KRPAILTYHDVGLNYKSCFQPLFQFGDMQEIIQNFVRVHVDAPGMEEGAPVFPLGYQYPS  120 
 
Query  361   LDQLADMIPCILQYLNFSTIIGVGVGAGAYILSRYALTHPDTVEGLVLINIDPNAKGWMD  540 
             LDQLADMIPCILQYLNFSTIIGVGVGAGAYILSRYALTHPDTVEGLVLINIDPNAKGWMD 
Sbjct  121   LDQLADMIPCILQYLNFSTIIGVGVGAGAYILSRYALTHPDTVEGLVLINIDPNAKGWMD  180 
 
Query  541   WAAHKLTGLTSSIPEMILGHLFSQEELSGNSELIQKYRNIITHAPNLENIELYWNSYNNR  720 
             WAAHKLTGLTSSIPEMILGHLFSQEELSGNSELIQKYRNIITHAPNLENIELYWNSYNNR 
Sbjct  181   WAAHKLTGLTSSIPEMILGHLFSQEELSGNSELIQKYRNIITHAPNLENIELYWNSYNNR  240 
 
Query  721   RDLNLERGGAVTLRCPVMLVVGDQAPHEDAVVECNSKLDPTQTSFLKMADSGGQPQLTQP  900 
             RDLNLERGGAVTLRCPVMLVVGDQAPHEDAVVECNSKLDPTQTSFLKMADSGGQPQLTQP 
Sbjct  241   RDLNLERGGAVTLRCPVMLVVGDQAPHEDAVVECNSKLDPTQTSFLKMADSGGQPQLTQP  300 
 
Query  901   GKLTEAFKYFLQGMGYMASSCMTRLSRSRTASLTSAASIDGNRSRSRTLSQGSESGTLPS  1080 
             GKLTEAFKYFLQGMGYMASSCMTRLSRSRTASLTSAASIDGNRSRSRTLSQGSESGTLPS 
Sbjct  301   GKLTEAFKYFLQGMGYMASSCMTRLSRSRTASLTSAASIDGNRSRSRTLSQGSESGTLPS  360 
 
Query  1081  GPPGHTMEVSC  1113 
             GPPGHTMEVSC 
Sbjct  361   GPPGHTMEVSC  371 
 
